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Abstract 
The conformational stability of a protein is a fundamental concern in formulating protein 
drug products, and development of analytical methods for stability characterization is critical 
for this purpose. Because of the complexity, relatively lower stability and variety of 
degradation pathways of protein molecules, the selection of appropriate analytical methods is 
important and needs to meet specific requirements for stability testing, screening 
formulations, as well as for product release. To characterize the stability of proteins 
comprehensively, the conformational stability of proteins is typically investigated using a 
variety of biophysical measurements as a function of environmental stresses such as pH and 
temperature. These multiple techniques typically require a variety of single function 
instruments. Each technique, however, provides information on only a particular aspect of a 
protein’s higher order structural integrity (secondary, tertiary, and quaternary). The 
combination of different techniques provides a better understanding of the overall 
conformational stability of a protein, although these measurements typically require large 
sample quantities and long experimental times. Therefore, the development of high 
throughput methods to comprehensively characterize protein stability with a single 
multifunctional instrument is needed to save both materials and time.  
In the first part of my work (Chapters 2-4), a new methodology is developed to obtain 
protein conformational stability data simultaneously, including UV absorption, light 
scattering, and near- and far- UV CD by employing a multimodal spectrometer (Chapter 2). 
Fluorescence spectral data are also collected on the same instrument although not 
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simultaneously. The method is developed by examining the thermal and pH stability of four 
model proteins. Results show reproducible and accurate data using this single instrument, and 
data collection is rapid with minimal protein sample requirements. This study also illustrates 
the application of this method for generating empirical phase diagrams (EPDs) to better 
characterize the overall conformational stability of proteins. This new approach facilitates the 
rapid characterization of protein structure and stability data in a single instrument. It is useful 
for analysis of unknown proteins, as well as screening of solution conditions to optimize 
stability for protein therapeutic drug candidates.   
I also describe the application of this new method (Chapter 2) to characterize the stability 
of the recombinant anthrax protective antigen (rPA) and its 2-fluorohistidine (2-FHis) labeled 
analogue (Chapter 3). Protective antigen (PA) is a key, non-toxic component of the anthrax 
toxin. It is also a primary antigenic component of the current formaldehyde inactived anthrax 
vaccine. An analogue of PA has been recently shown to block key steps in pore formation in 
the process of inducing cytotoxicity in cells. Thus, it can potentially be used as an antitoxin or 
a vaccine. This analogue is synthesized by incorporating the unnatural amino acid 
2-fluorohistidine (2-FHis). In this study, the effects of 2-FHis labeling on rPA antigen 
stability and its dynamic properties are investigated by various experimental techniques. 
Physical stability profiles of the two proteins (rPA and 2-FHis rPA) are created by using the 
empirical phase diagram (EPD) approach, and stability differences between them are 
identified. Results show that rPA and 2-FHis rPA have similar stability at pH 7-8. With 
decreasing pH, however, 2-FHis rPA is found to be more stable. Intramolecular dynamics 
sensitive measurements of the proteins at pH 5 find that 2-FHis rPA has increased internal 
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mobility under acidic pH conditions. The stability and dynamics characterization data provide 
information useful for the formulation development of 2-FHis rPA as a more stable antigen 
for vaccine development.  
In addition, the new multimodal spectrometer method (Chapter 2) is coupled to other 
techniques such as SDS-PAGE, static light scattering, dynamic light scattering, isoelectric 
focusing, size-exclusion liquid chromatography as well as micro flow imaging to characterize 
the stability of dominant-negative inhibitor (DNI) protein (Chapter 4). DNI is a 
translocation-deficient mutant of PA with double mutations of K397D and D425K. It is a 
promising candidate for treatment or prevention of anthrax disease, which can potentially 
provide high immunogenicity in vaccines and therapeutic activity in antitoxic therapy. The 
lyophilized protein formulated with common excipients was stored for about 8 years at 
refrigerated temperature. In my study, samples were placed at two selected temperatures (40 
and 70 ºC) for one to four weeks, and analyzed by the above mentioned methods. The 
chemical stability (deamidation) was also evaluated using capillary isoelectric focusing 
(cIEF). Results show that the thermally stressed DNI protein retained its native conformation 
at temperatures as high as 70 ºC for one month. The long-term stability of DNI was also 
demonstrated for samples stored at 4 ºC for about 8 years. These data provide valuable and 
encouraging information for development of an alternative recombinant anthrax vaccine 
using a mutated anthrax protective antigen.  
In the second part of my work (Chapters 5, 6), the research focuses on stability 
characterization and formulation of a pneumolysin mutant (L460D), a candidate for a 
vi 
 
pneumococcal vaccine (Chapter 5), and two virus-like particles (VLPs) as candidates for use 
against human filovirus infection (Ebola and Marburg, Chapter 6). In these studies, a three 
step experimental design is employed in the characterization and formulation processes. First, 
the conformational stability of the pneumolysin mutant and VLPs are characterized under 
stressed environmental conditions (pH 3-8 and temperature 10-87.5 ºC) by different 
analytical methods. Second, different types of biophysical data are summarized by using the 
empirical phase diagram (EPD) method, which is also used to define conditions for an 
excipients screening study. Finally, the pharmaceutical excipients are screened and potential 
stabilizers are identified by appropriate assays. In these studies, critical parameters (such as 
solution pH, temperature, ionic strength and stabilizers) affecting the stability of proteins are 
defined. These studies provide a basis for selection of optimized solution conditions for 
further long-term stability studies of pneumococcal antigens and Ebola and Marburg 
virus-like particles, and illustrate the utility of the multimodal spectrometer and EPD analysis 
for vaccine formulation development.  
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1.1 Overview of protein formulation  
Biopharmaceutical products represent a significant and growing proportion of the 
pharmaceutical industry, with more than 200 biopharmaceutical products presently on the 
market. The total global market for protein-based therapeutics is estimated to grow between 
7% and 15% annually over the next several years.
1
 Recombinant therapeutic proteins and 
monoclonal antibody-based (mAb-based) products represent the two biggest protein drugs 
categories, with an estimated market size of $61 billion for recombinant therapeutic proteins 
and $38 billion for mAb-based products in 2009.
2,3
 These drugs are used to treat nearly 150 
diseases, including cancer, infectious diseases, autoimmune diseases and AIDS/HIV1.
4
 In 
2010, 240 mAb products and 120 recombinant proteins were evaluated in clinical trials. 
Protein-based products are likely to represent four of the five top-selling drugs globally by 
2013.
3,5
 With the rapid increase in the biopharmaceutical market, the development of stable 
protein-based dosage forms is critical and a major challenge for pharmaceutical scientists. 
One of the greatest challenges in the formulation development of protein products is 
minimizing their physical and chemical instabilities during manufacturing, storage, and 
administration. The structural complexity of protein drugs has a significant impact on the 
development of stable protein-based therapeutics and vaccines. Proteins differ from 
conventional small molecule chemically synthesized drugs with respect to many properties, 
such as size, shape, conformation, amphotericity and heterogeneity of structures.
6
 The 
complexity of protein molecules means that there are many potential physical and chemical 
degradation pathways such as conformational changes including unfolding and aggregation, 
as well as chemical changes such as hydrolysis, deamidiation and oxidation, all of which can 
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shorten the drug’s shelf life and decrease its potency.
7
 Physical and chemical stresses such as 
temperature, pH, agitation, light, pressure, oxidants and certain solutes can all cause 
degradation of proteins, and hence, protein-based drugs.     
To maintain the stability and activity of protein-based drugs during pharmaceutical 
development processes, a procedure name as “formulation” is performed. During this process, 
the protein of interest at the appropriate concentration is mixed with certain 
pharmacologically inactive ingredients (known as “excipients” when they are actually 
included in a formulation), which are used to enhance stability and solubility of drugs. 
Protein drugs are usually formulated in liquid solution or solid-state (e.g. lyophilized or spray 
drying) forms. The simplest and most economical way, however, is to develop a solution 
formulation. During liquid formulation development, the protein of interest is mixed with 
certain excipients in selected solution conditions. Formulation studies should address the 
effects of various factors such as temperature, solution pH, buffer ion, salt, protein 
concentration and excipients on stability, as well as their effects on solubility.
8
 Although not 
addressed in the present work, other studies including photostability, agitation, and 
freeze-thaw cycling are also usually performed to evaluate the effect of other stresses. 
Preservative studies are also performed if the protein product is intended for multidose use 
with the preservative used to prevent microbial growth. Finally, material compatibility studies 
must be performed with containers or delivery or other medical devices to test the adsorption 
potential of a protein to surface present.
8,9
 The stabilizing effects of the above factors can be 
monitored by a wide variety of different analytical methods. Because proteins are complex 
molecules and a variety of environmental stresses can produce instability in proteins, a 
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number of separate analytical methods such as described below must be applied for protein 
characterization and formulation processes.  
An extensive physicochemical characterization of a protein forms the basis for the 
development of a stable formulation by using different analytical methods. The development 
of analytical methods usually starts with studies referred to as “preformulation”. 
Preformulation studies are used to understand the physico-chemical characteristics of a 
protein molecule and better understand which formulation conditions would be most suitable 
to maintain the stability of proteins.
10
 During preformulation, a wide variety of methods such 
as spectroscopic, hydrodynamic, calorimetric, electrophoretic, chromatography and mass 
spectrometry techniques are used to characterize the macromolecule systems. The selection 
of methods used for an individual protein is determined by the properties of the protein and 
the design criteria for the formulation.
10
 This analysis should detect the most common 
degraded forms of proteins, such as an unfolded protein, soluble and insoluble aggregates, 
and chemical modified proteins through reactions such as hydrolysis, deamidation and 
oxidation. The wide range of the methods selected for such analyses will provide different 
types of information. Typical physical and biological properties monitored include
6,10
:  
 Size: Studied by methods such as sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), size exclusion chromatography (SEC), light scattering, 
analytical ultracentrifugation (AUC), and mass spectrometry (MS). 
 Charge: Studied by methods such as isoelectric focusing (IEF), ion exchange 
chromatography (IEC) and Zeta-potential measurement. 
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 Conformation: Studied by methods like circular dichroism (CD), FTIR, ultra-violet 
(UV) absorbance, fluorescence, differential scanning calorimeter (DSC), SEC and 
MS. 
 Biological activity: Studied by various types of bioassays and specific binding assays 
to molecular and cellular targets.  
Changes in chemical properties can also be monitored by various analytical techniques. For 
example, deamidation of asparagine (Asn) and/or glutamine (Gln) side-chains is a common 
chemical change that can be monitored by IEF, IEC and MS techniques. Similarly, the 
oxidation of methionine and other amino acid residues can be detected by reverse-phase 
chromatography, hydrophobic interaction chromatography and MS techniques. Both types of 
analyses can now usually performed by a combination of LC and MS after proteolysis of a 
protein (peptide mapping). In summary, different techniques are used to characterize the 
stability of proteins comprehensively, and the selection of appropriate methods is critical for 
the development of stable drug formulations.  
1.2 Specific aims and chapter summaries 
1.2.1 Development of a high throughput method for biophysical characterization of   
protein stability 
As described above, for preformulation studies, the physical stability of macromolecules 
is often investigated by a combination of various techniques that can provide insight into 
different types of protein structure (primary, secondary, tertiary and quaternary), although any 
one technique can only offer a limited amount of the desired information. Therefore, several 
techniques are usually combined to obtain a better understanding of the system. Commonly 
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used spectroscopic techniques include UV absorbance, near and far UV CD, FTIR 
spectroscopy, intrinsic and extrinsic fluorescence as well as various forms of light scattering 
measurements. These measurements of protein stability are often performed as a function of 
environmental stresses such as temperature, pH or unfolding agents. Under these stressed 
conditions, an accelerated stability study will provide useful information on the stability of 
proteins with respect to these stresses. These accelerated stability studies can help us evaluate 
the long-term stability of protein drugs under selected formulation, storage and processing 
conditions.  
Spectroscopic experiments are typically performed on individual, single function 
instruments which can be quite expensive to purchase and maintain, and require large 
quantities of sample, and often result in long total data acquisition times. With the 
development of new technologies, multifunctional instruments are currently being developed 
by several vendors. One such instrument is the Applied Photophysics Chirascan-plus circular 
dichroism spectrometer which can acquire CD, UV absorption/optical density and 
fluorescence spectra. There is, however, no analytical method currently available to 
simultaneously acquire these spectroscopic data due to methodological constraints. For 
example, collecting both near and far UV CD data in a single spectroscopic scan has not been 
performed previously since the aromatic CD signals are much weaker than those in the 
peptide-sensitive far UV region.
11,12,13
 Thus, near UV CD spectrum acquisition typically 
requires higher protein concentration and longer cell path lengths. Successful simultaneous 
collection of near and far UV CD, UV absorbance and fluorescence spectra would therefore 
require a suitable cell path length, protein concentration and instrument parameter settings. 
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Therefore, a new analytical method needs to be developed to collect different types of 
biophysical data simultaneously and thus save experimental sample and time.  
In chapter 2, I propose a sensitive method using the Chirascan-plus instrument and a 
modest amount of protein sample to investigate protein stability by simultaneous collection of 
different types of data as a function of temperature (10-87.5
o
C) and pH (3-8). The method 
was developed by examining the thermal and pH stability of four model proteins (bovine 
serum albumin (BSA), lysozyme, α-chymotrypsin and aldolase).
14
 This method permits the 
collection of high quality near-far UV CD, UV absorption and optical density data 
simultaneously in a single sample run. Fluorescence emission spectra were also collected 
using this instrument in a subsequent experiment. Results demonstrate reproducible and 
accurate results from this single instrument, with rapid data collection and minimal protein 
sample requirements. The resulting method was sensitive, reproducible and robust when used 
to investigate the physical stability of proteins.  
I also illustrate the application of this method to the generation of empirical phase 
diagrams (EPDs) to better characterize the overall conformational stability of proteins. The 
empirical phase diagram (EPD) was constructed as described previously
15-16
 to summarize 
and facilitate the analysis of the complex data sets obtained. The EPD is used to identify 
coherent parameter regions that define protein structural states as a function of solution 
variables (temperature and pH in this case). The EPD approach has previously been applied 
to various macromolecule systems (e.g., proteins, DNA, viruses, and virus-like particles).
16
 In 
brief, the normalized experimental data at each coordinate (i.e., at specific temperature and 
pH combinations) are first converted into an N-dimensional vector, where N refers to the 
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number of variables included (i.e., number of different types of data). The complete data sets 
from all measurements are then defined as multi-dimensional vectors in a temperature/pH 
phase space. Projectors of each individual vectors are calculated and summed into an N × N 
density matrix. By definition, an N × N matrix has N sets of eigenvalues and eigenvectors. By 
applying the principal components analysis, the individual vectors at each coordinate are 
truncated into 3-dimensional vectors and re-expanded into a new basis set consisting of the 
three eigenvectors corresponding to the three largest eigenvalues. The resultant 3-dimensional 
vectors are used to construct an empirical phase diagram using a red, green, and blue (RGB) 
color system. Regions of similar color indicate similar protein conformational states under 
the investigated conditions.   
The newly developed methodology using simultaneous data collection linked to EPD 
analysis permits evaluation of protein conformational stability in a single process. The 
rapidly acquired data set provides a more complete assessment of a biomolecule’s physical 
stability, including effects on secondary and tertiary structure as well as aggregation behavior, 
as a function of a variety of environmental stresses. This new approach facilitates the rapid 
characterization of protein structure and stability in a single procedure. It is useful for 
analysis of unknown proteins as well as for screening of solution conditions to optimize 
stability for protein therapeutic drug candidates.  
1.2.2 Application of the high throughput method for the biophysical characterization of 
protein stability. 
After successful method development in section 1.2.1, the multi-measurement method is 
used to characterize the stability of several macromolecular systems, including (1) anthrax 
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recombinant protective antigen (rPA) and its 2-fluorohistidine (2-FHis) labeled analogue 
(2-FHis rPA); (2) ricin toxin A-chain (RTA) and 22 of its single, double and triple mutants. 
My colleague Justin Thomas and I applied this new approach successfully to characterize the 
stability and differentiate stability differences between RTA and many of its mutants. Detailed 
information and results will be presented in future papers. The successful application of the 
method to the characterization of these vaccine candidates demonstrates the utility of the 
method for analysis of unknown proteins. The reproducibility, sensitivity and robustness of 
the method are also demonstrated.  
Protective antigen (PA) is non-toxic but a key component of the anthrax toxin. It forms 
pores within the low pH environment of host endosomes, which is crucial for the 
pathogenesis of anthrax.
15,16,17
 It is also a primary component of current and developing 
anthrax vaccines. A novel analogue of PA designated 2-fluorohisidine protective antigen was 
recently found to have the capability to block the key step of pore formation. The analogue 
was synthesized by incorporating the unnatural amino acid 2-fluorohistidine (2-FHis) into 
rPA.
18
 This replacement was found to block low pH-induced pore formation with cells 
protected from the lethal effects of the toxin
19,20
, suggesting that the 2-FHis rPA could  
potentially be used as an antitoxin or a vaccine to treat or prevent anthrax infections. In this 
study, we examined the effect of 2-fluorohistidine labeling of rPA on its stability and 
dynamics by the various spectroscopic and light scattering techniques described in section 
1.2.1. Physical stability profiles of the two proteins (rPA and 2-FHis rPA) were created by 
using the empirical phase diagram (EPD) approach, and the stability differences between 
them were identified. Sensitive dynamic measurements of the proteins at pH 5 were also 
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performed using red edge excitation and high resolution ultrasonic spectroscopy techniques. 
The stability and dynamic characterization data provided information to better understand the 
similarities and differences of properties between the two proteins. These data were used to 
further the formulation development of the potential vaccine and/or antitoxin candidate 
2-FHis rPA with regards to selection of optimized solution conditions.  
1.2.3 Analytical characterization and adjuvant studies of dominant negative inhibitor as 
an anthrax vaccine 
In Chapter 4, the stability of a dominant-negative inhibitor (DNI) based on rPA was 
characterized under stressed conditions at elevated temperatures. DNI is a 
translocation-deficient mutant of PA with double mutations of K397D and D425K.
21
 This 
mutant strongly inhibits toxin action in cell culture and in an animal intoxication model, and 
is more immunogenic than PA in a mice study.
22
 These previous results suggest that DNI has 
the potential to be used as an antitoxin and/or as a potent immunnogen for anthrax therapy. 
To evaluate the structural integrity of DNI after eight years of storage, an accelerated stability 
study was performed. In this study, samples were placed at two selected temperatures (40 and 
70 ºC) for one to four weeks, and analyzed by different techniques. The lyophilized DNI 
proteins were reconstituted with water and then prepared in citrate phosphate buffers for 
biophysical characterization. Analytical methods include the techniques developed in section 
1.2.1 and others such as SDS-PAGE, static light scattering, dynamic light scattering as well 
as micro flow imaging techniques. Results showed that the thermally stressed DNI protein 
retained completely native conformation to temperatures as high as 70 ºC for one month. 
Long-term stability of DNI was also demonstrated after refrigerated storage for about 8 years. 
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Studies of DNI with aluminum adjuvants were further performed to study antigen/adjuvant 
interactions and the stability of DNI on the surface of the adjuvant. Because purified 
recombinant proteins are usually not highly immunogenic, an adjuvant is usually used to 
boost their immunogenicity.  
1.2.4 Physical characterization and formulation development of a recombinant 
pneumolysin mutant protein based pneumococcal vaccine 
In Chapter 5, the characterization and formulation development of a recombinant 
pneumolysin mutant protein was performed. Streptococcus pneumoniae (pneumococus) is a 
major cause of death, especially in children, due to fatal infections.
23,24,25
 Pneumococus has 
more than 90 known serotypes, which vary by geographical location. Pneumolysin, a 
sulfhydryl-activated cytolytic toxin, is produced by all invasive strains of S.pneumoniae and 
considered a putative virulence factor.
26,27,28,29
  
It has been shown to be immunogenic
30,31
 and 
has the potential to be used as a vaccine. To develop a stable pneumolysin vaccine, the 
conformational stability of a recombinant pneumolysin (L460D) was characterized by various 
spectroscopic and light scattering techniques over a wide pH and temperature range. 
Temperature/pH empirical phase diagrams (EPDs) of the pneumolysin was constructed to 
summarize the large volume of data generated. Excipient screening to identify protein 
stabilizers was performed using intrinsic fluorescence, static light scattering and differential 
scanning calorimetry (DSC). The stability of pneumolysin on the surface of alhydrogel was 
also examined in the presence and absence of excipients. Finally, an optimal formulation was 
identified which balances the physical stability of pneumolysin with its solution osmolality. 
This suggested formulation is now being used in animal studies.   
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1.2.5 Biophysical characterization and conformational stability of Ebola and Marburg 
virus-like particles 
The filoviruses, Ebola (EBOV) and Marburg (MARV), cause severe hemorrhagic fever 
with up to 90% human mortality.
32,33,34
 Virus-like particles of EBOV (eVLPs) and MARV 
(mVLPs) are attractive vaccine candidates, because they are safe, nonreplicating, easy to 
produce and can be used directly as immunogens.
35,36,37
 To further the development of stable 
version of these vaccines, the conformational stability of these two enveloped VLPs produced 
in insect cells was characterized by various spectroscopic techniques over a wide range pH 
and temperature. Temperature-induced aggregation of the VLPs at various pH values was 
monitored by light scattering. Temperature/pH empirical phase diagrams (EPDs) of the two 
VLPs were constructed to summarize the large volume of data generated. The 
characterization data and conformational stability profiles from these studies provide a basis 
for selection of optimized solution conditions for further vaccine formulation and stability 
studies of Ebola and Marburg VLPs. 
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2.1 INTRODUCTION 
One of the greatest challenges in the formulation development of protein-based 
therapeutics and vaccines is minimizing their physical and chemical instabilities during 
manufacturing, storage and administration.
1,2
 Protein instability can lead to problems such as 
aggregation and chemical degradation that can shorten the drug’s shelf life and decrease 
potency. The physical stability of macromolecules is often investigated by a combination of 
various spectroscopic and calorimetric techniques that each provides a certain insight into the 
behavior of different types of protein higher-order structure (secondary, tertiary and 
quaternary). Therefore, several techniques are usually combined to obtain a better 
understanding of the overall conformational stability of a protein. Commonly used 
spectroscopic techniques include ultra-violet (UV) absorbance, near and far UV circular 
dichroism (CD), FTIR spectroscopy, intrinsic and extrinsic fluorescence as well as various 
forms of light scattering measurements. These measurements of protein stability are often 
performed as a function of environmental stresses such as temperature, pH or unfolding 
agents.   
Spectroscopic experiments are typically performed on individual, single function 
instruments which can be quite expensive to purchase and maintain, require large quantities 
of sample, and often result in long total data acquisition times. With the development of new 
analytical technologies, however, measurements previously performed on separate 
instruments can now potentially be performed on a single device. Such multifunctional 
instruments are currently being developed by several vendors. One such instrument is the 
Applied Photophysics Chirascan-plus circular dichroism spectrometer, which can acquire CD, 
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UV absorption/optical density and fluorescence spectra, although currently it is primarily 
used for CD applications. 
There is, however, no currently available method to simultaneously acquire these 
spectroscopic data due to methodological constraints. For example, collecting both near and 
far UV CD data in a single spectroscopic scan has not been performed previously since the 
aromatic CD signals are much weaker compared to the peptide-sensitive far UV region.
3-5
 
Thus, near and far CD measurements must be performed separately. Typical cell path lengths 
used for far UV CD measurements are in the range of 0.01 to 0.1 cm with protein 
concentrations between 0.1 to 1.0 mg/ml. In contrast, the near UV  region requires a typical 
path length of 0.5 to 2 cm and protein concentrations of 0.5 to 2.0 mg/ml.
4
 
Successful simultaneous collection of near and far UV CD, UV absorbance and 
fluorescence measurements would therefore require a suitable cell path length, protein 
concentration and instrument parameter settings. In principal, it is difficult to find an 
acceptable tradeoff between concentration and cell path length, because both parameters have 
the same effect on absorbance. Longer path lengths and higher concentrations produce excess 
absorbance, which can lead to photomultiplier tube saturation and absorption flattening 
among other potential problems. In contrast, shorter path lengths and lower concentrations 
yield too little signal to permit collection of quality near UV CD and UV absorbance spectra. 
In fact, simultaneously collected near and far UV CD spectra during a single spectral run 
have never been successfully accomplished to the best of our knowledge. 
In this work, we propose a sensitive method using the Chirascan-plus instrument and a 
modest amount of protein sample to investigate protein stability by simultaneous data 
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collection of different types of information as a function of temperature and pH. This method 
permits the collection of high quality CD data in the near and far UV regions in a single 
sample run. We also use this method to simultaneously collect high resolution UV absorption 
spectra and light scattering data by measuring the optical density at 350 nm. Fluorescence 
emission spectra were also collected using this instrument in a subsequent experiment. The 
large sets of data obtained were combined into an “empirical phase diagram” (EPD) that 
summarizes all of the data collected into a form of colored diagram which displays structural 
changes induced by environmental stresses such as pH, temperature, protein concentration 
and solution ionic strength. The EPD approach has previously been applied to various 
macromolecule systems (e.g., proteins, DNA, viruses, and virus-like particles).
6
 The newly 
developed methodology using simultaneous data collection linked to EPD data analysis 
permits evaluation of protein conformational stability in a single process, enabling the 
acquisition of maximal information from a minimum amount of sample and experimental 
time. This rapidly acquired data set provides a more complete assessment of a biomolecule’s 
physical stability, including effects on secondary and tertiary structure as well as aggregation 
behavior, as a function of a variety of environmental stresses. The collection and evaluation 
of large data sets of lower-resolution biophysical data by high throughput methods offers an 
alternative, more generally accessible practical approach to rapidly evaluate protein structural 
integrity compared to higher resolution techniques such as X-ray crystallography and NMR. 
From a pharmaceutical perspective, this approach also offers the advantages of examining 
protein conformational stability in different formulation buffers in a high throughput manner 
with low sample requirements.  
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2.2 EXPERIMENTAL SECTION 
2.2.1 Materials. 
Four well characterized model proteins were used including bovine serum albumin 
(BSA), lysozyme (chicken egg white), α-chymotrypsin (bovine pancreas) and aldolase (rabbit 
muscle). Their secondary structure contents range from α-helix dominant to β-structure rich 
and their thermal transition temperatures vary from high to low (Supplemental Table 1). 
Proteins were purchased from Sigma-Aldrich (St. Louis, MO). Protein samples were prepared 
in 20 mM citrate phosphate buffer ranging from pH 3 to 8, at one pH unit intervals with the 
exception of aldolase which was prepared in the same buffer ranging from pH 5 to 8 (due to 
irreversible unfolding at pH values less than 4.5
7,8
). The ionic strength of the solutions was 
adjusted to 0.15 with sodium chloride. Samples of lysozyme, α-chymotrypsin and aldolase 
were dialyzed at 4 
o
C using Slide-A-Lyzer dialysis cassettes (Thermo Scientific, Rockford, IL) 
with a 3.5 kDa MW cutoff before measurements. BSA samples were prepared by dissolving 
sample into a specific pH citrate phosphate buffer, because of its high purity (98%). 
2.2.2 Instrumentation and Instrumental Conditions. 
CD, UV absorbance, optical density (OD) at 350 nm and fluorescence measurements 
were performed with the Chirascan-plus Circular Dichroism Spectrometer (Applied 
Photophysics Ltd, Leatherhead UK). The design features of the Chirascan-plus include a 
unique F/7 dual polarizing double prism monochromator and a solid state detector which 
permit higher light throughput and better detector quantum efficiency. Both of these factors 
contribute to improved signal to noise ratios. This instrument is equipped with a Peltier 
temperature controller and a 4-position cuvette holder. UV absorption spectra, light scattering 
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(OD at 350 nm), as well as near and far UV CD data were collected simultaneously. In a 
separate experiment, fluorescence emission spectra were also collected on this instrument.  
2.2.3.1 Optimization and Collection of Near UV CD Spectra of BSA. 
Instrument and sample parameters were investigated to optimize cell path length and 
protein concentration (Supplemental Table 2). Near UV CD spectra of BSA were collected in 
the range of 250-320 nm with a sampling time per wavelength of 4 sec and step size of 0.5 
nm. Filters were placed in front of the CD cell holders on the incident light direction. Criteria 
for spectra improvement included evaluation of peak resolution and signal to noise ratios. 
The initial optimized parameters obtained from BSA were selected as a starting point for 
evaluation of the other model proteins. Buffer blank scans were subtracted from BSA sample 
scans for linearity calculations. For the simultaneous near-far UV CD measurements 
described below, buffer blanks were not used since fluctuations in signal intensity from buffer 
scans may obscure some of the weak, finely structured peaks in the near UV region.
5
  
2.2.3.2 Optimization and Collection of Near-far UV CD Spectra of Four Model Proteins. 
To optimize protein concentration (0.2, 0.3, 0.4 and 0.5 mg/mL), the near and near-far 
UV CD spectra of BSA, lysozyme and α-chymotrypsin were collected separately at pH 7. Two 
instrumental parameters (step size and sampling time per wavelength) were optimized to reduce 
the measurement time without loss in reproducibility of the finely structured peak information 
in the near UV. The CD spectra of protein at pH 7 were recorded as a function of temperature 
(10 to 87.5 ºC) at 2.5 ºC intervals. Further optimization of sampling time, step size, and protein 
concentration was carried out by evaluating the thermal transition midpoint temperature (Tm) of 
the model proteins. Tm values were calculated using a Boltzmann function to produce a 
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sigmoidal curve using Origin 8.1 software. 
2.2.3.3 Simultaneous Collection of CD and UV Absorbance Data to Determine the Tm of 
Four Model Proteins.   
Near and far UV CD spectra of BSA (0.55 mg/mL), lysozyme (0.4 mg/mL), 
α-chymotrypsin (0.4 mg/mL) and aldolase (0.5 mg/mL) were collected from 200 to 360 nm 
using a 0.2 cm path length cuvette. An optimized sampling time of 3 sec, bandwidth of 1 nm, 
and step size of 1 nm were used, along with a heating rate of 1 ºC/min and equilibration time 
of 1 min at each temperature. The CD spectrum of each protein was recorded in triplicate as a 
function of temperature (10 to 87.5 ºC) and pH (3 to 8), except for aldolase samples which 
were measured from pH 5 to 8. In the data analysis, specific CD signals (peaks) in the near 
and far UV regions were monitored and smoothed using the Savitsky-Golay method (window 
size 3) using the Pro-Data Chirascan 4.1 (Applied Photophysics Ltd.) software. The Tm value 
was calculated using a non-linear curve fit (Boltzmann function) of thermal unfolding curves 
executed in Origin 7.0 software. The UV absorbance spectrum and light scattering data (OD 
350 nm) were obtained simultaneously with the CD spectrum using the same experimental 
parameters. 
2.2.3.4 Collection of Intrinsic Fluorescence Thermal Data of Four Model Proteins.   
The Chirascan-plus Circular Dichroism Spectropolarimeter has a fluorescence 
detector mounted at 90
o
 that can measure emission spectra. In separate experiments, the 
intrinsic fluorescence of the four model proteins was monitored using the same 
concentrations and temperature ramp program used in the CD measurements (section 2.3.3). 
Dual path length quartz fluorometer cells with an interior width (2 mm) and length (10 mm) 
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were used, and excitation of the proteins was carried out along the shorter path length axis (2 
mm). Samples were measured in triplicate using an excitation wavelength of 295 nm (>95% 
tryptophan emission). Emission spectra were collected from 310 to 400 nm using a 1nm step 
size. The excitation and emission slits were set at 3 and 9 nm, respectively. The position of 
the emission wavelength maximum was determined using a polynomial derivative fitting 
method executed in Origin 7.0 software.  
2.2.4 Collection of Spectroscopic Data from Separate Instruments. 
Various spectroscopic data from individual instruments were collected with BSA over 
the same temperature and pH ranges, and protein concentration (0.55 mg/ml), as employed 
above. Far-UV CD spectra were collected with a Jasco-810 Spectrophotometer (Jasco Inc., 
Easton, MD). Near-UV CD data were collected in the Chirascan-plus instrument. The 
intrinsic fluorescence spectra of BSA were measured using QuantaMaster Spectrofluorometer 
(Photon Technology International Inc., Birmingham, NJ). Optical density measurements were 
obtained using a Cary 100 UV-Visible Spectrophotometer (Varian Inc., Palo Alto, CA) with a 
cell path length of 1 cm. The same cells were used in the Chirascan experiments to minimize 
cell variability.  
2.2.5 Empirical Phase Diagram 
Empirical phase diagrams (EPDs) can be used to summarize the large amounts of data 
generated from multiple techniques and to visualize macromolecular stability as a function of 
various stress variables. A detailed description of EPD construction and interpretation is 
described elsewhere.
6
 EPDs are used to identify coherent parameter regions that define 
similar structural states. Regions of similar color correlate similar protein structures such as 
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native, molten globule, or aggregated states. Transitions between states are manifested as 
changes in colors; apparent phase boundaries can be identified based on color changes. 
Specific colors, however, do not possess meaning other than to identify areas of different 
protein behavior. 
2.3 RESULTS AND DISCUSSION 
2.3.1 Optimization and Collection of Near UV CD Spectra of BSA  
Optimization of concentration, path length and other instrumental parameters was first 
performed with BSA to obtain high-quality near CD spectra. Typical near UV CD spectra of 
BSA at different protein concentrations (0.2, 0.4, 0.6, 0.8 and 1.0 mg/ml) and cell path 
lengths (10, 4, and 2 mm) are shown in Figures 1A and 1C, respectively. There are two 
distinct minima at 261.5 and 268.5 nm observed in the near UV CD spectrum of BSA. These 
peaks arise from phenylalanyl side chains.
9,10 
As expected, CD signals decrease with 
decreasing protein concentration and cell path length. Although the near UV CD bands are 
weak, they are well resolved (Figure 1D). The repeatability of the triplicate measurements 
showed spectral overlap with each other after data smoothing. Similar experiments were also 
performed at 0.2 mg/ml BSA in a 2 mm (Figure 1B) and 0.4 mg/ml BSA in a 1 mm path 
length cell, but CD bands under these conditions were not always adequately resolved and 
had poor reproducibility. Signal to noise ratio was also low (e.g. CD peak at 268.5 nm in 
Figure 1B).  
The linearity of the CD signals at different BSA concentrations using the 2 mm path 
length cell (Figures 1E and 1F) was excellent (r
2
= 0.997, at both 261.5 and 268.5 nm). The 
linearity of the CD signals at different cell path lengths using 0.4 mg/ml BSA (Figures 1G and 
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1H) was also excellent (r
2
= 0.999, at both 261.5 and 268.5 nm). Increases in bandwidth had no 
apparent effect on the intensity of the CD signal, but some differences in spectral shape were 
observed. For example, the CD spectrum using a 4 nm bandwidth lost fine structure compared 
with that using a smaller bandwidth, while decreasing the bandwidth to 0.5 nm decreased the 
signal to noise ratio (Supplemental Figure 1).  
 
 
Figure 1. Near-UV CD spectra of BSA. (A): Different BSA concentrations with 2 mm cell path 
length. (B): 0.2 mg/ml BSA shown separately with an expanded view. (C): Different cell path 
lengths at 0.4 mg/ml BSA. (D): 0.4 mg/ml BSA using 2 mm cell path length shown separately 
with an expanded view. The linearity plots are shown from Figures 1E to 1H. The bandwidth 
was 1 nm. Linearity was calculated from data as described in text.  
 
Based on these results, the experimental parameter combination of protein concentration 
(0.4 mg/ml), cell path length (2 mm), sampling time (4 sec), step size (0.5 nm) and 1 nm 
bandwidth produced optimally well-resolved and reproducible CD peaks (Figure 1D). Although 
higher protein concentrations and longer cell path lengths can increase the CD signal in the near 
UV region, these changes negatively impact the far UV CD signal due to high absorption.  
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2.3.2 Optimization and Simultaneous Collection of Near and Far UV CD Spectra of 
Model Proteins. 
Besides tertiary structural information obtained in the near UV CD data described above, 
the far UV region of a CD spectrum (190-250 nm) primarily contains signals from peptide bond 
absorption and thus provides information about the secondary structure of a protein.
4  
The 
combined near and far UV CD spectra of three model proteins (BSA, lysozyme and 
α-chymotrypsin) at different concentrations (0.2, 0.3, 0.4 and 0.5 mg/ml) were collected using 
the optimized experimental parameters described above. At the lowest concentration tested (0.2 
mg/ml), the CD signals for each protein were not always well resolved (data not shown). At 
higher protein concentrations, good quality CD spectra were obtained covering both far and 
near UV regions in a single run, although lysozyme and α-chymotrypsin possessed lower 
signal-to-noise ratios (in the range of 200-210 nm at 0.5 mg/ml).  
Two instrumental parameters (sampling time per wavelength and step size) were also 
further optimized to reduce overall scanning times. When sampling time was changed from 4 to 
3 to 2 seconds (at 1 mg/ml protein), protein thermal transition (Tm) values for three model 
proteins were both precise and accurate (data not shown). At lower protein concentrations (0.4 
or 0.3 mg/ml), Tm values of the three model proteins were reproducible with the exception of 
the 2 second integration times (data not shown). After choosing a suitable sampling time (3 sec), 
the effect of increasing the step size from 0.5 to 1.0 nm was investigated. Two different protein 
concentrations were compared for BSA (0.6 and 0.5 mg/ml) and lysozyme and α-chymotrypsin 
(0.3 and 0.4 mg/ml). Reproducibility of results was not lost by decreasing sampling time and 
increasing step size, and overall results showed CD signals had excellent precision at lower 
protein concentrations. Typical protein stability (Tm) results for BSA with these different 
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experimental variables are summarized in Supplemental Table 3.  
After optimization, final parameters are as follows: cell path length of 2 mm, sampling 
time of 3 sec, step size of 1 nm, and bandwidth of 1 nm. The concentration may vary from 0.4 
to 0.6 mg/ml depending on the value of a protein’s extinction coefficient. Typical near-far UV 
CD spectra of the four model proteins at 0.4 or 0.5 mg/ml and 10 ºC are shown in the Figure 2. 
In the far UV region (190-250 nm), CD spectra of both BSA and aldolase (Figures 2A and G) 
manifest a strong double minimum at approximately 222 and 208-210 nm, consistent with both 
proteins containing the predicted significant amounts of α-helix. Lysozyme (Figure 2C) also 
showed two negative CD bands at 222 and 209 nm, but the 209 nm band has a larger intensity 
than the 222 nm signal suggesting the presence of both α-helices and β sheets.
11,12
 The CD 
spectrum of α-chymotrypsin (Figure 2E) contains two negative CD bands near 207 and 230 nm, 
which are characteristic of β-II proteins.
11,13
 α-chymotrypsin belongs to the β-II protein class 
and contains a significant amount of β-sheet structure which is either highly distorted or made 
up of short, irregular β strands.  
In the near UV region (250-320 nm), contributions of aromatic side chains are often 
utilized as sensitive probes of protein conformation. Additionally, distinctive vibronic fine 
structures make it possible in many cases to assign specific features in the near-UV CD to 
particular types of amino acid residues. In Figure 2 (Figures 2B, D, F, H), several distinct CD 
bands of the four model proteins are present in this near UV region. Generally, the CD bands at 
262, 266 and 269 nm arise from the phenylalanyl side chains and the band near 282 nm from 
tyrosyl residues. The CD bands at 288 and 289 nm can be attributed to tryptophanyl and/or 
tyrosyl side chains while the CD band near the 296 nm arises from indole groups.
5  
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Figure 2. Near and far UV CD spectra for four model proteins collected simultaneously. 
Near-far UV CD spectra of (A) 0.55 mg/ml BSA and (B) expanded view of its near UV region; 
(C) 0.4 mg/ml lysozyme and (D) expanded view of its near UV region; (E) 0.4 mg/ml 
chymotrypsin and (F) expanded view of its near UV region; (G) 0.4 mg/ml aldolase and (H) 
expanded view of its near UV region. 
 
2.3.3 CD Thermal Unfolding Measurements.   
Using the optimized instrument and sample parameters described above, the physical 
stabilities of the model proteins were investigated as a function of pH and temperature 
employing the multimodal spectrometer. These experiments used only 200-250 µg of protein 
sample and near- and far-UV CD data were collected simultaneously in about 4.5 hours 
(200-360 nm from 10 to 87.5 ºC).  Typical thermal unfolding curves of BSA and three other 
proteins at pH 7 are shown in Figure 3 and Supplemental Figures 2-4, respectively. Triplicate 
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measurements produced good reproducibility as indicated by the error bars. As expected, the 
model proteins lose both secondary and tertiary structure with increasing temperature. Based on 
the observed effects on the Tm of model proteins, as monitored in both the near and far UV 
regions of the CD spectra, the order of protein stability was as follows: α-chymotrypsin < 
aldolase < BSA < lysozyme (Table 1). The estimated Tm values for each model protein were 
very similar to those obtained in previous work.
14-17
 For BSA, lysozyme and α-chymotrypsin, 
similar Tm values were obtained from both near and far UV regions. For aldolase, the Tm value 
evaluated from the far UV CD was higher than those obtained in the near UV region, 
suggesting that a molten globule like state exists between these temperatures. Molten globules 
generally possess native-like secondary structure but lack significant tertiary structure.  
 
Figure 3. Thermal stability of BSA (0.55 mg/ml at pH 7) as monitored by CD signals at 222, 
262 and 269 nm as a function of temperature. Each data point represents the mean of three 
independent runs with error bars showing the standard deviation. The Tm value was 
calculated separately then averaged and standard deviation determined.  
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Protein 
Tm (far 
UV CD) 
(OC) 
Tm (near UV CD) (
OC) 
Tm 
(literature) 
(
O
C) 
BSA 64.2 ± 0.3 
64.1 ± 0.6 (262 nm)  
63.4 ± 0.5 (269 nm) 
61.8(15) a 
Lysozyme 75.5 ± 0.4 
73.6 ± 0.4 (261 nm)  
75.6 ± 0.5 (282 nm) 
75.7 ± 1.1 (289 nm)  
76.3 ± 1.3 (295 nm) 
74.0(16) a 
Chymotrypsin 46.0 ± 0.5 
46.3 ± 0.5 (261 nm)  
46.0 ± 0.7 (266 nm) 
48.6 ± 0.5 (288 nm)  
47.1 ± 1.2 (297 nm) 
44.0(17) b 
Aldolase 53.9 ± 0.3 
46.1 ± 0.6 (261 nm)  
46.4 ± 0.6 (282 nm) 
47.3 ± 0.4 (289 nm)  
46.7 ± 0.8 (296 nm) 
55.7(18) a 
a: differential scanning calorimetry. 
b: visible/ultraviolet spectrophotometer. 
 
Table 1. Thermal unfolding midpoint temperatures (Tms) for the model proteins BSA (0.55 
mg/ml), lysozyme (0.4 mg/ml), chymotrypsin (0.4 mg/ml), and aldolase (0.5 mg/ml) as 
determined by simultaneous data collection from near and far UV CD measurements. These 
experimentally measured Tm values are compared to Tm values obtained from the literature. 
There are several different Tm values obtained in the near UV CD region by monitoring 
characteristic CD peaks. Experimental parameters are (1) Sampling time per wavelength, 3 sec. 
(2) Step size, 1.0 nm. 
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2.3.4 Simultaneous UV Absorbance Measurements. 
Ultraviolet absorption spectroscopy can also be used to provide information concerning 
protein tertiary structure. By employing second derivative spectra, the overlapping peaks of 
phenylalanine, tyrosine, and tryptophan residues in the 250-300 nm range can be resolved at 
high resolution.
18
 Typical second derivative UV absorbance results for 0.4 mg/ml 
α-chymotrypsin are shown in Supplemental Figure 5. The thermal response of all three major 
derivative peak positions showed good reproducibility. For α-chymotrypsin, the Tm values 
obtained from UV absorption measurements (47.2 ± 0.6, 46.9 ± 0.8 and 45.6 ± 1.1 
o
C) are very 
similar to those obtained by near UV CD measurements (46.3 ± 0.5, 46.0 ± 0.7, 47.1 ± 1.2 and 
48.6 ± 0.5 
o
C). In contrast to these results, the other three model proteins did not display 
reproducible results due to low UV absorbance under the experimental conditions employed 
(data not shown). 
Ultraviolet spectroscopy can also be used to monitor the aggregation behavior of a 
protein by recording the optical density in a non-absorbing region of a protein’s UV spectrum 
(>320 nm). Increased scattering intensity is usually a consequence of protein association 
behavior. BSA and lysozyme showed aggregation behavior that was pH dependent with 
increased OD signals appearing at pH 5 and 7-8, respectively. Aldolase manifested aggregation 
behavior over the entire pH range from pH 5 to 8, while no aggregation was observed for 
α-chymotrypsin from pH 3 to 8 (data not shown). Typical optical density results as a function of 
temperature for BSA and other two model proteins at selected solution pH values are shown in 
Figure 4A and Supplemental Figure 6, respectively. 
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Figure 4.  Thermal stability of BSA (0.55 mg/ml) as a function of solution pH. (A) Optical 
density at 350 nm, and (B) Intrinsic Trp fluorescence emission maximum (peak position). Each 
data point represents the mean of three independent samples. 
 
2.3.5 Intrinsic Fluorescence Measurements.   
Intrinsic fluorescence spectroscopy is another common method employed for examining 
the tertiary structure of proteins. Proteins containing tryptophan typically produce strong 
fluorescence emission in the 310-355 nm region with the position of emission maximum very 
sensitive to the polarity of the indole side chain environment.  
Temperature dependent tryptophan fluorescence peak position shifts were observed for 
BSA and the three other proteins as a function of temperature and pH (Figure 4B and 
Supplemental Figure 7, respectively). In general, a red shift in the position of a Trp fluorescence 
maximum indicates increased exposure of Trp residues to a more polar environment, and thus a 
structural change resulting in partial unfolding of the protein. The fluorescence thermal 
unfolding results are overall consistent with the observations made from the CD and UV 
absorption measurements with similar effects of pH and temperature seen on the stabilities of 
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the proteins observed. From these data, it can be seen that BSA, lysozyme, α-chymotrypsin and 
aldolase showed the highest thermal stability at solution pH values of 6, 5, 5-6 and 7-8, 
respectively. 
2.3.6 Empirical Phase Diagrams 
Empirical phase diagrams of the four proteins were generated from the experiments 
described above and used to summarize all of the biophysical data collected. Using the 
Chirascan-plus instrument, the biophysical data were obtained simultaneously in a single scan 
at the individual temperature and pH values (with the exception of fluorescence which was 
collected subsequent to the simultaneous collection of near-far CD, UV and light scattering 
measurements). These results were then compared to EPDs generated from data collected on  
individual instruments. The EPDs of BSA generated from either a single instrument or by 
separate instruments are compared in Figure 5. The EPD from near and far UV CD data only 
(Figure 5A) show very similar defined “apparent” phases when compared with more 
comprehensive EPDs (Figures 5B-C) including CD, optical density and fluorescence data. 
EPDs produced from separate instruments (Figures 5D-F) are also very similar to those 
produced by the simultaneous methodology (Figures 5A-C), and show that data from a single 
multi-function instrument can provide similar results to those obtained from multiple single 
function instruments.  
There are two clear phases existing at low temperature for BSA, as shown in Figure 5A. 
In region 1, samples at pH 4-8 manifest a similar color below about 65 ºC, indicating a similar 
conformation of BSA. Samples at pH 6 show the highest thermal stability, and samples at pH 4 
show the lowest stability. In region 2, samples at pH 3 show a distinct color difference from 
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region 1 indicating the presence of altered structure compared to BSA in region 1. The 
distinction between region 1 and 2 and those at elevated temperature is evident with an apparent 
phase boundary around 65 
o
C at pH 6 which decreases as pH is increased or decreased from this 
value. Samples in the high temperature region are highly structurally altered or aggregated. 
The EPDs were generated for the other three model proteins using the single instrument 
(Supplemental Figure 8). The EPDs generated from the near and far UV CD data alone or 
produced from combined data from CD, fluorescence, optical density and UV absorbance 2nd 
derivative methods were also compared. Interestingly, all three proteins show similar and 
clearly defined “apparent” structural phase changes in both CD and comprehensive EPDs. For 
aldolase, region 4 (green color covering the region from pH 5 to 8) indicates the presence of a 
molten globule-like conformational state during the protein unfolding process. This observation 
is in agreement with the different Tm results obtained in CD measurements (Table 1). 
2.4 CONCLUSIONS 
Using four model proteins, a reproducible, accurate and sensitive method was developed 
to acquire near and far UV CD spectra simultaneously in a single sample. In addition, turbidity 
data and in some cases high resolution UV absorption data can also be obtained at the same 
time. Fluorescence capability was also demonstrated. Thus, different types of spectroscopic data 
can be obtained in a single set of experiments and used to investigate protein stability as a 
function of various types of environmental stresses (pH and temperature in this case). This 
method permits minimal use of protein, and thus saves material, time and resources. A complete, 
reproduced conformational stability profile of a protein as a function of pH and temperature can  
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Figure 5. Empirical phase diagrams of BSA. (A, B, C) EPDs were constructed using the data 
sets obtained from the Chirascan-plus, and (D, E, F) EPDs were generated from data sets 
obtained from the separate instruments. (A) and (D): EPDs were constructed using near and far 
UV CD data. (B) and (E): EPDs were constructed using near-far UV CD and optical density 
data. (C) and (F): EPDs were constructed using near-far UV CD, optical density and intrinsic 
fluorescence data. The apparent phase boundaries were constructed visually and by reference to 
the actual data. Region 1, native like state; region 2, structurally altered state.  
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be obtained within 3 days. We estimate the newly developed method saves at least 40% of 
protein sample and total data acquisition time compared to the same experiments performed on 
separate instruments. 
 Using the optimized instrumental and sample parameters with a 2 mm cell with the 
Chirascan instrument, empirical phase diagrams can be directly constructed from a single 
instrument instead of collecting different types of data from multiple single function 
instruments. This high throughput and robust method can be used to characterize the structural 
integrity and conformational stability of a wide variety of macromolecular systems such as 
proteins, plasmid DNA, viruses and virus-like particles.
6
 Critical solution parameters (e.g., pH, 
temperature and stabilizing and destabilizing solutes) which perturb the stability of 
macromolecules can be rapidly defined. In combination with EPD data analysis, the method can 
be used to characterize the stability of such biological systems as well as compare them in terms 
of various levels of macromolecular structure. This approach can also be used as a high 
throughput analytical strategy to screen for stabilizing agents and thus to design optimally 
stable formulations for protein therapeutic drug candidates.
19
 
2.5. ASSCOCIATED CONTENT
 
Supporting Information. Supplemental Tables 1-3 and Supplemental Figures 1-8.  
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Protein 
MW 
(Da) 
Extinction 
coefficient 
E %1280nm  
Alpha - 
helix % 
Beta - 
structure % 
Tm ºC 
Bovine serum 
albumin (BSA) 
66,267 6.78 67(1) 10(1) 61.8(1) 
Lysozyme  14,390 26.4 45(2) 19(2) 74.0(3) 
α-chymotrypsin 25,263 20.4 10(2) 49(2) 44.0(4) 
Aldolase  160,000 9.38 46(5) 14(5)  55.7(6) 
MW- molecular weight 
Tm- thermal unfolding temperature 
 
 (1) Murayama, K.; Tomida, M. Biochemistry. 2004, 43, 11526-11532. 
   (2) Byler, D. M.; Susi, H. Biopolymers. 1986, 25, 469-487. 
   (3) Liu, Y.; Sturtevant, J. M. Biochemistry. 1996, 35, 3059-3062. 
   (4) Lozano, P.; Diego, T.; Iborra, J. L. Eur. J. Biochem. 1997, 248, 80-85.  
   (5) Sawyer, L.; Fothergill-Gilmore, L. A.; Freemont, P. S.  Biochem J. 1988, 249, 789-793. 
   (6) Beernink, P. T.; Tolan, D. R. Protein Sci. 1994, 3, 1383-1391. 
 
   Supplemental Table 1. Basic biochemical and biophysical properties of four model proteins.   
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Variable parameters Values 
BSA concentration (mg/ml) 1.0, 0.8, 0.6, 0.4, 0.2 
Cell path length (mm) 10, 4, 2 
Bandwidth (nm) 0.5, 1.0, 1.5, 2.0, 4.0 
 
 
Supplemental Table 2. Instrument and sample parameters used in the optimization of experimental 
settings to measure the near UV circular dichroism (CD) spectrum of BSA. 
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Supplemental Figure 1. Near UV CD spectra of 0.4 mg/ml BSA using different bandwidths 
(0.5, 1.0, 2.0 and 4.0 nm). The cell path length was 4 mm. 
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Protein: BSA Tm (222 nm) Tm (261.5 or 262 nm) Tm (268.5 or 269 nm) 
1.0 mg/ml BSA 
(step size 0.5 nm) 
       —* 64.5±0.6 ºC 63.9±0.7 ºC 
0.4 mg/ml BSA 
(step size 0.5 nm) 
64.0±0.6 ºC 63.9±1.0 ºC 63.0±1.0 ºC 
0.5 mg/ml BSA  
(step size 1.0 nm) 
64.5±0.4 ºC 64.8±0.6 ºC 64.0±0.8 ºC 
 
*: 1.0 mg/ml BSA could not produce accurate far UV spectra due to high concentration. 
 
 
Supplemental Table 3. Thermal unfolding midpoint (Tm) values of BSA (0.4, 0.5 and 1.0 mg/ml) 
as monitored at specific near and far-UV CD signals at different step sizes. The Tm values were 
obtained from the non-linear curve fit (Boltzmann function). Experimental parameters are (1) 
Time per wavelength step was 3 sec, and (2) Step size was 0.5 nm for 0.4 and 1.0 mg/ml BSA, 
and 1.0 nm for 0.5 mg/ml BSA. 
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Supplemental Figure 2. Thermal unfolding temperature curves for lysozyme (0.4 mg/ml) as 
monitored by far- and near-UV CD signals (222, 261, 282, 289 and 295 nm) as a function of 
temperature. Each data point represents the mean of three independent runs with error bars 
showing the standard deviation. Tm value was calculated separately, and the three resulting Tm 
values were averaged and the standard deviation determined as shown in figure. 
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Supplemental Figure 3. Thermal unfolding temperature curves for α-chymotrypsin (0.4 mg/ml) 
as monitored by far- and near-UV CD signals (230, 261, 266, 288 and 297 nm) as a function of 
temperature. Each data point represents the mean of three independent runs with error bars 
showing the standard deviation. Tm value was calculated separately, and the three resulting Tm 
values were averaged and the standard deviation determined as shown in figure. 
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Supplemental Figure 4. Thermal unfolding temperature curves for aldolase (0.4 mg/ml) as 
monitored by far- and near-UV CD signals (222, 261, 282, 289 and 296 nm) as a function of 
temperature. Each data point represents the mean of three independent runs with error bars 
showing the standard deviation. Tm value was calculated separately, and the three resulting Tm 
values were averaged and the standard deviation determined as shown in figure. 
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Supplemental Figure 5. (A) UV absorption spectra of α-chymotrypsin, and (B) Second derivative 
UV absorption curve of α-chymotrypsin. (C), (D) and (E): The changes in second derivative peak 
position were plotted as a function of temperature at pH 7. Each data point represents the mean of 
three independent samples. Tm value was calculated separately, and three resulting Tm values 
were averaged and the standard deviation was determined. Protein concentration was 0.4 mg/ml. 
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Supplemental Figure 6. The change in optical density at 350 nm for lysozyme and aldolase were 
plotted as a function of temperature at a specific protein concentration and solution pH. Each data 
point represents the mean of three independent samples with error bars showing the standard 
deviation. 
 
 
 
 
 
 
 
47 
 
 
 
Supplemental Figure 7. Thermal stability of model proteins as monitored by change in intrinsic 
Trp fluorescence emission maximum (peak position) as a function of temperature and solution 
pH for (A) lysozyme, (B) chymotrypsin, and (C) aldolase. Each data point represents the mean 
of three independent samples. 
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Supplemental Figure 8. Empirical phase diagrams of model proteins were generated by 
different data sets obtained from Chirascan-plus. For lysozyme and aldolase, (A): EPD was 
constructed by using far and near UV CD data, (B): EPD was constructed by using near-far UV 
CD and optical density data, and (C): EPD was constructed by using near-far UV CD, optical 
density and fluorescence peak position data. For α-chymotrypsin, (A): EPD was constructed by 
using far and near UV CD data, (B): EPD was constructed by using near-far UV CD and UV 
2nd derivative data, and (C): EPD was constructed by using near-far UV CD, UV 2nd 
derivative and fluorescence peak position data. The apparent phase boundaries were constructed 
visually and by reference to the actual data. 
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Chapter 3 Application of the high throughput method for the biophysical 
characterization of protein stability 
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3.1 INTRODUCTION 
Anthrax, a lethal disease caused by spores of the Gram-positive bacterium Bacillus 
anthracis, attacks mammalian hosts by cutaneous, inhalation and gastrointestinal routes.  
Mortality from anthrax disease is high in untreated cases and varies by infective routes. The 
inhaled form of the disease is the most severe and results from the inhalation of airborne 
spores. The mortality in untreated inhalational anthrax cases is almost 100%.
1
 There are 
recent serious concerns about the inhaled form due to its potential use as a biological 
weapon.
2
 Therefore, major efforts have involved the development of effective anthrax 
countermeasures such as vaccines.  
Protective antigen (PA) is nontoxic by itself but essential for the toxic activity of Bacillus 
anthracis, the causative agent of anthrax. PA is an 83 kDa, four domain multifunctional 
protein, which is recognized by anthrax toxin receptors 1 and 2 on host cells.
3,4
 Following 
receptor binding, PA is cleaved by a furin-like protease to yield a 63 kDa fragment (PA63) 
and an N-terminal 20 kDa fragment (PA20).
5
 Cleaved PA63 assembles on the surface of cells 
into a heptameric
6
 or octameric
7
 donut-shaped structure called a prepore. The prepore 
subsequently combines with edema factor (EF) and lethal factor (LF) to create a number of 
different, but functionally similar, complex toxins such as edema toxin (EdTx) and lethal 
toxin (LeTx). After receptor-mediated endocytosis, and a subsequent conformational change 
in PA from a prepore to a pore in acidified endosomes (pH 5~6), actively toxic proteins EF 
and LF can be translocated through the pore into the cytoplasm of target cells, which results 
in cellular toxicity causing cell killing and host death.
5,8,9,10
 Since PA plays an important role 
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in the pathology of anthrax, yet is a non-toxic and a strongly immunogenic molecule, it is 
used as a primary antigen in anthrax vaccines.  
PA is the protein antigen component in the currently used vaccine and provides a certain 
level of protective immunity against anthrax infection. The licensed U.S. anthrax vaccine 
(AVA, BioThrax) contains predominantly protective antigen adsorbed to aluminum 
hydroxide. It is an effective vaccine for the protection of humans anthrax
5
, however, there are 
limitations of the current AVA vaccine. The AVA vaccine has limited duration of protection, 
and 6 doses are required over 18 months followed by annual boosters.
11
 The AVA is 
composed of PA and an incompletely defined culture supernatant adsorbed to the adjuvant, so 
the vaccine purity is not easily determined. Therefore, there is a need to develop newer 
versions of vaccines such as those based on recombinant PA, which have more defined 
composition and can produce the long-lasting immunity.   
A novel recombinant protein analogue of PA, designated 2-fluorohisidine recombinant 
protective antigen (2-FHis rPA), was recently found to have the capability to block the key 
step of pore formation.
12,13
 The preparation of the 2-FHis rPA analogue was achieved by 
incorporation of the unnatural amino acid 2-fluorohisidine, an isosteric analogue of histidine 
with a significantly reduced pKa (~1)
14
, during fermentation resulting in ten histidine 
residues in rPA being biosynthetically replaced by 2-fluorohistidines. The protein was 
structurally similar to the WT protein as determined by X-ray crystallography
13
, but this 
replacement was found to block low pH-induced pore formation with cells and thus protected 
52 
 
from the lethal effects of the toxin.
12,13
 These results suggested that 2-FHis rPA might 
potentially be used as an antitoxin or a vaccine to treat anthrax infections.  
We have therefore examined the effect of 2-fluorohistidine labeling of rPA on its 
stability and dynamics to further explore its potential use as a therapeutic entity. The 
conformational stability and dynamic properties of rPA and 2-FHis rPA were evaluated and 
compared as a function of solution pH and temperature. The physical stability of the two 
proteins was investigated as a function of pH (4-8) and temperature (10-85 ºC) using the 
developed method in Chapter 2. Near and far UV circular dichroism, intrinsic and extrinsic 
fluorescence as well as light-scattering optical density data were collected and empirical 
phase diagrams were constructed to summarize the large volume of the data collected. The 
physical stability profiles were then compared to distinguish stability differences between the 
two proteins. Based on the biophysical characterization results, the dynamic properties of the 
two proteins at pH 5 were then studied to better understand the difference in thermal stability 
observed between the two proteins at pH 5. The dynamic properties of proteins were 
investigated by red-edge excitation shifts and high-resolution ultrasonic spectroscopy.  
3.2 MATERIALS AND METHODS 
3.2.1 Materials  
Recombinant protective antigen (rPA) and its 2-fluorohistidine labeled analogue (2-FHis 
rPA) were produced by the Laboratory of Bioorganic Chemistry at Wichita State University 
(Wichita, KS) as liquid solutions (~20 mg/ml) in 20 mM Tris buffer containing 150 mM NaCl 
at pH 8. Expression, production, and purification of rPA and 2-FHis rPA were carried out as 
described previously.
14
 All other reagents including buffers and salts were purchased from 
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Sigma-Aldrich (St. Louis, MO). 
For the physical characterization studies, high concentrations of stock protein samples (~ 
20 mg/ml) were freshly prepared by dilution into 20 mM citrate phosphate buffer with an 
ionic strength of 0.15 (adjusted with sodium chloride) ranging from pH 4 to 8, at one pH unit 
intervals. The final experimental protein concentration was 0.5 mg/ml.  
For dynamic studies, high concentrations of stock protein samples were freshly diluted to 
approximately 1.5 mg/ml using 20 mM Tris buffer containing 150 mM NaCl at pH 8.  
Diluted samples were then dialyzed in 20 mM citrate phosphate buffer at pH 5 at 4 ºC using 
Slide-A-Lyzer dialysis cassettes (Thermo Scientific, Rockford, IL) with a 3.5 kDa MW cutoff.  
The pH value of 5 for the working buffer was determined from the biophysical 
characterization results. Protein concentration was 0.5 mg/ml for red-edge excitation shifts 
experiments, and was 0.9 mg/ml for both density and high resolution ultrasonic spectroscopy 
measurements. 
3.2.2 Biophysical Characterization 
3.2.2.1 Far and Near UV Circular Dichroism Spectroscopy 
Circular dichroism analysis was performed with a Chirascan-plus Circular Dichroism 
Spectrometer (Applied Photophysics Ltd, Leatherhead UK) equipped with a Peltier 
temperature controller and a 4-position cuvette holder. Far and near UV spectra of samples 
(0.5 mg/ml) were collected simultaneously in the range of 200-360 nm using a 0.2 cm path 
length cuvette (method described in Chapter 2).
15
 The step size of spectra scanning was 1 nm. 
A sampling time per point of 3 s and a bandwidth of 1 nm were used. The characteristic CD 
signals of proteins (pH 4-8) at 220, 262, 269, 284 and 291 nm observed in the near and far 
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UV CD regions were monitored as a function of temperature from 10 to 85 ºC at 2.5 ºC 
intervals. Triplicate measurements were made, and the equilibration time at each temperature 
was 1 minute. 
3.2.2.2 Optical Density Measurements 
Ultraviolet absorbance measurements were made simultaneously during the near and far 
UV CD experiments using the same experimental parameters.
15
 The aggregation behavior of 
rPA and 2-FHis rPA (0.5 mg/ml) was monitored by recording the optical density at 350 nm as 
a function of temperature (10-85 ºC) and pH (4-8).  
3.2.2.3 Intrinsic Fluorescence Spectroscopy 
In a series of separate experiments, fluorescence emission scan data were also collected 
on the Chirascan-plus instrument by using an attached fluorescence detector. A 2 x 10 mm 
quartz cuvette was used in all experiments, and excitation of the proteins was carried out 
along the shorter path length (2 mm). Fluorescence emission spectra of the two proteins (0.5 
mg/ml) were recorded using the same temperature program as used previously. Triplicate 
samples were measured using an excitation wavelength of 295 nm (> 95% tryptophan 
emission). Emission spectra were collected from 305 to 395 nm with a step size of 1 nm and 
2 s sampling time per point. The excitation and emission slits were set at 4 and 9 nm, 
respectively. The position of the emission wavelength maximum was determined using a 
polynomial derivative fitting method executed in Origin 7.0 software. 
3.2.2.4 Extrinsic Fluorescence Spectroscopy 
8-Anilino-1-naphthalene sulfonate (ANS) was used as an extrinsic probe to study 
conformational changes of the two proteins that result in changes in its surface polarity. The 
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interaction of ANS with the apolar surfaces of rPA and 2-FHis rPA were monitored as a 
function of temperature (10-85ºC) and pH (4-8) using a QuantaMaster Spectrophotometer 
(Photon Technology International (PTI), Inc., Birmingham, NJ). Each sample solution (0.5 
mg/ml) containing 89 µM diluted ANS (a molar ratio of the ANS to the protein of 15:1) was 
incubated at 10ºC in the dark for 20 minutes before measurement. Samples were excited at 
375 nm and spectra were collected from 400 to 600 nm at 2.5ºC intervals, with a 3 min 
equilibration time at each temperature. Duplicate measurements were made using a 2 mm 
path length quartz cuvette to check for inner filter effects (none were seen). Buffer baselines 
containing ANS were subtracted from each sample spectrum prior to analysis. Peak positions 
and intensities of the emission spectra were obtained using a polynomial derivative fitting 
method as described above (Section: Intrinsic Fluorescence Spectroscopy). 
3.2.2.5 Empirical Phase Diagram (EPD) 
The empirical phase diagram (EPD) was constructed as described previously
16,17
 to 
summarize and facilitate the analysis of the complex biophysical data sets obtained. The EPD 
is used to identify coherent parameter regions that define protein structural states as a 
function of solution variables (temperature and pH in this case). CD signals at 220, 262, 269, 
284 and 291 nm, optical density, intrinsic Trp fluorescence peak positions, and extrinsic 
fluorescence intensities data were used for construction of the EPDs of rPA and 2-FHis rPA. 
All calculations were performed using Matlab software (MathWorks, Natick, MA). 
3.2.3 Dynamic Properties Measurements 
3.2.3.1 High Resolution Ultrasonic Spectroscopy 
Ultrasonic spectroscopy measurements were performed using an HR-US 102 
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Spectrometer (Ultrasonic Scientific, Dublin, Ireland) with a frequency range of 2–18 MHz 
and a resolution of 0.2 mm/s for velocity and 0.2% for attenuation measurements. The 
differential velocity and attenuation between sample and reference cells were monitored at 12 
MHz from 10 to 85
o
C and pH 5. The sample and reference solutions (0.9 mg/ml) were 
thoroughly degassed before each measurement. The sample and reference cells contained 1 
ml of protein and buffer solution, respectively. The temperature of the cells was controlled by 
a Phoenix P2 water circulator (Thermo Haake, Newington, NH). Data were analyzed using 
HRUS v4.50.27.25 software. The coefficient of adiabatic compressibility (βs) was determined 
using the equations described previously.
18
 The adiabatic compressibility of the sample and 
buffer are related to the density (ρ) and ultrasonic velocity (u) by the Laplace equation, 
β=1/ρu
2
. 
3.2.3.2 Density  
The densities of the two protein solutions (0.9 mg/ml) and corresponding buffer solutions 
were measured using a DMA-5000 high precision densitometer (Anton Paar, Graz, Austria) 
at a precision of 1 x10
-6
 g/cm
3
 and ±0.001
o
C. The densities of degassed solutions were 
measured from 5–22
o
C and 5–32
o
C for rPA and 2-FHis rPA in their unfolding pre-transition 
ranges, respectively. The increment of the temperature was 1
o
C. The instrument was 
calibrated with dry air and degassed water before analysis. 
3.2.3.3 Red-Edge Excitation Shifts 
Fluorescence measurements used in the determination of red-edge excitation shifts were 
performed with the PTI QuantaMaster Spectrophotometer. Protein concentration was 0.5 
mg/ml. Excitation wavelengths of 292, 296, 300 and 304 nm were used, and the emission 
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spectra were collected from 300 to 400 nm. The excitation and emission slit widths were set 
to 2 nm. The data were collected from 10 to 50ºC in 2ºC increments with a 3 minutes 
equilibration time. Triplicate measurements were made using a 2 mm path length quartz 
cuvette. The relative change in peak position was determined using a mean spectral center of 
mass (MSM) method spanning the emission spectra range of 310 to 400 nm. This range of 
data analysis and the lower pathlength employed for fluorescence measurements (2 mm) 
should minimize the contribution of Rayleigh scattering even when the data is collected at 
304 nm (the highest excitation wavelength employed) as well as the lower excitation 
wavelengths used in these studies. The mean spectral center of mass method is a peak picking 
algorithm to determine the peak maximum. The maximum peak position is based on the 
center-of mass position of the area in a selected peak integration region (from 310- 400 nm in 
this case). The peak position maxima obtained by the MSM method are generally ~8-10 nm 
higher than the actual peak position obtained by derivative analysis but result in a better 
signal to noise ratio. 
3.3 RESULTS 
3.3.1 Biophysical Characterization 
3.3.1.1 Near and Far UV Circular Dichroism Spectroscopy 
Near and far UV CD spectra of 0.5 mg/ml rPA and 2-FHis rPA at pH 7 and 10ºC are 
shown in Figure 1. In the far- UV region (200-250 nm), both proteins display a broad peak 
with a minimum at around 210 nm and a shoulder at 220 nm, suggesting that proteins contain 
a mixture of α-helix and β-sheet structures. In the near-UV region (250-320 nm), four 
characteristic peaks at 262, 269, 284 and 291 nm were observed, presumably due to the 
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aromatic amino acid side chains.
19,20 
 
Figure 1: Near- and far-UV CD spectra for rPA and 2-FHis rPA at pH 7 and 10C. Near and 
far UV CD (A, C) and Near-UV CD (B, D) spectra are shown for (A) 0.5 mg/ml rPA at pH 7 
and (B) expanded view of its near-UV region. (C) 0.5 mg/ml 2-FHis rPA at pH 7 and (D) 
expanded view of its near-UV region. 
The effect of temperature on the two protein’s secondary and tertiary structures was 
further investigated by using thermal melt analysis. CD signals at five characteristic peaks 
(220, 262, 269, 284 and 291 nm) were monitored across the pH range of 4-8. Typical thermal 
unfolding curves of 2-FHis rPA and rPA at pH 7 are shown in Figure 2 and Supplemental 
Figure S1, respectively, with triplicate measurements resulting in good reproducibility. The 
rPA and 2-FHis rPA proteins show similar pattern in their CD thermal unfolding curves across 
the entire pH range examined. Although an overall loss in secondary and tertiary structures is 
observed as a function of increasing temperature for both proteins, the thermal transition 
midpoint (Tm) values vary greatly between the two proteins as the pH value decreases. For 
example, the two proteins show a significantly lower thermal stability at pH 5 (Supplemental 
Figures S2 and S3). The Tm values from CD thermal melt curves were calculated for both 
proteins and results are summarized in Table 1. The two proteins show similar conformational 
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stability at pH 7 and 8. Differences in thermal stability between the two proteins are, however, 
observed at pH 5 and 6 (see Table 1), especially at pH 5. Interestingly, the Tm value for 
2-FHis rPA at pH 5 evaluated from the Far-UV CD data was greater than that obtained from 
the near-UV CD data, suggesting that a molten globule like state exists in the temperature 
range from 35 – 41 
o
C. Molten globules generally possess native-like secondary structure but 
lack significant tertiary structure. While the Tm values for both proteins decrease as a function 
of pH, the 2-FHis rPA exhibits a slightly higher thermal stability than rPA at pH 6, and the 
analogue rPA has significantly higher stability than rPA at pH 5 with an increased Tm value of 
approximately 10 ºC.  
3.3.1.2 Intrinsic Fluorescence Spectroscopy 
Alternations in tertiary structure as a function of temperature and solution pH of the two 
rPA proteins were also investigated by intrinsic fluorescence spectroscopy. Figures 3A and B 
show the changes in the position of the emission peak maximum and structural changes 
occurred in both proteins but at different temperatures depending on pH. rPA and 2-FHis rPA 
show their highest thermal stability at pH 7-8 and 6-8, respectively. The stability of rPA 
decreases much more dramatically compared to 2-FHis rPA between pH 4 and 6 (see Table 1 
for the calculated Tm values). At pH 7 and 8, both proteins show comparable structural 
integrity with initial peak positions of about 329 nm at low temperatures. With increasing 
temperature, the emission peak maximum shifts to about 342 nm, indicating the proteins were 
conformationally altered but not completely unfolded at elevated temperatures. In summary, 
both proteins show their highest thermal stability at pH 7 and 8, and manifest lower thermal 
stability with decreasing pH.  
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Figure 2. Thermal stability of 2-FHis rPA (0.5 mg/ml at pH 7) as monitored by CD signals at 
indicated values (220, 262, 269, 284 and 291 nm) as a function of temperature. Each data 
point represents the mean of three independent runs, with error bars showing the standard 
deviation. 
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Sample pH 
Circular Dichroism  
Optical 
Density 
Intrinsic 
Fluorescence 
ANS 
Fluorescence 
220 
nm 
262 
nm 
269 
nm 
284 
nm 
291  
nm 
rPA  8 49.0 50.0 50.5 50.5 50.5 51.0 46.5 46.5 
2-FHis 
rPA  
8 47.0 49.0 49.0 49.0 49.0 48.5 45.0 46.5 
rPA  7 49.0 48.5 48.5 48.5 48.5 48.5 46.5 48.5 
2-FHis 
rPA  
7 49.0 47.0 47.0 48.5 48.5 46.5 46.5 50.5 
rPA  6 43.5 41.0 41.0 41.0 41.0 43.5 39.0 41.0 
2-FHis 
rPA  
6 44.0 43.5 43.5 43.5 43.5 43.5 43.5 44.0 
rPA  5 28.5 26.0 26.0 26.0 26.0 28.5 33.5 29.0 
2-FHis 
rPA  
5 41.0 34.5 36.5 36.5 36.5 39.0 43.0 41.0 
rPA  4 36.0 36.0 36.0 36.0 36.0 34.0 29.0 31.0 
2-FHis 
rPA  
4 36.0 34.0 34.0 33.5 34.0 34.0 34.0 29.5 
 
Table 1: Thermal unfolding temperature values (Tm, ºC) calculated from the thermal 
unfolding curves using different biophysical techniques. Indicated Tm values were calculated 
from the first derivative of the thermal unfolding curves from each technique. Values are ± 
0.5ºC. 
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Figure 3. Thermal stability of rPA (Figures A and C) and 2-FHis rPA (Figures B and D) at 0.5 
mg/ml as a function of solution pH: (A) and (B) intrinsic Trp fluorescence emission 
maximum (peak position) was monitored; (C) and (D) optical density at 350 nm was 
monitored. Each data point represents the mean of three independent samples, with error bars 
showing the standard deviation.  
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3.3.1.3 Optical Density Measurements 
Optical density (OD) data at 350 nm were collected simultaneously during CD 
measurements. rPA and 2-FHis rPA both manifested aggregation as measured by increases in 
OD values with increasing temperature (Figures 3C and D). The temperature dependent OD 
changes (i.e., protein aggregation) are overall consistent with the observations made from the 
CD and intrinsic fluorescence measurements, with similar trends of pH and temperature. 
Again, 2-FHis rPA was significantly more stable than rPA at pH 5, where the midpoint of the 
aggregation values for rPA and 2-FHis rPA were 39.0
o
C and 28.5
o
C, respectively. 
Interestingly, the 2-FHis rPA analogue is actually more stable at pH 5 than at pH 4, in contrast 
to the recombinant rPA protein.  
3.3.1.4 Extrinsic Fluorescence Spectroscopy 
ANS is a fluorescent dye that binds to apolar regions in proteins, resulting in large 
increases in fluorescence quantum yield and a blue shift in peak position.
21
 This observation 
must always be qualified, however, by the possibility of electrostatic interactions of the 
negatively charged dye with a protein. Figure 4 shows the thermal melting curves of the two 
proteins at various pH values. These curves were obtained by monitoring the ANS emission 
peak intensity as a function of temperature. At pH 4, ANS data for rPA show significant 
fluorescence intensity even at low temperatures (Figure 4A). This increased fluorescence 
intensity is presumably induced by the binding of ANS to the structurally altered rPA protein 
under acidic conditions. Increased ANS fluorescence intensity with increases in temperature 
is observed over the pH range of 4 to 8. The Tm values for these transitions are summarized in 
Table 1. In agreement with results obtained from other biophysical techniques, 
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Figure 4. ANS fluorescence intensity values in the presence (A) rPA and (B) 2-FHis rPA as a 
function of temperature and solution pH. Both samples were at 0.5 mg/ml. Each data point 
represents the mean of two independent samples, with error bars showing the standard 
deviation.  
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both proteins show their greatest structural stability at pH 7-8. At pH 6, 2-FHis rPA is slightly 
more stable than rPA. Again, at pH 5, the maximum difference in the stability of two proteins 
is observed. 
3.3.1.5 Empirical Phase Diagrams  
 Empirical phase diagrams are used to summarize large amounts of data to provide a more 
comprehensive view of the stability profiles of proteins. Such diagrams should not be 
confused with thermodynamic phase diagrams, however, since no equilibrium between 
phases is implied. The EPDs of rPA and 2-FHis rPA generated from all of the collected data 
are shown in Figures 5A and B, respectively. Overall, the EPD of the rPA protein (Figure 5A) 
shows similar defined “apparent” phases compared to those in the EPD of 2-FHis rPA (Figure 
5B). There are two major phases seen for both proteins. In region 1, both proteins at pH 5-8 
show a similar color below about 48
o
C, suggesting that they exist in similar structural states. 
By examining the data obtained from the specific techniques, region 1 at low temperatures 
from pH 5-8 is presumably the native state of protein. rPA and 2-FHis rPA show similar 
apparent phase boundaries across the pH range 6 to 8. In contrast, rPA shows lower stability 
than 2-FHis rPA at pH 6 as evidenced by a decreased Tm value of about 2.5
o
C (Table 1). At 
pH 5, there is a much more significant thermal stability difference between the two proteins. 
Both the EPDs and the individual experimental methods all show that 2-FHis rPA has much 
greater thermal stability (Tm value difference of 10-12
o
C). Unlike the EPD of 2-FHis rPA, the 
EPD of rPA displays an additional region (Region 2 in Figure 5A) based on phase color 
changes. In region 2, rPA samples at pH 4 show a distinct color (green) difference from 
region 1. This observation clearly arises from results obtained from extrinsic (ANS)  
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Figure 5. Empirical phase diagrams (EPDs) of (A) rPA and (B) 2-FHis rPA. The EPD was 
prepared from near/far-UV CD, optical density, intrinsic fluorescence (peak position), and 
extrinsic (ANS) fluorescence data collected across a pH range from 4 to 8 and a temperature 
range from 10°C to 85°C. 
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fluorescence data. As discussed previously, at pH 4, rPA with ANS shows significant 
fluorescence intensity even at low temperature (Figure 4A), suggesting the binding of ANS to 
a partially unfolded protein at this acidic condition. At high temperatures, both proteins are 
structurally altered and aggregate as indicated by the presence of region 3. From the EPDs, 
we can see that the most stable region of two proteins is in the pH range of 7 to 8.  
3.3.2 Dynamic Properties Measurements 
3.3.2.1 High Resolution Ultrasonic Spectroscopy (HR-US) 
HR-US spectroscopy employs high-frequency sound waves to probe intramolecular 
forces in materials such as proteins.
22,23
 Oscillating compression (and decompression) of the 
ultrasonic wave causes oscillations in internal molecular rearrangement. A protein will 
respond by corresponding compression and expansion of its volume. In HR-US 
measurements, attenuation and velocity of ultrasonic waves were determined. Combined with 
high precision density measurements, the adiabatic compressibility of each protein sample 
was calculated.  
Protein compressibility is influenced by both a protein’s internal fluctuations in volume 
and its hydration. Because 2-FHis rPA showed greater stability than rPA at pH 5, based on the 
EPD characterization results discussed above, measurements of the dynamic properties of the 
two proteins were made under this condition. The magnitude of a protein’s apparent adiabatic 
compressibility has positive contributions from a protein’s intrinsic volume fluctuations and 
negative contributions from the hydration water.
24
 In Figure 6A, the apparent adiabatic 
compressibility values were found to increase with increases in temperature for both rPA and 
2-FHis rPA . 2-FHis rPA displays higher values of adiabatic compressibility than those of rPA 
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at low temperatures where both proteins exist in their native states. The negative 
compressibility, however, suggests a dominant contribution of hydration water to the 
experimentally determined compressibility values. The increase in compressibility with 
temperature for rPA and 2-FHis rPA therefore could either represent increases in their 
intrinsic fluctuations and/or reflect alterations in hydration dynamics around the protein’s 
surface due to temperature. Figure 6B shows Trp peak position shifts as a function of 
temperature for rPA and 2-FHis rPA when excited at 304 nm (obtained from red-edge shifts 
measurements). Excitation of Trp by 304 nm radiation should probe residues with greater 
degrees of solvent exposure which are presumably located on the surface of the protein. The 
Trp peak position at 10
o
C was red-shifted for rPA compared to 2-FHis rPA. This red-shift in 
peak position could be due to the differences in protein’s tertiary structure and/or hydration of 
the surface. The magnitude of the red-shift, however, was greater when probed with 304 nm 
compared to 292 nm light (data not shown), suggesting that hydration contributions to the 
red-shift are possible. This result along with the compressibility data (Figure 6A) suggests 
that the native structure of rPA and 2-FHis rPA may have differences in their hydration state. 
Generally, increased dynamic motions, flexibility, void volume changes and elasticity of 
proteins will result in higher values of adiabatic compressibility. In contrast, hydration of 
proteins, which reduces many of the above processes, will decrease values of compressibility. 
3.3.2.2 Red-Edge Excitation  
Red edge excitation spectroscopy is a fluorescence based technique used for studying the 
dynamic properties of proteins. For fluorophores under conditions where solvent relaxation is 
not complete (such as the viscous environment surrounding the buried protein fluorophore),  
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Figure 6. Measurements of dynamic properties of rPA and 2-FHis rPA collected at pH 5. (A) 
Ultrasonic measurements of the adiabatic compressibility of the two proteins. (B) Emission 
peak positions’ comparison between rPA and 2-FHis rPA at an excitation wavelength of 304 
nm. Tryptophanyl dynamics were examined by red-edge excitation shifts of (C) rPA and 
2-FHis rPA based on excitation at 292, 296, 300 and 304 nm. (D) red-edge excitation shifts 
compared between excitation at 292 and 304 nm for both proteins. Each data point represents 
the mean of three independent runs, with error bars showing the standard deviation.  
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emission spectra shift to longer wavelengths when excitation wavelengths move to longer 
wavelengths.
25,26
 In less viscous environments, where solvent relaxation is more complete, 
the magnitude of the red-edge effect decreases with shifts disappearing in fluid solvents.  
The effect of red-edge excitation on tryptophan fluorescence is quantified here as the shift in 
the emission peak when excited at 296, 300, and 304 nm relative to 292 nm. In Figure 6C, 
both proteins show clear red shifts at 10
o
C when the excitation wavelength increases. These 
results show that the magnitude of the red-shifts increase as excitation is moved to longer 
wavelengths. Similar results were obtained throughout the pre-transition temperature range 
(10-20
o
C for rPA, and 10-30
o
C for 2-FHis rPA) of their thermal unfolding curves. This 
observation suggests that Trp residues located in restricted environments can be sampled and 
probed to study the differences in dynamics of such environments in both rPA and 2-FHis rPA. 
In Figure 6D, the red-edge excitation shifts, representing the difference in emission maxima 
upon red-edge excitation from 292 to 304 nm, are compared for both rPA and 2-FHis rPA. 
The magnitude of the shift of rPA is always larger than 2-FHis rPA at low temperatures prior 
to thermal structural perturbation. This observation suggests that 2-FHis rPA displays more 
dynamic behavior compared to rPA at pH 5. Above the unfolding temperature, rPA and 
2-FHis rPA are prone to aggregate and eventually precipitate out of solution. 
3.4 DISCUSSION 
In the present study, the physical stability of rPA and 2-FHis rPA was investigated using 
the analytical method developed in Chapter 2. Temperature/pH stability profiles of the two 
proteins were created and compared. The proteins exhibited similar CD and fluorescence 
spectra at low temperatures. The estimated secondary structure contents of the two proteins 
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are very similar to each other, although 2-FHis rPA displays an increased (about 6.5 %) 
α-helix content and a corresponding decrease in β-structure compared to rPA
12
, as estimated 
by the spectral deconvolution software CDNN. Similar thermal unfolding profiles of the two 
proteins were also obtained by different techniques at pH 6-8. We conclude that the overall 
structural integrity and conformational stability of the protein was not affected by 
incorporation of 2-FHis around neural pH values. These results are in agreement with a 
previous study of the equilibrium stability of rPA and 2-FHis rPA using urea in which both 
proteins showed similar urea denaturation profiles.
12
   
At lower pH values, however, differences in the conformational stability of 2-FHis rPA 
and rPA were noted. At pH 5, and to a lesser extent at pH 6, 2-FHis rPA exhibited higher 
stability than rPA. This result suggests that 2-FHis incorporation into rPA inhibits pH 
dependent unfolding under these mildly acidic pH conditions. Thus, the 2-FHis rPA is much 
more thermally stable at lower pH compared to rPA (Table 1).  
To better understand why the two rPA proteins demonstrate a stability difference at pH 5, 
the dynamic properties of the proteins were compared by red-edge excitation shifts and 
HR-US measurements. HR-US measurements suggest that both rPA and 2-FHis rPA may 
have differences in their hydration and/or intrinsic fluctuations in which rPA may be more 
hydrated than 2-FHis rPA. It is well known that fluorinated compounds exhibit increased 
hydrophobicity compared to their hydrogenated counterparts.
27
 Such increased apolar 
character in 2-FHis rPA may cause increased water mobility and less residence times near 
such regions.
28,29
 It is therefore possible that 2-FHis rPA has different hydration 
characteristics than rPA but this hypothesis needs further investigation. In addition, red-edge 
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excitation shift results indicate that 2-FHis rPA has greater dynamic character than rPA at pH 
5. It is often assumed that more dynamic proteins possess less stability.
30,31,32
 Many 
thermostable proteins are, however, quite dynamic, so an increase in thermostability does not 
necessarily correlate with a decrease in dynamic behavior.
33,34,35,36,37
 The relationship between 
protein dynamics and stability is not fully understood. The lower extent of hydration and/or 
higher dynamic character may increase the stability of the 2-FHis rPA at lower pH. Solution 
pH can potentially alter the microenvironmental pH around proteins, especially in their 
hydration layer. If such a phenomenon occurs at lower pH in these studies, a greater extent of 
hydration (with higher residence time) may explain the inverse relationship between the 
extent of hydration and stability for rPA and 2-FHis rPA. rPA was earlier determined to be 
potentially more hydrated than 2-FHis rPA using HR-US studies. The two methods used in 
this study both reflect the global dynamic properties of the two proteins at a specific pH 
condition. More detailed information about the dynamic properties of proteins can be 
obtained by methods such as NMR and H-D exchange mass spectrometry, which provide 
information about the local dynamic properties in specific regions of proteins.  
This study provides important biophysical information about the effect of 2-FHis on the 
conformational stability of rPA in response to environmental stress factors such as pH and 
temperature. Our results show that the two proteins have similar stability at pH 7 to 8. The 
2-FHis rPA analogue is slightly more stable at pH 6 and shows dramatically increased 
stability at pH 4-5. The 2-FHis rPA protein is also more dynamic than rPA at pH 5. These data 
provide useful information to better understand the similarities and differences in physical 
properties of the two proteins in solution. PA is a primary component in the currently licensed 
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anthrax vaccine. In comparison, 2-FHis rPA possesses higher thermal stability under acidic 
conditions and has the capability to block key steps in its cellular cytotoxicity. These data 
suggest that 2-FHis rPA has the potential to for use as an alternative, more stable antigen in 
newer, recombinant versions of the anthrax vaccine. Given the potential need for long term 
storage of anthrax vaccines as a counter-terrorism measure, the increased stability of the 
2-FHis analogue is an attractive property of this form of the rPA protein. The pH/temperature 
stability profile of 2-FHis rPA was generated through a comprehensive biophysical 
characterization of the secondary and tertiary structural integrity, as well aggregation 
behavior, of the protein. These data can be used as a starting point for further formulation 
development of the 2-FHis rPA as a potential anthrax vaccine or as a potential antitoxin to 
treat anthrax during the infection.  
3.5 ASSCOCIATED CONTENT 
Supplemental Figures 1-3.  
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Supplemental Figure S1. Thermal stability of rPA (0.5 mg/ml at pH 7) as monitored by CD 
signals at indicated values (220, 262, 269, 284 and 291 nm) as a function of temperature.  
Each data point represents the mean of three independent runs, with error bars showing the 
standard deviation.  
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Supplemental Figure S2. Thermal stability of 2-FHis rPA (0.5 mg/ml at pH 5) as monitored 
by CD signals at indicated values (220, 262, 269, 284 and 291 nm) as a function of 
temperature.  Each data point represents the mean of three independent runs, with error bars 
showing the standard deviation.   
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Supplemental Figure S3. Thermal stability of rPA (0.5 mg/ml at pH 5) as monitored by CD 
signals at indicated values (220, 262, 269, 284 and 291 nm) as a function of temperature.  
Each data point represents the mean of three independent runs, with error bars showing the 
standard deviation.  
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4.1. INTRODUCTION 
In Chapter 3, I introduced the background concerning anthrax disease caused by Bacillus 
anthracis. The anthrax toxin, a tripartite toxin, plays a key role in the pathogenesis of 
anthrax.
1
 It is formed by three nontoxic proteins secreted by B. anthracis, namely protective 
antigen (PA), lethal factor (LF), and edema factor (EF).
2
 The combination of PA with LF and 
EF results in complex toxins such as edema (EdTx) and lethal toxin (LeTx).
2,3
 Because PA 
plays an important role in the pathology of anthrax and its highly immunogenic, it is used as 
the major antigen in most anthrax vaccine formulations. As described in Chapter 3, the 
current licensed US anthrax vaccine (AVA, BioThrax) has a very limited duration of 
protection and requires multiple immunizations and yearly boosts.
4
 In addition, it may not be 
optimal and/or safe to administer a PA-based vaccine for post-exposure vaccination, because 
the administration of native PA may aid in anthrax toxin formation with disasterous 
consequesnces.
5,6,7
 Therefore, there is a need to develop improved versions of anthrax 
vaccines. Specific mutations of PA in domains 2 and 3 have been constructed to block the 
translocation and/or self-assembly of the toxin.
5-8
 These mutants have shown both potential 
improvements in safety (diminished toxicity) and immunogenicity.   
A dominant-negative inhibitor (DNI) of the anthrax toxin has been demonstrated to be a 
potential antitoxin and a potent imunnogen as an anthrax vaccine. DNI is a 
translocation-deficient mutant of anthrax protective antigen with the double mutation of 
K397D and D425K. This mutant co-oligomerizes with the wild-type PA protein and blocks 
its ability to translocate LF or EF into the cell cytosol. Thus inhibiting cellular toxicity caused 
by LF/EF.
8
 DNI strongly inhibits toxin action in cell culture and in animal intoxication 
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models
5,8
. This suggests that it has the therapeutic potential to be used as an antitoxin. Aside 
from the therapeutic potential of DNI, previous studies have shown that DNI is more 
immunogenic than PA in a mice study in which DNI elicited a higher antibody titer than 
PA.
5,6
 Because of the enhanced immunogenicity of DNI, the use of DNI as a replacement for 
PA in anthrax vaccines has significant potential. In summary, DNI is a promising candidate 
for use in the treatment of anthrax, which can potentially provide both improved 
immunogenicity in vaccines and therapeutic activity in antitoxic therapy.  
In the present study, to evaluate the physical stability of the lyophilized DNI protein that 
had been stored at 4 ºC for about eight years, the stability of the reconstituted proteins under 
unstressed and stressed conditions (at elevated temperatures of 40 and 70 ºC for one, two and 
four weeks) was characterized by various techniques at pH 7 from 10 to 80 ºC. SDS-PAGE, 
near and far circular dichroism (CD), intrinsic fluorescence, and optical density 
measurements were used, as well as a static light scattering technique. The size of the 
proteins was characterized by dynamic light scattering and micro-flow imaging methods. The 
soluble aggregates of the samples were characterized by size-exclusion liquid 
chromatography. In addition, the chemical stability (deamidation) was also evaluated using 
capillary isoelectric focusing (cIEF). The Studies of DNI with aluminum adjuvants were 
further performed to study antigen/adjuvant interactions and the stability of DNI on the 
surface of the adjuvant. Because purified recombinant proteins are usually not highly 
immunogenic, an adjuvant is usually needed to boost their immunogenicity. In addition, the 
biophysical characterization results of DNI were compared to those obtained from the 
unmodified recombinant protective antigen, and the physicochemical properties of rPA and 
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its mutant (DNI) were compared. Through these characterization studies, the conformational 
stability of lyophilized DNI was comprehensively evaluated. These results provide important 
information about the conformational integrity of DNI that had been stored for eight years. 
Key parameters such as pH, temperature, and buffers were also defined to facilitate for 
further formulation development. 
4.2 MATERIALS AND METHODS 
4.2.1 Materials  
The dominant negative inhibitor antigen was produced by Pharmaceutical Solutions LLC 
(Bloomington, IN) as a lyophilized powder in sealed glass vials. The vials of the DNI protein 
contained 25 mg of protein, 113 mg mannitol, 33 mg sucrose, and 2.4 mg dibasic sodium 
phosphate. They were reconstituted with 3.3 ml of water for injection (WFI), the 
reconstituted protein concentration was 91 µM. 10 mg of recombinant protective antigen was 
also purchased from List Biological Laboratories Inc (Campbell, CA). 
For the physical characterization of unstressed samples, individual protein solutions at 
pH 6-8 were prepared by reconstituting 2.0 ml of water and then diluting with 20 mM citrate 
phosphate buffer with a total ionic strength of 0.15 (adjusted with NaCl). Before making 
measurements, the samples of DNI were dialyzed at 4 °C using Slide-A-Lyzer® Dialysis 
Cassettes (Thermo Scientific, Rockford, IL) with a 3.5 kDa MW cutoff. For adjuvant studies, 
10 mM histidine buffer containing 150 mM NaCl at pH 7 was used. DNI protein was 
reconstituted with 2.0 ml water then dialyzed into 10 mM histinde buffer containing 150 mM 
NaCl overnight at 4 °C. The adjuvants aluminum hydroxide (Alhydrogel
®
) and aluminum 
phosphate (Adju-Phos
®
) were purchased from Brenntag Biosector (Frederikssund, Denmark). 
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For the stressed study at elevated temperatures, vials were placed at 40 and 70 °C. Vials 
were withdrawn at three time points; one week, two weeks and four weeks. Then the vial was 
reconstituted with 2.0 ml of water. The stressed sample was then diluted to 0.5 mg/ml with 20 
mM citrate phosphate buffer containing NaCl (I=0.15) at pH 7. The same biophysical 
analysis was conducted as performed with the unstressed DNI samples.  
4.2.2 Analytical Characterization 
4.2.2.1 SDS-PAGE 
Unstressed and stressed DNI samples were characterized by reducing SDS-PAGE. The 
amount of protein loaded was 20 µg. For the experiments, DNI protein was mixed with 50 
mM reducing agent dithiothreitol (DTT). All samples including the molecular standards were 
heated at 80 ºC for five minutes before loading. 
4.2.2.2 Far and Near UV Circular Dichroism Spectroscopy 
Circular dichroism analysis was performed with a Chirascan-plus circular dichroism 
spectrometer (Applied Photophysics Ltd, Leatherhead UK) equipped with a Peltier 
temperature controller and a 4-position cuvette holder. Far and near UV spectra of samples 
(0.5 mg/ml) were collected in the range of 200-360 nm using a 0.2 cm path length cuvette 
sealed with a Teflon stopper. A sampling time per point of 3 s and a bandwidth of 1 nm were 
used. The characteristic CD signals of the samples at 220, 262, 269, 284 and 291 nm were 
monitored as a function of temperature from 10 to 80 ºC at 2.5 ºC intervals. Triplicate 
measurements were made with a heating rate of 1 ºC/min, and an equilibration time at each 
temperature of 1 minute.  
For the 70 °C, one week stressed samples, because low signal to noise ratios were 
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observed in the far UV CD region, the CD signal was monitored at 229 nm instead of 220 nm. 
Measurements of far UV CD were also performed separately from near UV CD 
measurements using lower protein concentration and cell path length. Far UV spectra of 
samples (0.2 mg/ml) were collected in the range of 200-260 nm using a 0.1 cm path length 
cuvette. A sampling time per point of 1 s and a bandwidth of 1 nm were used. The CD signals 
of the samples at 220 nm were monitored as a function of temperature from 10 to 80 ºC at 2.5 
ºC intervals. Triplicate measurements were made. 
4.2.2.3 Intrinsic Fluorescence Spectroscopy 
The intrinsic fluorescence of DNI (0.5 mg/ml) was measured using a QuantaMaster 
Spectrofluorometer (Photon Technology International, Inc., Birmingham, NJ) equipped with 
a 4-position cell holder and Peltier temperature control device. Fluorescence emission spectra 
of samples were recorded as a function of temperature (10-82.5 ºC). Duplicate samples were 
measured using an excitation wavelength of 295 nm (> 95% tryptophan emission). Emission 
spectra were collected from 300 to 400 nm with a step size of 1 nm and an integration time of 
1 s. The excitation and emission slits were set at 2 and 3 nm, respectively. The spectra were 
collected at 2.5 ºC intervals with a 3 min equilibration time at each temperature. A 2 x 10 mm 
quartz cuvette was used in all experiments. Data analysis was performed using FelixTM 
(Photon Technology International, Inc.) software. The position of the emission wavelength 
maximum was determined using a polynomial derivative fitting method executed in Origin 
7.0 software.  
4.2.2.4 Optical Density Measurements 
The aggregation behavior of DNI was determined simultaneously during the near and far 
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UV CD experiments. The optical density at 350 nm was obtained as a function of temperature 
(10-80 ºC). 
4.2.2.5 Static Light Scattering 
The aggregation behavior of DNI was also determined simultaneously during the 
intrinsic fluorescence experiments employing a second photomultiplier located 180° to the 
fluorescence detector and using a 0.25 nm slit width. The scattering intensities at 295 nm 
were obtained as a function of temperature (10-82.5 ºC).  
4.2.2.6 Dynamic Light Scattering 
The mean effective hydrodynamic diameters of the DNI (0.5 mg/ml) were monitored by 
dynamic light scattering at 25 ºC, and five measurements were taken at this temperature. Data 
was collected on a ZetaPALS Zeta Potential Analyzer (Brookhaven Instrument Corp., 
Holtzille, NY). A digital autocorrelator (BI-9000 AT) was used to create the autocorrelation 
function. The diffusion coefficients of the particles were extracted by cumulant analysis of 
the auto correlation functions. The effective hydrodynamic diameter was calculated from the 
diffusion coefficient by the Stokes-Einstein equation. Viscosity and refractive index 
corrections were applied to each measurement using NanoDLS Particle Sizing software 
(Brookhaven Instrument). 
4.2.2.6 Deamidation studies using capillary isoelectric focusing (cIEF) 
The cIEF experiments were performed on an iCE280 instrument from Convergent 
Biosciences (Toronto, Canada) to characterize the charge variants of the protein. All 
experiments were performed at 10 ºC using a temperature controlled auto-sampler.  
Unstressed and stressed DNI samples in 10 mM histidine buffer at pH 7 were mixed with 
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12 M urea stock solution, 1% methyl cellulose solution (Convergent Bioscience, Toronto, 
Canada), Pharmalyte 3-10 (GE Healthcare, Uppsala, Sweden) and two PI markers. The pH 
values of the pI markers were 4.65 and 8.18. The final protein concentration used was 0.4 
mg/ml and the urea concentration was 6 M. Duplicate measurements were run. Qualification 
and quantification of charge variants were performed using Chrom Perfect
®
 software. 
4.2.2.7 Size-Exclusion Liquid Chromatography 
 The size-exclusion liquid chromatography experiments were performed on a Shimadzu 
HPLC system (Columbia, MD) to characterize the soluble aggregates of samples under 
unstressed and stressed conditions. A protein concentration of 1.0 mg/ml in 10 mM histidine 
buffer (pH 7) containing 150 mM NaCl was used. A TSKgel G2000SWxL analytical column 
(7.8mm x 30cm, 5µm) was used and the column temperature was 30 
o
C. The mobile phase 
was 50 mM sodium phosphate buffer at pH 6.8 containing 200 mM NaCl. The injection 
volume was 50µl and the flow rate was 0.65 mg/ml. Triplicate measurements were made. 
Two observed peaks corresponding two major species were quantified by their peak areas 
using LCsolution software (Shimadzu Corporation). 
4.2.2.8 Micro flow imaging 
A micro-flow imaging (MFI) instrument from Brightwell Technologies® was used for 
subvisible particle characterization from 2 micron and up, using the set point 3 mode (low 
magnification and open aperture settings). One ml of the unstressed or stressed samples (0.5 
mg/ml) were pipetted in barrier tips and used in the MFI experiments. Optimization of 
illumination was done using the respective buffer solutions of a given sample. The particle 
size and count distribution was subjected to a 0.85 aspect ratio cut off to remove any 
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interference by air bubbles.  
4.2.2 Adjuvant-Antigen study 
The experiments in the presence of the adjuvants were conducted by adding 
Alhydrogel® or Adjuphos® to the protein. The binding of DNI to the two adjuvants was 
tested in the presence of three different buffers: histidine, imidazole and citrate-phosphate at 
pH 7. After finding maximum adsorption to Alhydrogel in the histidine buffer, this buffer was 
retained as the buffer of choice in further experiments in the presence of adjuvant. The 
protein antigens were first tested to determine whether DNI adsorbs preferentially to 
Alhydrogel® or Adjuphos®. This was done by adding 100 µg of protein to 250 µg of 
adjuvant. The amount of unadsorbed protein was determined by measuring the amount of 
protein in the supernatant using UV absorbance spectroscopy after centrifugation. An 
adsorption isotherm was constructed for each protein in the presence of 0.25 mg/ml 
Alhydrogel® using various protein concentrations (0.05 – 1.0 mg/ml). 
4.3. Results 
4.3.1 Anlytical Characterization 
4.3.1.1 SDS-PAGE 
The DNI protein was analyzed using SDS-PAGE electrophoresis. Figure 1 shows a gel of 
the non-stressed and stressed DNI samples at various time points. The samples in the various 
lanes are described below in the Table 1. All samples were analyzed in the presence of a 
reducing agent.  
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Figure 1: Reducing SDS-PAGE analysis of DNI under various stressed and non-stressed 
conditions, along with the molecular weights of the markers (in kDa) in the left. Lanes 1 and 
7, molecular weight markers; lanes 2 and 3, unstressed DNI and rPA; lanes 4, 5, and 6, DNI 
protein stressed at 40 ºC for one week, two weeks and four weeks; lanes 8, 9, and 10, DNI 
protein stressed at 70 ºC for one week, two weeks and four weeks. 
 
 
Lane Sample 
1 Marker 
2 DNI Protein at time 0 
3 rPA  
4 DNI protein Stressed at 40 ºC for 1 Week 
5 DNI protein Stressed at 40 ºC for 2 Week 
6 DNI protein Stressed at 40 ºC for 4 Week 
7 Marker 
8 DNI protein Stressed at 70 ºC for 1 Week 
9 DNI protein Stressed at 70 ºC for 2 Week 
10 DNI protein Stressed at 70 ºC for 4 Week 
Table 1: The different samples used in the SDS-Page gel. 
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The DNI protein and the control rPA are shown in lanes 2 and 3 in Figure 1. No 
significant differences were seen in the two proteins, except for the band between 17 kDa and 
14 kDa. No significant differences were seen when DNI were exposed to 40 ºC for up to four 
weeks (lanes 4, 5, and 6). The marker is again shown in lane 7. The DNI protein stressed at 
70 ºC is shown in lanes 8, 9 and 10 (stressed for one, two and four weeks respectively). The 
only significant difference noticed when DNI was stressed at 70 ºC is the appearance of a 
high molecular weight species between the 188 kDa and the 98 kDa bands. This appears after 
one week at 70 ºC and increases in intensity when stressed for longer times.  
The multiple bands seen for the DNI protein at time 0 and other conditions may indicate 
impurities or products of degradation. These bands are very light compared to the monomer 
that shows up between the 98 kDa and 62 kDa bands. 
4.3.1.2 Near and Far UV Circular Dichroism Spectroscopy 
Non-Stressed Samples of DNI and rPA  
Typical near- and far-UV CD spectra of 0.5 mg/ml DNI at pH 6 at 10 ºC are shown in 
Figure 2. In the far-UV region (200-250 nm), DNI displays a broad peak with a minimum CD 
signal near 215 nm. In the near-UV region (250-320 nm), four characteristic peaks at 262, 269, 
284 and 291 nm were observed, which arise from the aromatic amino acid residues.  
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Figure 2: Near- and far-UV CD spectra for DNI protein collected simultaneously. 
Near/far-UV CD spectra are shown for (A) 0.5 mg/ml DNI at pH 6 and (B) expanded view of 
the near-UV region. 
 
The effect of temperature and pH on the DNI’s secondary and tertiary structures was 
further investigated by using thermal melt analysis. CD signals at five characteristic peaks 
(220, 262, 269, 284 and 291 nm) were monitored across the pH range of 6-8 (Figure 3-5). An 
overall loss in secondary and tertiary structures is observed as a function of increasing 
temperature. In the near- or far- UV CD regions, the onset temperature (Ton) of thermal 
transitions occurs at about 32.5 °C at pH 6, 45 °C at pH 7, and 47.5 °C at pH 8, suggesting 
that proteins at pH 8 are the most stable. 
For the rPA standard protein at pH 7, similar near- and far- UV CD spectra at 10 ºC were 
obtained compared to the spectrum produced by DNI (Figure 2). The CD thermal melt curves 
monitored at different wavelengths are shown in Figure 6. The Ton temperature occurs at 
about 42.5 °C, which is 2.5 °C lower than that observed for the DNI protein at pH 7.  
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Figure 3. Thermal stability of DNI (0.5 mg/ml at pH 6) as monitored by CD signals at 220, 
262, 269, 284 and 291 nm as a function of temperature. Each data point represents the mean 
of three independent runs, with error bars showing the standard deviation. 
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Figure 4. Thermal stability of DNI (0.5 mg/ml at pH 7) as monitored by CD signals at 220, 
262, 269, 284 and 291 nm as a function of temperature. Each data point represents the mean 
of three independent runs, with error bars showing the standard deviation. 
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Figure 5. Thermal stability of DNI (0.5 mg/ml at pH 8) as monitored by CD signals at 220, 
262, 269, 284 and 291 nm as a function of temperature. Each data point represents the mean 
of three independent runs, with error bars showing the standard deviation. 
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Figure 6. Thermal stability of rPA (0.5 mg/ml at pH 7) as monitored by CD signals at 220, 
262, 269, 284 and 291 nm as a function of temperature. Each data point represents the mean 
of three independent runs, with error bars showing the standard deviation. 
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Stressed Samples of DNI 
The near- and far-UV CD spectra of stressed samples (40 and 70 °C for one and two 
weeks) at pH 7 display similar spectra to those at 10 ºC (data not shown). For the samples at 
pH 7 (DNI at 40 °C for one, two and four weeks, DNI at 70 °C for one, two and four weeks), 
the thermal melts at 220, 264, 269, 284, and 291 nm all initiate at about 45 
o
C monitored in 
both the near and far UV CD regions (Figures 7A-E and Figures 8A-E for samples stressed at 
40 and 70 °C, respectively); the same results are seen in the non-stressed DNI samples. This 
suggests that lyophilized DNI manifests high resistance to physical degradation even after a 
month of exposure to 70 °C. The thermal melts do not change significantly when exposed to 
temperatures of 40 °C or 70 °C for four weeks. In addition, non-stressed and stressed DNI 
proteins show a 2.5 °C higher Ton value than rPA.  
 
Figure 7. Thermal stability of DNI stressed at 40 °C for one to four weeks (0.5 mg/ml at pH 7) 
as monitored by CD signals at 220, 262, 269, 284 and 291 nm as a function of temperature. 
Non-stressed DNI and rPA were added for comparison. Each data point represents the mean 
of three independent runs, with error bars showing the standard deviation. 
95 
 
 
Figure 8. Thermal stability of DNI stressed at 70 °C for one to four weeks (0.5 mg/ml at pH 7) 
as monitored by CD signals at 220, 262, 269, 284 and 291 nm as a function of temperature. 
Non-stressed DNI and rPA were added for comparison. Each data point represents the mean 
of three independent runs, with error bars showing the standard deviation. Because of the 
noise in the far UV region, the CD signal of DNI one week stressed samples was monitored 
at 229 nm instead of 220 nm. 
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4.3.1.3 Intrinsic Fluorescence Spectroscopy 
Non-Stressed Samples of DNI and rPA  
Figure 9A shows the changes in the peak maximum position of the fluorescence emission 
as a function of temperature for rPA and DNI. Both proteins show a peak position of about 
328 nm at low temperatures. With increasing temperature, the proteins begin to unfold, 
shifting the emission peak maximum by about 10 nm to 338 nm. This suggests less than 
complete unfolding where a λmax > 350 nm would be expected. This change in conformation 
occurs at about 40 
o
C, which is typically the Ton temperature for anthrax protective antigen. 
DNI was found to be least stable at pH 6, a condition which showed changes in peak position 
as early as 30 
o
C. High standard deviations were noted at high temperatures, presumably due 
to differences in aggregation pathways and final states. 
Stressed Samples of DNI 
When lyophilized DNI was exposed to temperatures of 40 and 70 °C, no significant 
changes in thermal profiles were seen. Figure 9B details the changes in fluorescence peak 
position maxima when exposed to 40 °C for up to four weeks. Reference rPA was also added 
for comparison. No changes in Ton values (40 °C) were observed for DNI when the proteins 
were maintained at 40 °C for four weeks. High standard deviations were observed at high 
temperatures, presumably due to aggregation. Figure 9C illustrates the changes in 
fluorescence peak position maxima when exposed to 70 °C for four weeks. Minor decrease in 
Tm was noticed for DNI when exposed to 70 °C for one week, although these small changes 
were within the standard errors of the measurements. A slight drop in Tm was also observed 
for DNI when exposed to 70 °C for four weeks. Overall, very similar thermal transition 
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curves were observed from both the non-stressed and stressed samples, suggesting that 
formulated DNI proteins have high thermal stability and are able to resist surprisingly 
elevated temperature stress at long incubation times. 
 
Figure 9 Intrinsic fluorescence peak position shifts as a function of temperature for (A) 
Non-stressed DNI and rPA samples, (B) DNI samples stressed at 40 
o
C, and (C) DNI samples 
stressed at 70 
o
C. Non-stressed DNI and rPA were added for comparison. Error bars reflect 
standard deviations from two separate runs. 
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4.3.1.4 Optical density measurements 
Non-Stressed Samples of DNI and rPA 
Optical density (OD) data at 350 nm were collected simultaneously during CD 
measurements. DNI showed aggregation a reflected by increased OD intensity with 
increasing temperature (Figure 10). The OD thermal unfolding results are overall consistent 
with the observations made from the CD measurements, with similar effects of pH and 
temperature seen on the aggregation stabilities of the proteins. Again, DNI at pH 6 shows a 
lower stability than samples at pH 7 and 8.  
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Figure 10. Thermal stability of DNI (0.5 mg/ml at pH 6, 7 and 8) as monitored by optical 
density at 350 nm. Each data point represents the mean of three independent runs, with error 
bars showing the standard deviation. 
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Stressed Samples of DNI 
For the stressed DNI protein (at 40 °C for one, two and four weeks, DNI protein at 70 °C 
for one, two and four weeks), the Ton of thermal transitions occurs at about 45 °C at pH 7 
(Figure 11A-B). Again, the same Ton values of the unstressed and stressed values were 
observed, indicating that the stressed samples manifest the same structural integrity as native 
DNI. 
 
 
Figure 11. Thermal stability of stressed DNI (0.5 mg/ml at pH 7) as monitored by optical 
density at 350 nm. (A) DNI at 40 °C for one to four weeks. (B) DNI at 70 °C for one to four 
weeks. Non-stressed DNI and rPA were added for comparison. Each data point represents the 
mean of three independent runs, with error bars showing the standard deviation. 
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4.3.1.4 Static Light Scattering 
Non-Stressed Samples of DNI and rPA 
Light scattering was also monitored while acquiring intrinsic fluorescence data using a 
secondary detector placed 180
o
 to the primary fluorescence detector. Increases in light 
scattering are observed due to the formation of aggregates. Figure 12A shows the changes in 
light scattering intensity as a function of temperature. Increases in light scattering were 
observed at about 45 °C for rPA and DNI at pH 7. This increase in scattering was delayed 
slightly for DNI at pH 8. DNI was found to be least stable at pH 6. Increases in light 
scattering were observed as early as 40 
o
C for DNI at pH 6. 
Stressed Samples of DNI  
Similar to the results observed by intrinsic fluorescence spectroscopy and other 
techniques, no significant differences in the transition onset temperatures were observed 
when DNI was stressed at 40 
o
C for up to four weeks. The changes in light scattering 
intensity as a function of temperature are shown in Figure 12B for DNI samples exposed to 
40 
o
C. When DNI was stressed for two weeks at 70 
o
C, a slight reduction in the transition Ton 
was observed. This is shown in Figure 12C. Very high standard deviations were observed in 
most samples, however, presumably due to variations in the settling of the protein aggregates 
in the cuvette.    
4.3.1.5 Dynamic Light Scattering 
The hydrodynamic properties of the DNI proteins were measured by dynamic light 
scattering. Results show that native unstressed proteins at pH 7 have a diameter of 6.7±0.4 
nm based on analysis of particle number distribution. All of the stressed samples have a 
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similar diameter around 6.7 nm. These results suggest that stressed and unstressed samples 
have similar hydrodynamic properties. 
  
 
Figure 12. Thermal stability of stressed DNI (0.5 mg/ml at pH 7) as monitored by static light 
scattering. (A) Non-stressed DNI and rPA samples, (B) DNI at 40 °C for one to four weeks. 
(C) DNI at 70 °C for one to four weeks. Non-stressed DNI and rPA were added for 
comparison. Each data point represents the mean of three independent runs, with error bars 
showing the standard deviation. 
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4.3.1.6 Deamidation studies using capillary isoelectric focusing (cIEF) 
In the absence of urea, DNI only shows poorly separated peaks (data not shown). In the 
presence of urea (6 M), however, DNI shows five major peaks with moderate resolution. 
Figure 13 shows the cIEF results of day 0’s DNI. Five major peaks could be easily identified 
at day 0, which suggests that this material was a heterogeneous mixture of charge isoforms. 
However, the peak at pI value around 6.00 is very small compared to the other four peaks. 
Figure 13 also shows the cIEF profiles of DNI protein at elevated temperature (40 and 70 °C) 
with increased incubation time (four weeks). For the four weeks stressed sample at 
40 °C(Figure13B), the cIEF profile is similar to that of the unstressed sample. For the four 
weeks stressed sample at 70 °C (Figure13C), the largest peak (pI=6.19) decreases while other 
four smaller peaks increase. The amount of three acidic isoforms (pIs around 6.00, 6.05 and 
6.12) increase, and one basic isoform with pI value of 6.27 also increases. By quantification 
of the peak areas of five isoforms (Table 2 and Table 3), for the samples stressed at 40 °C, we 
see that the major isoform with pI value of 6.19 decreases slightly from 59.6% to 56.0%, 
while other isoforms increase their area percentages slightly (Table 2). In contrast, for the 
samples stressed at 70 °C, the major isoform (pI=6.19) decreases dramatically from 59.6% to 
40.2%, and other four isoforms increase their area percentages (Table 3). These observations 
suggest that the DNI samples maintain their chemical stability under the condition of the 
40 °C for up to 4 weeks. And DNI samples are prone to deamidate at higher temperature such 
as 70 °C with increased incubation time. 
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Figure 13. cIEF electropherograms of 0.4 mg/ml stressed DNI at pH 7. (A) DNI at Time 0. (B) 
DNI at 40 °C for four weeks. (C) DNI at 70 °C for four weeks. 
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 Time 0 Time 1 week 
40°C 
Time 2 weeks 
40°C 
Time 4 weeks 
40°C 
Peak 1  1.42± 0.16% 1.48±0.13% 1.55±0.32% 1.85±0.15% 
Peak 2 7.22±0.16% 7.46±0.10% 7.79±0.20% 8.24±0.27% 
Peak 3  27.10±0.21% 27.83±0.38% 28.38±0.05% 29.15±0.29% 
Peak 4  59.62±0.18% 58.62±0.73% 57.35±0.52% 55.93±0.60% 
Peak 5  4.64± 0.03% 4.61± 0.11% 4.93± 0.05% 4.81± 0.11% 
 
Table 2: Quantification of the isoform’s peak area of the unstressed and stressed samples at 
40°C for four weeks. 
 
 
 Time 0 Time 1 week 
70°C 
Time 2 weeks 
70°C 
Time 4 weeks 
70°C 
Peak 1  1.42± 0.16% 2.69±0.01% 3.47±0.15% 4.15±0.31% 
Peak 2 7.22±0.16% 10.75±0.21% 12.63±0.02% 14.79±0.32% 
Peak 3  27.10±0.21% 31.00±0.29% 32.13±0.30% 32.67±0.18% 
Peak 4  59.62±0.18% 48.90±0.37% 44.33±0.42% 40.24±0.58% 
Peak 5  4.64± 0.03% 6.66± 0.14% 7.43± 0.04% 8.15± 0.58% 
 
Table 3: Quantification of the isoform’s peak area of the unstressed and stressed samples at 
70°C for four weeks. 
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4.3.1.7 Size-Exclusion Liquid Chromatography 
The typical chromatographs of 1.0 mg/ml DNI at pH 7 at time 0, time four weeks 40 
o
C 
and time four weeks 70 
o
C are shown in Figure 14. Two SEC peaks are observed at retention 
times of 10.4 and 11.7 mins, respectively. The molecular weights of the species were 
estimated by using standard proteins’ calibration plot. The bigger peak (peak 2) corresponds 
to the monomer of the protein, and the smaller peak (peak 1) corresponds to the dimmer of 
the protein. There seems to be no differences between the samples at time 0 and the samples 
at time four weeks 40 
o
C. For the sample stressed for four weeks at 70 
o
C, the dimmer peak 
area increases from 4.9 % to 9.1% while the monomer peak area decreases from 95.1% to 
90.9%. By quantification of the peak area (Table 4), no significant differences of the peak 1 
area (about 5%) and peak 2 area (about 95%) were observed when DNI was stressed at 40 
o
C 
for up to four weeks. Only about 0.5% slight changes of the peak areas of peak 1 and peak 2 
were observed with increased incubation time up to four weeks. These observations suggest 
that formulated DNI proteins have high thermal stability to resist elevated temperature up to 
40 
o
C with increased incubation time. However, for the stressed samples at 70 
o
C, we see 
bigger changes of the two peak areas. The peak 1 area increases progressively from 4.9% to 
9.1% and the peak 2 area decreases from 95.1% to 90.9% with increasing the incubation time. 
These results suggest that the samples stressed at 70 
o
C are easy to form small amount of the 
aggregates at high temperature. However, majority of samples (about 90.9%) still maintain in 
the monomer state. 
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Figure 14: Size exclusion HPLC chromatograms of 1.0 mg/ml stressed DNI at pH 7. Black 
curve: DNI at Time 0. Red curve: DNI at 40 °C for four weeks. Blue curve: DNI at 70 °C for 
four weeks. 
 
 
 Time 0 Time 1 week 
40°C 
Time 2 weeks 
40°C 
Time 4 weeks 
40°C 
Peak 1  4.9± 0.13% 5.0±0.03% 5.2±0.06% 5.4±0.05% 
Peak 2 95.1±0.13% 95.0±0.03% 94.8±0.06% 94.6±0.05% 
 Time 0 Time 1 week 
70°C 
Time 2 weeks 
70°C 
Time 4 weeks 
70°C 
Peak 1  4.9± 0.13% 6.8±0.06% 7.5±0.03% 9.1±0.04% 
Peak 2 95.1±0.13% 93.2± 0.06% 92.5± 0.03% 90.9± 0.04% 
 
Table 4. Quantification of the SEC peak 1 and peak 2 areas for DNI samples stressed at 40 
o
C 
and 70 
o
C from one to four weeks. Triplicate measurements were made. 
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4.3.1.8 Micro flow imaging 
The unstressed and stressed samples of DNI at pH 7 were analyzed for sub-visible 
particles or aggregates in the 2-100 µm range using micro-flow imaging. The particle count 
and size distribution for DNI stressed at 40 
o
C are shown in Figure 15A. At time 0, very few 
particles are seen at all size ranges. The number of protein particles progressively increase 
with time when the samples are stressed at 40 
o
C. Very similar trends were seen when DNI 
was exposed to 70 
o
C, as shown in Figure 15B, although a more significant increase in 
particle count was observed after two weeks. It must be noted that even after weeks of 
exposure at high temperatures, the particle count remained below the USP guidelines for the 
number of sub-visible particles for injectables, which is about 6000 per 10 µm particles and 
600 per 25 µm particles.  
4.3.2 Adjuvant-Antigen study 
4.3.2.1 Adsorption studies 
Initial adsorption studies were conducted to determine whether DNI preferentially binds 
to Alhydrogel or Adjuphos. These experiments were done separately in three different buffers: 
20 mM phosphate, 10 mM histidine or 10 mM imidazole. Figure 16A shows the percent 
adsorption of DNI to Alhydrogel and Adjuphos in the different buffer systems tested. Near 
100% adsorption of DNI to Alhydrogel was observed in histidine and imidazole buffers. 
Phosphate presumably lowered adsorption of DNI to Alhydrogel by modifying the surface 
charge by converting aluminum hydroxide to aluminum phosphate. Histidine was therefore 
chosen as the buffer of choice in which to perform adjuvant studies. Extremely low levels of 
adsorption to Adjuphos were observed. Adsorption isotherms were constructed for both DNI 
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and rPA in the histidine buffer. In Figure 16B, Alhydrogel demonstrated a high adsorption 
capacity for DNI. 125 µg of Alhydrogel was able to adsorb over 240 µg of DNI and rPA.  
 
 
Figure 15: Particle count and size distribution for DNI samples stressed at 40 
o
C (top) and 70
 
o
C (bottom). 1 ml of DNI sample was analyzed for each run. 
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Figure 16 (A) Initial adsorption studies of DNI to Alhydrogel and Adjuphos in three different 
buffers. 0.2 mg/ml of antigen was adsorbed to 0.5 mg/ml adjuvant in 0.5 ml dose. 
 
 
Figure 16 (B) Adsorption isotherms for DNI and rPA in presence of 0.5 mg/ml Alhydrogel. 
 
 
 
 
110 
 
4.3.2.2 Stability of DNI on the surface of Alhydrogel 
The stability of DNI on the surface of Alhydrogel was assessed using intrinsic 
fluorescence. The protein was adsorbed onto Alhydrogel as described in section 2.2. The 
resulting suspension was then transferred to a 1 mm cuvette and allowed to settle overnight. 
The resulting pellet was then analyzed with intrinsic fluorescence spectroscopy. Figure 17 
shows the melting curves for DNI and rPA on the surface of the Alhydrogel. The melting 
curves of protein alone are included as well. The buffer used in these experiments was again 
10 mM histidine. A significant decrease in thermal stability is seen in the case of both DNI 
and rPA when adsorbed onto the surface of Alhydrogel. The steep transition is replaced by a 
gradual transition that initiates at around room temperature. DNI appears to be slightly more 
stable than the rPA control while adsorbed onto the surface, as evidenced by the small blue 
shifts in the peak positions between the two melting curves, but additional studies need to be 
undertaken to verify this.  
 
Figure 17: Intrinsic fluorescence peak position shifts as a function of temperature for DNI 
and rPA control when adsorbed on the surface of Alhydrogel. Melting curves of protein alone 
are added for comparison as well. 
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4.4 CONCLUSIONS 
 By using a variety of spectroscopic, hydrodynamic and particle-sizing techniques, the 
conformational stability of the DNI was characterized comprehensively under unstressed and 
stressed conditions. These techniques provide insight into different levels of protein structure 
(secondary and tertiary) and aggregation behavior of DNI and rPA. Comparing the stability 
profiles of DNI and rPA at pH 7 with various technqiues, both proteins show overall similar 
conformational stability. Comparing the stability profiles of non-stressed and stressed DNI 
showed that the thermally stressed molecule appears to retain its native structure up to 
temperatures as high as 70 
o
C for a month. Lyophilized DNI was formulated with common 
excipients that permit preservation of protein structure in the dried state. The long-term 
stability of DNI was also demonstrated after refrigerated storage for about eight years. 
Adjuvant adsorption studies showed that DNI had much more efficient binding to aluminum 
hydroxide than aluminum phosphate. Both adsorbed DNI and rPA showed a significant 
decrease in thermal stability through monitoring with intrinsic fluorescence. More 
importantly, our collaborator’s work (Soligenix Inc.) showed that animals vaccinated with an 
aluminum salt adjuvanted DNI-based vaccine developed high titer neutralizing antibodies 
that confer protection against anthrax (results not illustrated).  
 This study provides important stability information for the development of an anthrax 
vaccine to protect against anthrax disease either as a pre-exposure prophylactic vaccine or 
post-exposure vaccine. DNI demonstrates significant improvements in safety and 
immunogenicity compared to PA in mice studies.
5
 This suggests that DNI has significant 
potential to be used as an alternative antigen in anthrax vaccines. Since the primary use of an 
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anthrax vaccine is for bioterrorism defense, the remarkable thermostability of DNI should 
permit it to be stored for long periods of time for use when necessary. In addition, DNI can 
potentially provide therapeutic activity in antitoxic therapy, which provides immediate 
protection against anthrax toxins in vivo.
8,5
 The data described here define critical parameters 
(such as solution pH, temperature and buffers) affecting the stability of the DNI protein. It 
should thus be useful to aid in the development of stable DNI-based anthrax vaccines.   
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Chapter 5 Physical Characterization and Formulation Development of a 
Recombinant Pneumolysoid Protein based Pneumococcal Vaccine 
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5.1 Introduction 
Streptococcus pneumoniae (pneumococcus) is one of the leading causes of death 
affecting high-risk populations such as infants, the elderly and patients with 
immunodeficiency.  Pneumococcal disease is responsible for more than half a million deaths 
annually for children under five years of age.
1,2,3
 S. pneumoniae has 40 serogroups 
comprising more than 90 serotypes worldwide, and presents in various populations based on 
geographical location and age. The major clinical effects of pneumococcal disease are 
pneumonia, bacteremia and meningitis, which can lead to high morbidity and mortality, 
particularly in the young and elderly.
4
 In the United States, up to 175,000 hospitalizations 
from pneumococcal pneumonia occur per year, with approximately 50,000 cases of 
pneumococcal bacteremia and 3000-6000 cases of pneumococcal meningitis annually.
4
 The 
pneumococcal disease can be treated with antibiotics or prevented by vaccines, although their 
efficacy is limited due to the wide variety of bacterium serotypes, the diversity of 
geographical regions and populations affected, and the resistance of pneumococci to 
antibiotics. Therefore, major efforts have been undertaken to develop effective vaccines 
against pneumococcal infections using common protein antigens to effectively cover as many 
serotypes as possible for both regional and global use.  
Currently, polysaccharide and polysaccharide-conjugate based vaccines are 
commercially available in the US. Although these vaccines are effective against the 
most-prevalent serotypes causing invasive pneumococcal disease, their efficacy is limited 
worldwide due to the restricted number of serotypes recognized by these prophylactic 
agents.
4,5
 Non-vaccine serotypes have the potential to become the main disease causing 
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agents, thereby accentuating the disease (known as “replacement disease”) in the future.
4
  
Thus, the long-run efficacy of currently marketed vaccines could be threatened by serotype 
replacement. In addition, worldwide use of current vaccines is potentially restricted due to 
serotype differences in different geographic locations. 
Alternatives to current serotype-specific vaccinations are being investigated. The 
development of recombinant protein-based vaccines, which target common pneumococcal 
protein antigens across different serotypes, is attractive for several reasons.
4,6
 Protein-based 
vaccines are T-cell dependent in nature, and are expected to be immunogenic in infants and 
the elderly. More importantly, coverage of protein-based vaccines is expected to be broader 
since they contain protein antigens common to all or most pneumococcal serotypes. In 
addition, protein-based vaccines are also expected to be less expensive because of their 
relative simplicity in production since they contain fewer components than multivalent 
conjugate vaccines currently on the market. Protein–based vaccines are thus an attractive and 
promising approach to the prevention and treatment of invasive pneumococcal disease. 
Multiple putative pneumococcal virulence proteins have been investigated and 
pneumolysin has emerged as a promising vaccine protein antigen candidate. Pneumolysin, a 
sulfhydryl-activated cytolytic toxin (53 kDa), is produced by virtually all invasive strains of S. 
pneumoniae and is considered an important virulence factor.
7,8,9,10
 It is involved in the 
pathogenesis of invasive pneumococcal disease and has been shown to be immunogenic in 
numerous animal models
11,12,13
 and humans
14,15
, and thus has become a promising vaccine 
target. Due to its cytolytic effects, however, pneumolysin cannot be used directly in a vaccine. 
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Non-toxic, genetically altered pneumolysin toxoid mutants have been generated and shown to 
be immunogenic.
16,17
 We have used a recombinant pneumolysin mutant (L460D) where the 
L460D mutation removes toxic cytolytic activity.
18,19
 The pneumolysoid antigen (L460D) has 
been shown to be effective against Streptococcus pneumoniae colonization in the lungs of 
mice
20,21
 and thus is a promising vaccine candidate for pneumococcal disease.   
To develop a stable pneumolysoid (L460D) based vaccine formulation, the structural 
stability of the pneumolysin mutant protein was characterized and assays were developed to 
screen potential stabilizers. The physical stability of the L460D pneumolysoid was 
characterized by various techniques over the pH range of 3 to 8 from 10 to 87.5ºC. Purified 
recombinant proteins are generally not highly immunogenic and thus an adjuvant is usually 
used to boost their immunogenicity.
22,23
 Studies of L460D pneumolysoid with an aluminum 
hydroxide adjuvant (Alhydrogel) were thus performed to characterize antigen/adjuvant 
interactions and to better understand the stability of protein antigen on the surface of 
Alhydrogel. 
5.2 MATERIALS AND METHODS 
5.2.1 Materials  
The pneumolysoid (L460D) antigen was supplied by St. Jude Children’s Research 
Hospital (Memphis, TN) as a solution in 10% glycerol in phosphate buffered saline (PBS). 
For the physical characterization, individual protein solutions at pH 3-8 were prepared by 
dissolving L460D pneumolysoid in 20 mM citrate phosphate buffers with a total ionic 
strength of 0.15 (adjusted with NaCl).  Before making measurements, the samples of L460D 
pneumolysoid were dialyzed twice at 4 °C using Slide-A-Lyzer® Dialysis Cassettes (Thermo 
117 
 
Scientific, Rockford, IL) with a 3.5 kDa MW cutoff.  For excipient screening and adjuvant 
studies, 10 mM histidine buffer at pH 6 was used. The adjuvant alhydrogel was purchased 
from Brenntag Biosector (Frederikssund, Denmark). 
5.2.2 Physical Characterization 
5.2.2.1 Far-UV Circular Dichroism Spectroscopy 
Circular dichroism analysis was performed with a Chirascan-plus circular dichroism 
spectrometer (Applied Photophysics Ltd, Leatherhead UK) equipped with a Peltier 
temperature controller and a 4-position cuvette holder.  Far UV spectra of samples (0.1 
mg/ml) were collected in the range of 200-260 nm using a 0.1 cm path length cuvette.  A 
sampling time per point of 1 s and a bandwidth of 1 nm were used.  The CD signals of the 
samples at 217 nm were monitored as a function of temperature from 10 to 87.5ºC at 2.5ºC 
intervals. Duplicate measurements were made with an equilibration time at each temperature 
of 1 minute.  
5.2.2.2 Intrinsic Fluorescence Spectroscopy 
The intrinsic fluorescence of L460D pneumolysoid (0.1 mg/ml) was measured using a 
QuantaMaster Spectrofluorometer (Photon Technology International (PTI), Inc., Birmingham, 
NJ) equipped with a 4-position cell holder. Fluorescence emission spectra were recorded as a 
function of temperature (10-87.5ºC) and pH (3-8). Duplicate samples were measured using an 
excitation wavelength of 295 nm (> 95% tryptophan emission).  Emission spectra were 
collected from 300 to 400 nm with a step size of 1 nm. The spectra were collected at 2.5ºC 
intervals with a 3 min equilibration time at each temperature.  A 1 cm path length quartz 
cuvette was used in all experiments. Data analysis was performed using FelixTM (Photon 
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Technology International, Inc.) software. The position of the protein’s emission wavelength 
maximum was determined using a mean spectral center of mass method (msm) executed in 
Origin 7.0 software. This results in a value that is shifted to a 8-12 nm higher wavelength 
than the actual peak position.  
5.2.2.3 Extrinsic Fluorescence Spectroscopy 
8-Anilino-1-naphthalene sulfonate (ANS) was used as an extrinsic probe to study the 
appearance of apolar binding sites in the protein under the various forms of stress employed.  
The interaction of ANS with the hydrophobic surfaces of the L460D pneumolysoid was 
monitored as a function of temperature (10-87.5ºC) and pH (3-8) using the PTI 
spectrophotometer. Each sample solution (0.1 mg/ml) contained 25 µM diluted ANS (an 
optimized molar ratio of the ANS to the protein of 15:1). Samples were excited at 375 nm 
and spectra were collected from 400 to 600 nm at 2.5ºC intervals. Duplicate measurements 
were made using a 1 cm path length quartz cuvette.  Buffer baselines containing ANS were 
subtracted from each sample spectrum prior to analysis. Peak intensities of the emission 
spectra were obtained using the msm method as described above. 
5.2.2.4 Static Light Scattering 
The aggregation behavior of L460D pneumolysoid was determined simultaneously 
during the intrinsic fluorescence experiments employing a second photomultiplier located 
180° to the fluorescence detector. The scattering intensities at 295 nm were obtained using 
the same temperature program described above. Buffer baselines were subtracted from each 
sample spectrum before data analysis. 
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5.2.2.5 Data Visualization Techniques 
Three-index empirical phase diagrams, radar charts and Chernoff face diagrams are 
used to summarize the large amounts of biophysical data generated from multiple techniques 
and to visualize macromolecular stability of L460D pneumolysoid as a function of various 
environmental stress variables. These techniques visualize data using (1) a red, green and 
blue (RGB) color system, (2) equiangular polygons, and (3) human facial features, 
respectively. The diagrams are used to identify coherent parameter regions that define protein 
structural states as a function of temperature and pH, in this case.  
In brief, the secondary structure index (SI), tertiary structure index (TI), and 
aggregation index (AI) are calculated from the collected data sets. These indices represent the 
difference amounts of structure (secondary, tertiary and quaternary) of a macromolecule 
under a given set of environmental conditions. In this study, the secondary, tertiary, and 
aggregation indices are calculated from far UV CD signals at 217 nm, intrinsic fluorescence 
peak positions, and static light scattering data, respectively. A structural index is defined as 
the degree of corresponding structural change within a given range of environmental stress 
conditions. The structure index varies from a value of zero to one, indicating the lowest to 
highest amount of the corresponding structure seen over the entire range of solution variables. 
For example, native secondary or tertiary structure is represented by a value of 1, while the 
most significantly structurally altered state is represented by 0. Similarly, the AI is also 
defined a value from 0 to 1. The number 0 of AI implies no protein aggregation while a value 
of 1 reflects the maximum level of aggregation.  
The three-index EPD is constructed by mapping each structural index to an RGB 
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color component. We have assigned SI to red, TI to green, and AI to blue. Thus, a color 
produced by the summation of these three color components can be mapped to a specific 
structural state of the macromolecule.  For example, yellow or shades of yellow typically 
represent the native state of a protein, while the blue color indicates an aggregated state. The 
three-index EPD provides a meaningful relationship between color itself and molecular 
features.  It cannot, however, include data from more than three experimental methods.   
The radar chart and the Chernoff face diagram can display more than three 
experimental data sets. ANS data are also used in both cases in this study. All data are 
adjusted to represent the native state either as a dot or a smiling face (along with a short nose 
combined with no hair or ears). Because both original diagrams require more space to 
represent molecular features (see supplemental Figure S1) compared to the three-index EPD, 
the clustered versions of diagrams are used to symbolize characteristics of macromolecules in 
selected regions. The apparent phase boundaries are first calculated using a k-Means 
clustering algorithm then manually corrected based on interpretation of the raw data. The 
objective of the clustering analysis is to find groups of solution variables where the 
macromolecule is observed to have a similar conformational state. For each solution variable, 
it is possible to construct a vector of measurements that detect the structural behavior of the 
macromolecule. This vector can be represented as a single point in the multidimensional 
measurement space. The k-Means clustering algorithm tries to partition these points into k 
clusters (groups) in which each point belongs to the cluster with the nearest distance. The 
assumption is that if a group of points that is close in Euclidean distance, the macromolecule 
with the associated solution variables can be considered to be in a similar conformational 
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state.
24,25,26,27,28
 Each cluster is represented by a single radar chart and Chernoff face. These 
single iconic plots are then generated by an average value of the data inside a cluster. A more 
complete description of the construction and interpretation of these three phase diagrams are 
described elsewhere.
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5.2.3 Excipient Screening  
Based on the initial characterization studies, L460D pneumolysoid was found to be most 
stable at pH 6-7. Based on this, a common buffer consisting of 10 mM histidine at pH 6 was 
employed for the excipient screening and adjuvant work. NaCl was not used in these studies 
to decrease the osmolarity of the formulations. Intrinsic tryptophan fluorescence spectroscopy 
and static light scattering as a function of temperature were used to screen for stabilizing 
excipients for the L460D pneumolysoid antigen.  
In the initial round of screening, higher concentrations of the excipients were tested to 
facilitate the selection of the more promising stabilizers under accelerated stress conditions.  
These stabilizers were then evaluated in the second round over a wider range of concentration.  
The effect of the selected stabilizers (sucrose and trehalose at 10 or 15% weight percent) on 
the stability of L460D pneumolysoid (at 0.1, 0.5, 1.0 and 4.0 mg/ml) was then examined (see 
results). Because a high concentration (4.0 mg/ml) of protein was used in the fluorescence 
and static light scattering studies, a short pathlength cell (2 mm x 10 mm) was used. 
Excitation of the proteins was carried out along the short path length axis (2 mm). For other 
protein concentrations, the 10 mm x 10 mm pathlength cells were used.  
The extent of stabilization of L460D pneumolysoid by the excipients was measured 
by their ability to shift the melting temperature (Tm) of the protein to higher temperatures. 
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The melting temperature is defined as the temperature at which the transition from folded to 
unfolded states is half complete. Tm values were calculated using a Boltzmann function to 
produce a sigmoidal curve using Origin 8.1 software. 
The stabilizing effects of sucrose and trehalose (at 10 or 15% weight percent) were 
examined by differential scanning calorimetry (DSC) at 1.0 mg/ml. A capillary differential 
scanning calorimeter (MicroCal LLC, Northampton, MA) was used for these measurements.  
A scan rate of 60 ºC/hour was used from 6 to 82ºC. DSC data were analyzed using Origin 
version 7.0 software. The thermogram for buffer alone was subtracted from the thermograms 
of the proteins in solution prior to data analysis.  
5.2.4 Adjuvant-Antigen Studies 
5.2.4.1 Adsorption Study 
 Experiments to study L460D pneumolysoid in the presence of adjuvant were conducted 
by adding Alhydrogel to the protein solution. An adsorption isotherm was constructed for 
L460D pneumolysoid at nine protein concentrations from 0.05 to 3.25 mg/ml (concentrations 
are listed in Supplemental Figure S3) in the presence of 0.6 mg/ml Alhydrogel. Protein 
solutions containing Alhydrogel were prepared and tumbled in an end-over-end rotator for 30 
minutes at 4ºC. The resultant suspension was centrifuged at 5,000xg for 4 minutes to pellet 
the adjuvant using an IEC MicroMax microcentrifuge (International Equipment Company, 
Needham Heights, MA). The amount of protein in solution (non-bound) was determined by 
measuring the protein concentration in the supernatant using UV absorbance spectroscopy 
and an extinction coefficient of 69960 M
-1
cm
-1
. 
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5.2.4.2 Stability of L460D Pneumolysoid on the Surface of the Aluminum Hydrogel  
The thermal stability of the adsorbed protein was assessed by front-face fluorescence 
spectroscopy and DSC. Front face fluorescence was used to probe changes in the tertiary 
structure of the protein, both in solution and when adsorbed to adjuvant. Front face sampling 
geometry was necessary because of the opacity of the adjuvant suspensions. Samples of 
protein adsorbed onto the adjuvant were prepared as described previously for the binding 
isotherms.  For all front face fluorescence studies, protein concentration was 1.0 mg/ml. For 
samples containing adjuvant, the alhydrogel concentration was 1.2 mg/ml. Samples 
containing adjuvant were allowed to settle in the cuvettes for about 14 hours at 4ºC to 
minimize variability due to settling of the adjuvant during the course of the experiment. An 
excitation wavelength of 295 nm was employed, and emission spectra were recorded from 
305 to 390 nm using a PTI spectrophotometer.  
For DSC studies, the thermal transition temperatures were determined separately for 
protein in solution and protein adsorbed onto the adjuvant. Samples containing protein (1.0 
mg/ml) completely adsorbed onto the surface of the adjuvant (0.6 mg/ml) were prepared as 
described for the binding isotherms. Both the protein samples and buffers containing adjuvant 
were settled in the DSC cells for about 10 hours at 4ºC to minimize variability. A scan rate of 
60 ºC/hour was used to scan from 6 to 82ºC. Buffers containing adjuvant and samples 
containing adjuvant were analyzed separately.   
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5.3 Results 
5.3.1 Physical Characterization 
5.3.1.1 Far-UV Circular Dichroism Spectroscopy 
Representative CD spectra of L460D pneumolysoid at 10ºC are shown in Figure 1A. 
Samples at pH range of 3 to 8 have CD spectrum displaying a broad minimum at near 217 nm 
and a shoulder at 208 nm. At pH 7, the secondary structure components were estimated by 
CDNN CD spectra deconvolution software
29 
to be as follows: α-helix (~35%), β-structure 
(~33%) and random coil (~31%). The CD spectra at pH 6 and 7 show the two strongest CD 
signals compared to those at other pH values. The spectrum at pH 4 shows the weakest CD 
signals in the far UV CD region, suggesting a loss of secondary structure at low pH.  
The effect of temperature on L460D pneumolysoid secondary structure was investigated 
using CD thermal melt analysis at 217 nm (Figure 1B). An overall loss in the secondary 
structure is observed as a function of increasing temperature across the pH range 4 to 8, 
excluding the sample at pH 3. At pH 3, a very small CD signal change is seen, suggesting that 
the protein exists in a conformationally altered state. The onset temperature (Tonset) of thermal 
transitions occurs at about 43°C at pH 5, 50°C at pH 6 and 7, and 45°C at pH 8, suggesting 
that protein at pH 6 and 7 is most stable. At pH 4, the protein is much less stable and the 
transition onset is near 33°C.  Based on these CD studies, the most conformationally stable 
form of the protein in terms of overall secondary structure exists between pH 6 and 7. 
5.3.1.2 Intrinsic Fluorescence Spectroscopy 
 Alterations in the tertiary structure of L460D pneumolysoid were studied by monitoring 
the changes in its tryptophan emission peak position as a function of pH and temperature 
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(Figure 1C).  At pH 4 to 8, a trend of decreasing peak position followed by a sharp blue shift 
in the Trp emission maximum is observed with increasing temperature, suggesting that the 
L460D pneumolysoid aggregates with increasing temperature (i.e., the blue shift indicating 
burial of indole side chains rather than to red shifts expected for exposure).  In contrast, at  
 
Figure 1. Biophysical characterization of recombinant L460D pneumolysoid. (A) Far-UV 
circular dichroism (CD) at 10°C. Thermal stability of protein as a function of temperature and 
solution pH: (B) CD signal at 217 nm, (C) intrinsic Trp fluorescence emission maximum 
(peak position), (D) static light scattering intensities, (E) ANS fluorescence intensities, (F) an 
enlargement of Y axis of Figure 1E.  Each data point represents the mean of two 
independent samples, and error bars show the standard deviation. Protein concentration was 
0.1 mg/ml in a citrate-phosphate buffer with NaCl at indicated pH values. 
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pH 3 a gradual linear increase in the emission peak position is observed and no shift to lower 
wavelength is seen. This difference again suggests that the protein exists in a 
conformationally altered state at low pH. The Tonset temperatures occur at about 28°C at pH 4, 
43°C at pH 5 and 8, and 45°C at pH 6 and 7. These Tonset values suggest that the protein is 
most stable at pH 6-7. The Tonset values were approximately 5°C lower than that seen with 
CD, suggesting molten-globular state formation under these conditions. Other than this, the 
temperature-dependent Trp fluorescence data show results generally similar to those obtained 
in the CD studies (Figure 1B). 
5.3.1.3 Static Light Scattering 
The aggregation behavior of the L460D pneumolysoid was examined by monitoring the 
scattered light at the fluorescence excitation wavelength of 295 nm. The protein manifests 
aggregation behavior over the pH range 4 to 8, while no aggregation is observed at pH 3, 
presumably due to its altered structure (Figure 1D).  At pH 4, an increase in scattering 
intensity is observed at about 28°C, whereas at pH 5, 6, 7, and 8, the increases in light 
scattering occur near 40, 45, 48 and 43°C, respectively. The overall effects of pH and 
temperature on the structural stability observed by static light scattering are similar to the 
results obtained from CD (Figure 1B) and intrinsic fluorescence (Figure 1C).  
5.3.1.4 Extrinsic Fluorescence Spectroscopy 
ANS is a fluorescent dye that binds to nonpolar regions in proteins, resulting in large 
increases in its fluorescence quantum yield and a blue shift in peak position. It should be 
noted, however, that there may be an electrostatic component to this interaction. Figure 1E 
and 1F shows the thermal melting curves of L460D pneumolysoid at various pH values. 
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These curves were obtained by monitoring the ANS emission peak intensity as a function of 
temperature. At pH 3, ANS fluorescence shows significant fluorescence intensity even at low 
temperatures (Figure 1E). This increased fluorescence intensity is presumably induced by the 
binding of ANS to the structurally altered protein at low pH. This observation is in agreement 
with results obtained from Figures 1B-1D.  Increased ANS fluorescence intensity is 
observed over the pH range of 4 to 8 (Figure 1F).  The Tonset values for these transitions 
occur at about 28°C at pH 4, 43°C at pH 5 and 8, 48°C at pH 6 and 45°C at pH 7. As 
observed with other techniques, the L460D pneumolysoid shows its greatest structural 
stability in the pH range of 6-7.  
5.3.1.5 Data Visualization Techniques 
The various types of data generated were integrated into three visual diagrams to 
provide a more global picture of L460D pneumolysoid behavior under the stressed conditions 
of temperature and pH (Figures 2A to C). The non-clustered plots of Figures 2B and C are 
shown in the Supporting Figure S1. Five similar apparent structural phases for the protein can 
be recognized in all three diagrams (Figure 2A, B, C and S1). In the three-index EPD (Figure 
2A), regions of continuous color define uniform structural states, while abrupt changes in 
color identify alterations in the physical state of the protein over the conditions examined.  
In Region 1, samples at pH 5 to 8 manifest a similar color (yellow or shades of yellow) below 
47.5°C, suggesting a similar conformation for native L460D pneumolysoid across this pH 
range.  Samples at pH 6 and 7 show the highest stability. Samples at pH 5 and 8 show 
similar stability, but lower compared to samples at pH 6 and 7. In Regions 2 and 3, samples at 
pH 3 and 4 show distinct colors from those in Region 1. The sample at pH 4 probably 
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contains protein in a partially unfolded state, while the sample at pH 3 contains protein in a 
more structurally altered state, even at low temperatures. Region 4 (blue color) indicates that 
the protein in the high-temperature region are highly structurally aggregated. Region 5 
defines a structurally altered state with a lower degree of aggregation compared to that in 
Region 4. Similar results were observed in the radar chart (Figure 2B) and Chernoff face 
diagrams (Figure 2C).  From the three different EPD displays of the biophysical data, we 
can see that the most stable region for formulations of L460D pneumolysoid is in the pH 
range of 6 to 7 and below 48°C. 
5.3.2 Excipient Screening 
Following the physical characterization of L460D pneumolysoid, a screening study was 
performed to identify stabilizers that enhance thermal stability and minimize aggregation in 
solution. Based on the EPD displays, pH 6 was used for this study (using a 10 mM histidine 
buffer). Tryptophan fluorescence spectroscopy and static light scattering techniques were 
used to screen for stabilizing compounds from a GRAS (Generally Regarded as Safe) library 
of excipients (see Table 1 and text below).  
Results of fluorescence spectroscopy measurements of 0.1 mg/ml L460D pneumolysoid 
in the presence of selected destabilizers and stabilizers are shown in Figures 3A and B. The 
thermal transition of the protein is shifted to lower temperatures in the presence of 
destabilizers (e.g. guanidine), and is shifted to higher temperatures in the presence of 
stabilizers (e.g. trehalose, sucrose and sorbitol). Similar results were observed by static light 
scattering measurements (Figure 3C).  In Figure 3C and Table 1, it can be seen that 
compared to the Tm of the L460D pneumolysoid alone, 0.3 M guanidine decreases the Tm by  
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Figure 2. (A) Three-Index EPD, (B) clustered radar chart, and (C) clustered Chernoff face 
diagram for the conformational stability of L460D pneumolysoid. The three-index EPD was 
prepared from CD at 217 nm, intrinsic fluorescence (peak position) and static light scattering 
data.  The radar chart and the chernoff face diagram use same three data sets but also 
include extrinsic (ANS) fluorescence as a fourth data set. Each cluster is represented as a 
radar chart or chernoff face diagram which averages the data of all images that belong to the 
cluster. For complete diagrams see supplementary Figure S1. 
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Figure 3. Conformational stability of L460D pneumolysoid in presence of various excipients.  
(A): The intrinsic Trp fluorescence emission maximum (peak position), (B): the emission 
peak intensity and (C): Static light scattering intensity of protein as a function of temperature 
with and without selected excipients.  Protein concentration was 0.1 mg/ml in a 10mM 
histidine buffer at pH 6. 
 
 
 
 
 
 
 
 
131 
 
  
Excipient  
(Molarity (M) or weight 
percent (%)) 
Intrinsic fluorescence  Static light 
scattering 
peak 
position  
Tm (
O
C) 
△Tm of 
peak 
position 
emission 
peak 
intensity 
T onset 
(
O
C) 
 
△T onset 
(
O
C) of 
emission 
peak 
intensity 
Tm (
O
C) △Tm 
(
O
C)  
Protein without excipients 
(0.1mg/ml) 
48.6  47.5  48.3  
Dextran T 70 (7.5x10
-6 
M) 48.8 0.2 47.5 0 48.4 0.1 
Aspartic Acid (0.075M) 49.1 0.5 47.5 0 49.5 1.2 
Glutamic Acid (0.15M) 48.1 -0.5 47.5 0 48.3 0 
Lactic Acid (0.15M) 48.7 0.1 47.5 0 48.6 0.3 
Malic Acid (0.15M) 50.0 1.4 47.5 0 51.3 3.0 
Dietanolamine (0.3M) 46.3 -2.3 45.0 -2.5 47.7 -0.6 
Guanidine (0.3M) 41.5 -7 40.0 -7.5 41.7 -6.6 
Histidine (0.2M) 47.4 -1.2 45.0 -2.5 47.8 -0.5 
Proline (0.3M) 48.7 0.1 47.5 0 49.0 0.7 
Glycine (0.3M) 48.6 0 47.5 0 47.8 -0.5 
Calcium Chloride (0.015M) 48.1 -0.5 47.0 -0.5 47.8 -0.5 
Sodium Citrate (0.2M) 49.7 1.1 47.5 0 51.0 2.7 
Brij 35 (0.1%) 47.8 -0.8 47.0 -0.5 47.8 -0.5 
Tween 20 (0.1%) 47.3 -1.3 46.0 -1.5 46.6 -1.7 
Tween 80 (0.1%) 49.3 0.7 47.5 0 48.6 0.3 
Pluronic F-68 (0.1%) 48.8 0.2 47.5 0 48.6 0.3 
Lactose (20%) 51.8 3.2 51.0 3.5 53.6 5.3 
Trehalose (20%) 51.9 3.3 52.0 4.5 53.5 5.2 
Dextrose (20%) 52.2 3.6 52.0 4.5 54.8 6.5 
Sucrose (20%) 51.6 3.0 52.0 4.5 52.5 4.2 
Mannitol (10%) 51.8 3.2 52.0 4.5 52.6 4.3 
Sorbitol (20%) 53.4 4.8 52.5 5.0 55.3 7.0 
Glycerol (20%) 50.3 1.7 50.0 2.5 50.4 2.1 
 Cyclodextrin(CD) (2.5%) 48.0 -0.6 47.5 0 48.3 0 
2-OH propyl ɤ-CD (2.5%) 49.5 0.9 48.0 0.5 49.7 1.4 
 
Table 1: The effect of various GRAS excipients on the tertiary structural stability (Tm and T 
onset) of L460D pneumolysoid was determined by intrinsic fluorescence spectroscopy and 
static light scattering. Duplicate measurements were run for pneumolysin alone, and one 
measurement for pneumolysin with each excipient. The precision of the T values is estimated 
to be ± 0.5ºC. Protein concentration was 0.1 mg/ml in a 10 mM histidine buffer at pH 6. 
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about 6.6°C (Table 1), while the other three excipients (20% trehalose, sucrose and sorbitol) 
increase the Tm significantly from 4 to 7°C (Table 1). These results show that the two 
techniques are sensitive enough to investigate the stabilizing and destabilizing effects of 
excipients on the L460D pneumolysoid. 
A complete list of excipients examined and their effect on L460D pneumolysoid tertiary 
structural stability and aggregation are shown in Table 1. The Tm and Tonset values of thermal 
unfolding curves were calculated and are listed in this table. Excipients such as 
diethanolamine and guanidine have destabilizing effects. Excipients such as sugars and sugar 
alcohols exhibit stabilizing effects.  The more promising stabilizers (trehalose, sucrose and 
sorbitol) were then examined at different concentrations. Table 2 shows the Tm and Tonset 
values of 0.1 mg/ml L460D pneumolysoid using selected stabilizers at concentrations ranging 
from 5 to 20%. For the fluorescence measurements, the Tm and Tonset values increase with 
increasing amounts of trehalose and sucrose in solution. Sucrose shows slightly better 
stabilizing effects than trehalose at the same weight percent. Sorbitol shows the best 
stabilizing effects. For the static light scattering measurements, similar observations were 
obtained as the fluorescence results, although, the Tm obtained from the static light scattering 
is about 1-3°C higher than the Tm obtained from the fluorescence technique. The increases in 
Tm and T onset seen in the second round of screening experiments suggest that the selected 
stabilizers are good candidates to enhance the physical stability and minimize aggregation of 
L460D pneumolysoid at high temperatures and potentially at lower storage temperatures as 
well. 
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Excipient  
weight percent 
Fluorescence  
(Flu) peak 
position  Tm 
(
O
C) 
∆Tm of 
flu peak 
position 
Flu 
emission 
peak 
intensity 
T onset 
(
O
C) 
 
∆T onset 
(
O
C) of flu 
emission 
peak 
intensity 
Static light 
scattering 
Tm (
O
C) 
∆Tm (
O
C) 
of static 
light 
scattering 
Protein without 
excipients 
47.9±1.1  47.0  46.6±0.5  
       
Trehalose (5%) 49.0±0.1 1.1 47.5 0.5 47.3±0.2 0.7 
Trehalose (10%) 49.5±0.8 1.6 47.5 0.5 48.5±0.7 1.9 
Trehalose (15%) 50.0±0.8 2.1 50 3.0 51.3±0.8 4.7 
Trehalose (20%) 52.0±0.2 4.1 51 4.0 53.0±0.7 6.4 
       
Sucrose (5%) 49.3±0.4 1.4 47.5 0.5 47.8±0.1 1.2 
Sucrose (10%) 50.4±0.4 2.5 50 3.0 48.9±1.6 2.3 
Sucrose (15%) 51.1±0.5 3.2 50 3.0 51.1±1.0 4.5 
Sucrose (20%) 51.7±0.9 3.8 52.5 5.5 52.5±0.2 5.9 
       
Sorbitol (5%) 49.2±0.3 1.3 47.5 0.5 47.8±0.02 1.2 
Sorbitol (10%) 50.7±1.0 2.8 50 3.0 49.5±1.4 2.9 
Sorbitol (15%) 52.4±0.3 4.5 52.5 5.5 52.1±0.03 5.5 
Sorbitol (20%) 53.2±0.3 5.3 52.5 5.5 54.1±1.7 7.5 
Table 2. The effect of stabilizer concentration on the tertiary structural stability and 
aggregation behavior of L460D pneumolysoid as measured by fluorescence spectroscopy and 
static light scattering.  Duplicate measurements were run. The Tm value was calculated 
separately for each measurement, the values were averaged, and the standard deviation was 
determined. Protein concentration was 0.1 mg/ml in a 10 mM histidine buffer at pH 6. 
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The solution osmolarity was measured for buffers containing the selected stabilizers at 
various concentrations, and the results are summarized in Supplemental Table S1. Buffers 
containing sorbitol show much higher osmolarity than those containing sucrose or trehalose 
at the same concentration. Therefore, sorbitol was not examined further. Both 20% sucrose 
and 20% trehalose have relatively high osmotic pressure values that are not generally suitable 
for injection. Both 5% sucrose and 5% trehalose have reasonable osmotic pressure values, but 
formulations at these concentrations show a smaller increase in Tm values than those using 10 
or 15% concentrations. Therefore, in further experiments, only 10% and 15% sucrose and 
trehalose were used. These two concentrations of excipients show good stabilizing effects on 
L460D pneumolysin, as observed by both fluorescence and static light scattering techniques 
(Table 2) and provide an acceptable range of osmotic pressures. 
In the next experiment, the protein concentration was varied, and tryptophan 
fluorescence spectroscopy and static light scattering were again used to monitor protein 
stability. Four concentrations (0.1, 0.5, 1.0 and 4.0 mg/ml) of L460D pneumolysoid were 
selected. These samples were investigated with and without sucrose and trehalose (10% and 
15% concentrations). For samples without excipients, typical fluorescence and static light 
scattering curves of L460D pneumolysoid at different protein concentrations are shown in 
Figure 4. For the fluorescence studies (Figures 4A-B), the thermal transition shifts of the 
emission peak position are similar at the different protein concentrations (Figure 4A), 
although 4.0 mg/ml L460D pneumolysoid shows an earlier transition shift of the emission 
peak intensity than the other concentrations (0.1, 0.5 and 1.0 mg/ml) (Figure 4B). For the 
static light scattering studies (Figures 4C), the thermal transitions observed at the lower  
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Figure 4. Effect of protein concentration on the conformational stability of L460D 
pneumolysoid (A): The intrinsic Trp fluorescence emission maximum (peak position), (B): 
the emission peak intensity, and (C) Static light scattering intensity of protein at different 
concentrations as a function of temperature. Due to different slit widths used in the 
experimental settings for lower and higher protein concentrations, the fluorescence intensity 
and scattering intensity data were normalized. Each data point represents the mean of two 
independent samples. Protein samples were prepared in a 10 mM histidine buffer at pH 6. 
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protein concentrations are similar, but, at 4.0 mg/ml, the protein aggregated at a lower 
temperature of about 40°C. Due to different slit widths used in the experimental settings for 
lower and higher protein concentrations, scattering intensity can’t be compared directly 
between the samples, and the data was normalized. The Tm results for L460D pneumolysoid 
with and without excipients at different protein concentrations are shown in Supplemental 
Table S2. Overall, concentrations of 10% or 15% trehalose and sucrose have similar 
stabilizing effects on L460D pneumolysoid across the range of protein concentrations studied 
(0.1-4.0 mg/ml) using results from both intrinsic fluorescence spectroscopy and static light 
scattering as criteria. The Tm results show that the selected excipients have the weakest 
stabilizing effects on 4.0 mg/ml of protein and the strongest stabilizing effects on 0.1 mg/ml 
of protein. These excipients have intermediate and good stabilizing effects on the other two 
concentrations (0.5 and 1.0 mg/ml) of protein.  
The stabilizing effects of various excipients on the L460D pneumolysoid at 1.0 mg/ml 
were further investigated using differential scanning calorimetry (DSC). A typical DSC 
thermogram of 1.0 mg/ml L460D pneumolysoid without excipients is shown in Supplemental 
Figure S2 (A).  A sharp DSC peak is observed at 52.4°C. The Tm values from the DSC 
studies are summarized in Table 3, both sucrose and trehalose at concentrations of 10% and 
15% increase the Tm values by about 2-3°C.    
5.3.3 Adjuvant-Antigen studies 
5.3.3.1 Adsorption Study 
The binding of L460D pneumolysoid to alhydrogel (0.6 mg/ml) was investigated where 
the protein showed efficient binding to aluminum hydroxide adjuvant. An adsorption  
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Sample Tm value from DSC study (
O
C) 
△Tm (
O
C) 
Pneumolysin  52.4±0.1   
Pneumolysin + 10% sucrose 54.3±0.2 1.9 
Pneumolysin + 15% sucrose 54.9±0.1 2.5 
Pneumolysin + 10% trehalose 54.7±0.1 2.3 
Pneumolysin + 15% trehalose 55.2±0.1 2.8 
 
Table 3: Thermal unfolding temperatures (Tm) of L460D pneumolysoid (1.0 mg/ml) with and 
without excipients. Data were obtained using differential scanning calorimetry. Duplicate 
measurements were run, the Tm value was calculated separately for each measurement, the 
values were averaged, and the standard deviation was determined. Protein concentration was 
0.1 mg/ml in a 10 mM histidine buffer at pH 6. 
 
isotherm of protein and adjuvant is shown in Supplemental Figure S3. For L460D 
pneumolysoid concentrations between 0.05 and 1.5 mg/ml, the protein binds completely to 
the surface of the aluminum hydroxide adjuvant. The adsorption isotherm reaches a plateau at 
a protein concentration greater than 2.5 mg/ml.  Pneumolysin, with at pI of 4.9, has a 
negative charge at pH 6.0, and hence would be expected to bind to the positively charged 
alhydrogel presumably at least partially through electrostatic interactions.  
5.3.3.2 Stability of L460D pneumolysoid on the Surface of the Aluminum Hydroxide Adjuvant 
The conformational stability of L460D pneumolysoid bound to the surface of the 
alhydrogel adjuvant was investigated by front face fluorescence spectroscopy. Front face 
fluorescence was used to probe changes in the tertiary structure of the protein in solution and 
when adsorbed to adjuvant as a function of temperature. Results are shown in Figure 5 (no 
excipients), Supplemental Figure S4 (with 15% sucrose), and Supplemental Figure S5 (with 
15% trehalose).  The sharp blue shift of the emission peak position (Tonset around 45-47.5°C) 
that is observed for L460D pneumolysoid in solution (either with or without excipients) is not 
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evident in the samples containing adjuvant. This result suggests a significant effect of surface 
adsorption on the structural properties of protein antigen, although the exact nature of this 
phenomenon is currently unknown.  For the samples containing adjuvant, the initial peak 
position was decreased by about 2 nm. The slopes of the pre-transition curves of samples 
with and without adjuvant, however, were similar (Figures 5B, Figure S4B and Figure S5B), 
and the observed transitions also do not seem to be affected by previously identified 
stabilizers. This observation may suggest that the adsorption of the protein on alhydrogel 
does not significantly affect its stability, although some effect of the adjuvant surface on the 
properties of the protein is clearly evident in the change in cooperativity of the thermal 
unfolding transitions. For samples with adjuvant, the increase in fluorescence intensity seen 
between 10 and 50°C (Figures 5C, Figure S4C and Figure S5C) might be explained by 
fluorescence excitation and emission of a zone of protein molecules at higher concentration, 
because proteins packed on the surface of adjuvant are much more concentrated than they are 
in solution, although again, this idea is highly speculative. The heterogeneous distribution of 
protein on the adjuvant surface may be another reason for this observed increase in 
fluorescence intensity. 
The stability of L460D pneumolysoid on the surface of alhydrogel was further examined 
by DSC. The DSC transition peak of pneumolysin with adjuvant is noisier and broader than 
the peak obtained with protein in solution due to the presence of adjuvant (Figure S2 (B)). 
This may suggest the presence of a heterogeneous population of proteins on the adjuvant 
surface and that a fraction of bound protein has been conformationally altered. The averaged  
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Figure 5. Comparison of tertiary structure stability of L460D pneumolysoid determined by 
front face fluorescence spectroscopy in solution and when adsorbed to alhydrogel adjuvant. 
(A): Fluorescence emission maximum (peak position) as a function of temperature. (B): 
Enlargement of part of the pre-transition regions from (A). (C): emission peak intensity as a 
function of temperature. Each data point represents the mean of two independent samples, 
and error bars show the standard deviation.  Protein samples were prepared in a 10 mM 
histidine buffer at pH 6. 
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Tm value of the L460D pneumolysoid with adjuvant is 51.7 ± 2.1°C, which is similar to the 
average Tm value in solution (52.4 ± 0.1°C), however, Tonset value of the protein in solution is 
about 5°C higher compared to the adjuvant–adsorbed protein. Although the similarity in Tm 
values suggests that there may be little effect of adsorption to alhydrogel on the structure and 
thermal stability of L460D pneumolysoid, differences in Tonset values may suggest some 
differences in conformational stability. 
5.4 Summary and Discussion 
     The development of recombinant protein-based vaccines offers an alternative way 
to produce cheaper, robust and broader coverage pneumococcal vaccines in comparison to 
current polysaccharide and polysaccharide-conjugate based vaccines.  Common 
pneumococcal proteins such as pneumococcal surface protein A (PspA), pneumococcal 
surface protein C (PspC), pneumococcal surface adhesion A (PsaA) and pneumolysin are 
currently being evaluated as vaccine candidates against S. pneumoniae infection.
4
 
Pneumolysin is a lead vaccine candidate which has been long known to be highly 
immunogenic. The protein can potentially be used as an antigen itself or as a carrier protein 
to the polysaccharides in current vaccine preparations, and in the case of the latter, it may 
increase the immunogenicity of conjugated vaccines.
8,30
  By the use of site-directed 
mutagenesis, immunogenic pneumolysin mutants with reduced cytotoxicity have been 
constructed 
16,17
, with pneumolysoid (L460D) being one of these detoxified forms. 
In this study, the conformational stability of the recombinant L460D pneumolysoid was 
characterized by various biophysical techniques. The overall secondary and tertiary structure 
of the protein antigen was highly sensitive to pH and temperature. The protein manifests the 
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highest stability at pH 6-7, much lower stability at pH 4, and at pH 3 the protein is 
significantly structurally altered even at low temperature (10°C). Both pH and temperature 
also affect the aggregation behavior of the L460D pneumolysoid. Samples at pH 4 to 8 have a 
strong tendency to aggregate at elevated temperatures as monitored by static light scattering. 
No aggregation behavior is observed at pH 3 presumably due to proteins’ altered structure as 
this pH.  Temperature induced structural changes of L460D pneumolysoid at pH 6 were also 
monitored by FTIR.  We observed that thermal unfolding leads to a loss of native structural 
bands at 1655 (α-helix), and 1636 cm
-1
 (β-sheet),
 
and the appearance of a new band near 1620 
cm
-1
 (data not shown). The latter observation is indicative of the formation of intermolecular 
beta sheets with increases in temperature. The results obtained from multiple techniques thus 
provide a comprehensive overview of physical stability of L460D pneumolysoid as a function 
of pH and temperature.  
Excipients such as trehalose, sucrose and sorbitol induce stabilizing effects on L460D 
pneumolysoid with respect to improving thermal transition temperatures and minimizing its 
aggregation. These excipients are generally known to stabilize the proteins in solution by the 
mechanism of preferential hydration.
31,32,33
  The effect of protein concentration on stability 
was also examined, because rates of degradation may vary as a function of protein 
concentration.  Stabilizing excipients had the weakest effect on 4.0 mg/ml of protein (by 
increasing the Tm by only 1-3°C), and had the strongest effect on 0.1 mg/ml protein (by 
increasing the Tm by 3-5°C). The observed lower stabilizing effect produced by excipients at 
high protein concentrations could be a natural consequence of increased aggregation rates at 
higher protein concentrations
34
 and/or changes of the key ratio of protein:excipient.
35,36
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Finally, an optimized formulation candidate containing 15% trehalose in 10 mM histidine 
buffer at pH 6 was identified, which balances the effects of increased conformational stability, 
decreased tendency to aggregate, and solution osmolality. 
Adjuvant-antigen interaction studies were also performed using aluminum hydroxide 
adjuvant.  L460D pneumolysoid binds efficiently to alhydrogel.  For protein samples with 
and without adjuvant, the slopes of the pre-transition curves of front-face fluorescence data 
were similar. Furthermore, similar Tm values were also obtained in a DSC study. Therefore, 
the stability of L460D pneumolysoid on the surface of alhydrogel does not seem to be 
affected in a major way by adsorption to the alhydrogel, either with or without excipients, 
although the noncooperative nature of the surface transition remains unexplained. In addition, 
the adsorbed antigen shows greater heterogeneity than that of unadsorbed antigen as observed 
by a noisier and broader DSC thermogram.  
In summary, this study provides a better understanding of the inherent characteristics of a 
vaccine candidate pneumolysin mutant (L460D). This protein antigen has the potential to be 
developed as an alternative, more broadly immunogenic, yet less expensive pneumococcal 
vaccine. The effects of various pH /temperature conditions, buffers and excipients on the 
physical stability of the L460D pneumolysoid were illustrated and optimal stabilizers were 
identified.  The interaction of the protein antigen with aluminum adjuvant was also 
characterized.  This preformulation work provides the basis for the development of a 
rational strategy in the next stage of formulation development, which should include 
chemical stability studies (e.g., Asn deamidation and Met oxidation) as well as the effect of 
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other environmental stresses such as agitation, freeze-thaw cycling and material compatibility 
on protein stability.  In addition, studies to evaluate the immunogenicity and long-term 
storage stability of adjuvanted candidate formulations of the pneumolysin mutant (L460D) 
are also needed.   
5.5. ASSCOCIATED CONTENT
 
Supporting Information. Supplemental Tables 1-2 and Supplemental Figures 1-5. 
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  Weight percent Osmotic pressure 
(mosm/kg H
2
O) 
  
△Tm of fluorescence 
peak position  
△Tm (
O
C) of 
static light 
scattering  
  
Trehalose 
5% 151.5 ± 2.1 1.1 0.7 
10% 291.5 ± 3.5 1.6 1.9 
15% 459.0 ± 1.4 2.1 4.7 
20% 683.5 ± 3.5 4.1 6.4 
  
Sucrose 
5% 168.5 ± 3.5 1.4 1.2 
10% 322.5 ± 2.1 2.5 2.3 
15% 502.5 ± 2.1 3.2 4.5 
20% 768.5± 17.7 3.8 5.9 
  
Sorbitol 
5% 298.3 ± 4.7 1.3 1.2 
10% 597.7 ± 11.0 2.8 2.9 
15% 953.3 ± 24.6 4.5 5.5 
20% 1361.7 ± 8.0 5.3 7.5 
 
Supplemental Table S1. △Tm (°C) and osmolarity values for L460D pneumolysoid in the 
selected stabilizers at various concentrations. For osmotic pressure values, triplicate 
measurements were run, the results were averaged, and the standard deviation was 
determined. The △Tm (°C) values are the same as those in Table 3. Protein concentration is 0.1 
mg/ml in a 10 mM histidine buffer at pH 6. 
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Excipient  
weight percent 
Fluorescence  
peak position  
Tm (
O
C) 
△ Tm of 
fluorescence 
peak position 
Static light 
scattering Tm 
(
O
C) 
△Tm (
O
C) of 
static light 
scattering 
Pneumolysin  
0.1 mg/ml 
47.7±0.5  49.9±0.4  
0.5 mg/ml 47.7±0.9  49.4±0.5  
1.0 mg/ml 47.1±0.6  48.9±0.2  
4.0 mg/ml 47.8±0.1  47.1±0.1  
     
0.1 mg/ml protein 47.7±0.5  49.9±0.4  
Trehalose (10%) 51.2±0.2 3.5 52.7±0.2 2.8 
Trehalose (15%) 51.8±0.1 4.1 53.2±0.1 3.3 
Sucrose (10%) 51.7±0.5 4.0 52.5±0.4 2.6 
Sucrose (15%) 52.6±0.4 4.9 53.1±0.1 3.2 
     
0.5 mg/ml protein 47.7±0.9  49.4±0.5  
Trehalose (10%) 50.6±0.2 2.9 52.0±0.004 2.6 
Trehalose (15%) 51.2±0.1 3.5 52.9±0.04 3.5 
Sucrose (10%) 50.6±0.3 2.9 51.8±0.1 2.4 
Sucrose (15%) 51.1±0.2 3.4 52.5±0.1 3.1 
     
1.0 mg/ml protein 47.1±0.6  48.9±0.2  
Trehalose (10%) 50.4±0.04 3.3 51.6±0.1 2.7 
Trehalose (15%) 51.0±0.2 3.9 52.2±0.1 3.3 
Sucrose (10%) 50.1±0.2 3.0 51.3±0.1 2.4 
Sucrose (15%) 50.2±0.2 3.1 51.4±0.03 2.5 
     
4.0 mg/ml protein 47.8±0.1  47.1±0.1  
Trehalose (10%) 49.5±0.7 1.7 48.0±0.7 0.9 
Trehalose (15%) 50.2±0.1 2.4 49.1±0.2 2.0 
Sucrose (10%) 49.3±0.1 1.5 47.9±0.4 0.8 
Sucrose (15%) 50.7±0.3 2.9 49.7±0.5 2.6 
 
Supplemental Table S2: Tm results of L460D pneumolysoid (0.1, 0.5, 1.0 and 4.0 mg/ml) with 
and without excipients. Data were obtained from the intrinsic fluorescence spectroscopy and 
static light scattering techniques. Duplicate measurements were run, the Tm value was 
calculated separately for each measurement, the values were averaged, and the standard 
deviation was determined. Protein was prepared in a 10 mM histidine buffer at pH 6. 
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Figure S1. (A) Radar chart and (B) Chernoff face diagram of the conformational stability of 
L460D pneumolysoid. The diagrams were prepared from CD at 217 nm, intrinsic 
fluorescence (peak position), static light scattering and ANS fluorescence data. All data were 
adjusted represent to the native state as (A) a dot and (B) a smiling face. Blue lines indicate 
an example of clustering results. 
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Supplemental Figure S2. Representative DSC thermograms. (A) 1.0 mg/ml L460D 
pneumolysoid alone and (B) L460D pneumolysoid adsorbed to alhydrogel adjuvant in 10 
mM histidine buffer at pH 6. Duplicate measurements were run, each Tm value was 
calculated separately, and then the values were averaged and reported in the text. 
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Supplemental Figure S3. Adsorption isotherm of L460D pneumolysoid to alhydrogel 
adjuvant.  Protein concentrations were 0.05, 0.15, 0.3, 1.0, 1.5, 2.0, 2.5, 3.0 and 3.25 mg/ml. 
The alhydorgel concentration was 0.6 mg/ml. Sample volume was 200 µl. The amount of 
protein bound to adjuvant was determined by subtracting the amount of protein remaining in 
solution from the amount of protein added. Each data point represents the mean of two 
independent samples, and error bars show the standard deviation. Protein samples were 
prepared in a 10 mM histidine buffer at pH 6. 
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Supplemental Figure S4. Comparison of tertiary structure stability of L460D pneumolysoid 
determined by front face fluorescence spectroscopy in solution and when adsorbed to 
alhydrogel adjuvant in the presence of 15 % sucrose. (A): Fluorescence emission maximum 
(peak position) as a function of temperature. (B): Enlargement of part of the pre-transition 
regions from (A).  (C): emission peak intensity as a function of temperature.  Each data 
point represents the mean of two independent samples, and error bars show the standard 
deviation.  Protein samples were prepared in a 10 mM histidine buffer at pH 6. 
 
 
 
 
 
 
 
 
153 
 
 
Supplemental Figure S5. Comparison of tertiary structure stability of L460D pneumolysoid 
determined by front face fluorescence spectroscopy in solution and when adsorbed to 
alhydrogel adjuvant in the presence of 15 % trehalose. (A): Fluorescence emission maximum 
(peak position) as a function of temperature. (B): Enlargement of part of the pre-transition 
regions from (A). (C): emission peak intensity as a function of temperature.  Each data point 
represents the mean of two independent samples, and error bars show the standard deviation.  
Protein samples were prepared in a 10 mM histidine buffer at pH 6. 
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Chapter 6 Biophysical Characterization and Conformational Stability of 
Ebola and Marburg Virus-like Particles 
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6.1 INTRODUCTION 
The Ebola (EBOV) and Marburg (MARV) viruses infect both humans and nonhuman 
primates and cause severe hemorrhagic fevers. They are members of the Filoviridae family, 
which consists of filamentous, enveloped, nonsegmented, negative-sense RNA viruses.
1-3
 
Mortality rates in humans are as high as 90% for EBOV and MARV.
1,4
 Viral infection is 
zoonotic, with African fruit bats recently identified as a potential natural reservoir.
5-7
  
Person-to-person transmission occurs primarily through physical contact with body fluids of 
infected animals or patients.
8,9
 The filoviruses have a low lethal infectious dose and can be 
transmitted by droplets or small-particle aerosols.
10
 Furthermore, there is a concern for their 
potential use as biological weapons because of their high virulence, weaponization in form of 
aerosol in former USSR, and potential to be produced in large quantities.
11-14
   
The EBOV and MARV viruses share a common morphology and are similar in structure.  
Their genomes have a length of approximately 18.9 kb for EBOV and 19.1 kb for MARV, 
which are two of the largest known negative-stranded RNA virus genomes.
1
 Their linear 
genomes encode seven major structural proteins: nucleoprotein (NP), virion protein 35 (VP) 
35, VP40, glycoprotein (GP), VP30, VP24 and polymerase (L) protein. Four of them (NP, 
VP30, VP35, and L) are nucleoproteins, which are essential for transcription and replication. 
The remaining three are membrane-associated.
1,15,16
  
Vaccines are needed for protection against filovirus infections. Currently, there are no 
licensed vaccines or chemotherapeutic agents available for the treatment of prevention of 
these viral infections. Thus, development of an efficacious vaccine to protect public health is 
crucial. In the last ten years, significant progress has been made and several vaccine strategies 
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have been used to protect immunized animals against filovirus challenge with varying 
efficacy. These strategies include inactivated or attenuated viruses, individual viral protein, 
DNA and recombinant viral-vector-based vaccines, as well as virus-like particles (VLPs).
17-21
 
Among these vaccine strategies, vector-based vaccines and VLPs are the most promising 
strategies to date. VLPs have several potential advantages over other candidate vaccines. 
VLPs lack viral genomic material (and, thus, cannot replicate), lack issues involving 
pre-existing immunity to a viral vector vaccine, are relatively easy to produce in large 
quantities, and can be administrated repeatedly to boost the levels of immune responses.
22
  
As shown by the two currently available VLP based vaccines, hepatitis B and human 
papillomavirus vaccines, their multimeric nature is especially conducive to strong humoral 
responses.
23-25
  
Recent studies have demonstrated that monovalent and multivalent VLP vaccine 
strategies are efficacious and offer protection to several species, including mice, guinea pigs, 
and nonhuman primates (monkeys), against lethal dose challenge by Ebola and/or Marburg 
viruses.
26-32
 These VLP particles have been produced in both mammalian and insect cell 
cultures. Expression and production of viral structural proteins lead to the assembly and 
release of VLPs which resemble virions in size and morphology.
 26,30-38 
The Ebola VLPs 
(eVLPs) and Marburg VLPs (mVLPs), comprised of the homologous GP, VP40, and NP, 
elicited strong neutralizing antibody responses as well as cellular immune responses against 
filoviruses in animal models.
22,30,31
 These studies have convincingly demonstrated the 
potential of a VLP vaccine strategy for use against human filovirus infection.  
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The formulation of viral antigens into stable, efficacious protein-based vaccine dosage 
form is critical to their successful development into commercial vaccines. The long term 
storage stability of such vaccines in liquid formulations can be maximized by optimizing the 
properties of the solution (e.g. antigen concentration, solution pH, and addition of excipients 
such as buffers, salts, and stabilizers). Characterization of the stability of these vaccines by a 
number of biophysical methods will help us better understand potential structural changes 
produced by various types of environmental stresses. This work focuses on the 
characterization of the temperature and pH stability of the eVLPs and mVLPs with the goal 
of developing stable vaccine formulations as a next step. Various spectroscopic techniques 
were employed to investigate the conformational stability of these two enveloped VLPs in 
solution. These techniques include intrinsic fluorescence, extrinsic (laurdan) fluorescence, 
and circular dichroism (CD) over a wide range in pH and temperature, from pH 3 to 8 and 10 
to 87.5 ºC, respectively. Temperature-induced aggregation of the VLPs at various pH values 
was monitored by static and dynamic light scattering. These large biophysical data sets were 
summarized through the use of empirical phase diagrams (EPDs) for both the eVLPs and 
mVLPs. The EPDs describe physical changes in the enveloped VLP particles under stressed 
environmental conditions, including elevated temperature and acidic pH. From the results of 
each biophysical technique and the resultant EPDs, a temperature/pH stability profile of each 
VLP was created. This information can be used as a starting point in the development of 
stable formulations for these two enveloped VLPs. 
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6.2 MATERIALS AND METHODS 
6.2.1 Generation of VLPs  
For expression in the insect cell system, the homologous Ebola virus (Zaire strain) 
(ZEBOV) or Marburg virus (Musoke strain of Lake Victoria) (MMARV) glycoprotein (GP), 
nucleoprotein (NP), and viral protein 40 (VP40) genes were inserted into a baculovirus vector 
system (Bac-to-Bac, Invitrogen) for expression in insect cells. Integrated Biotherapeutics Inc. 
(IBT) produced a three-gene bacmid construct to allow a single baculovirus to produce each 
respective ZEBOV or MMARV VLP particle type. The triple construct has each gene (ordered 
NP, VP40, and GP) flanked by the polyhedrin promoter and SV40 polyadenylation sequence 
for high expression of these genes. Recombinant baculoviruses containing the filovirus 
proteins of interest were recovered and amplified with another passage through Sf9 cells. The 
final viruses were introduced into Sf9 insect cells for VLP production, and the VLPs were 
recovered from the culture supernatants by high-speed concentration, purified on sucrose 
gradients, and resuspended in phosphate buffered saline. Purified VLPs were characterized by 
SDS-PAGE followed by Western blot using antibodies against ZEBOV or MMARV viral 
proteins. The total concentrations of the VLPs preparations were determined by using a BCA 
protein assay (Thermo Scientific). 
6.2.2 Preparation of virus-like particles for biophysical analysis 
Individual VLPs solutions at pH 3-8 were prepared by centrifuging 1.0 ml of the 
concentrated stock solutions of the VLPs (2.0 mg/ml) for 10 minutes at 13,000 x g at 4 ºC 
using a Fisher Scientific accuSpin
TM
 Micro centrifuge (Fisher Scientific., Pittsburgh, PA). 
The resulting pellet was resuspended in 1.0 ml of 20 mM citrate-phosphate buffer with an 
159 
 
ionic strength of 0.15 M adjusted with sodium chloride. The buffer exchange process was 
repeated three times in total. Samples at pH 3 and 4 contained 30% sucrose to retard 
particulate settling seen at low pH.  Experimental concentrations were 0.1 mg/ml for all 
fluorescence and light scattering measurements, and was 0.4 mg/ml for circular dichroism 
studies to increase the strength of the CD signals. 
6.2.3 Electron microscopy 
The eVLPs and mVLPs at pH 7 (20 mM citrate-phosphate buffer) were examined on 
a JEOL EX transmission electron microscope at 80 kV after the samples were negatively 
stained with 1% uranyl acetate, as previously described, for the electron microscopy 
study.
26,29
 These studies were performed as a service by the Pathology Division at the United 
States Army Research Institute of Infectious Diseases. 
6.2.4 Far-UV Circular Dichroism Spectroscopy 
Circular dichroism study was performed with a Jasco-810 spectrophotometer equipped 
with a Peltier temperature controller and a 6-position cuvette holder (Jasco Inc., Easton, MD). 
Far UV spectra of eVLPs and mVLPs (0.4 mg/ml) were collected in the range of 190-260 nm 
using a 0.1 cm path length cuvette sealed with a Teflon stopper. A scanning speed of 20 
nm/min with a response time of 1 s and a bandwidth of 1 nm were used. The CD signals of 
eVLPs and mVLPs at 225 nm were monitored as a function of temperature at 0.5 ºC intervals 
from 10 to 87.5 ºC. The heating rate was 15 ºC/h. At minimum, duplicate samples at each pH 
were measured. Baseline measurements of buffers were taken and subtracted from sample 
measurements prior to data analysis. 
160 
 
6.2.5 Intrinsic Fluorescence Spectroscopy 
The intrinsic fluorescence of eVLPs and mVLPs (0.1 mg/ml) was measured using 
QuantaMaster 810 spectrofluorometer (Photon Technology International, Inc., Birmingham, 
NJ) equipped with a 4-position cell holder and Peltier temperature control device. 
Fluorescence emission spectra of eVLPs and mVLPs were recorded as a function of 
temperature (10-87.5 ºC) and pH (3-8). Triplicate samples were measured using an excitation 
wavelength of 295 nm (> 95% tryptophan emission). Emission spectra were collected from 
310 to 400 nm with a step size of 1 nm and 1 s integration time. The excitation and emission 
slits were set at 3 nm and 8 nm respectively, for eVLPs, and 3 nm and 12 nm for the mVLPs. 
The spectra were collected at 2.5 ºC intervals with a 5 min equilibration time at each 
temperature. A 1 cm path length quartz cuvette was used in all experiments. To maintain 
solution homogeneity during measurements, samples were stirred using a magnetic stirrer. 
Buffer baselines were subtracted from each spectrum before data analysis. Data analysis was 
performed using FelixTM (Photon Technology International, Inc.) software. The position of 
the emission wavelength maximum was determined using a polynomial derivative fitting 
method executed in Origin 7.0 software. The fluorescence emission intensity data were 
normalized between 0 and 1 for each sample.  
6.2.6 Extrinsic Fluorescence Spectroscopy 
Laurdan (2-dimethylamino-6-lauroylnaphthalene) was used as an extrinsic fluorescent 
probe to study changes in membrane fluidity of eVLPs and mVLPs. The interaction of 
laurdan with the membranes was monitored as a function of temperature (10-87.5 ºC) and pH 
(3-8) using the PTI Quanta Master 810 spectrophotometer. Triplicate samples were measured, 
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and samples were stirred using a magnetic stirrer. A stock solution of laurdan was prepared 
by dissolving 1.0 mg of the laurdan into 1.5 ml of dimethylsulfoxide (DMSO). Each sample 
solution containing 10 µM diluted laurdan was incubated at 10 ºC in the dark for 20 minutes 
before measurement. Samples were excited at 340 nm and spectra were collected from 
400-500 nm at 2.5 ºC intervals with a 5 min equilibration time at each temperature in a 1 cm 
path length quartz cuvette. Emission peak intensities at 440 nm and 480 nm (I440 and I480) 
were used to calculate the generalized polarization (GP) of laurdan fluorescence, where GP = 
(I440-I480) / (I440+I480). Buffer baselines containing 10 µM laurdan were subtracted from each 
sample spectrum prior to analysis. 
6.2.7 Static Light Scattering 
The static light scattering intensities of eVLPs and mVLPs (0.1 mg/ml) were recorded 
simultaneously using a 1 nm slit width during the intrinsic fluorescence experiments by 
employing a second photomultiplier located 180° to the fluorescence detector. The scattering 
intensities at 295 nm were plotted as a function of temperature (10-87.5 ºC) to monitor the 
aggregation behavior of the VLPs. Buffer baselines were subtracted from each sample 
spectrum before analysis. 
6.2.8 Dynamic Light Scattering 
The mean effective hydrodynamic diameters of the VLPs (0.1 mg/ml) were monitored by 
dynamic light scattering from 10 to 87.5 ºC. Measurements were recorded at 2.5 ºC intervals 
with a 5 min equilibration time at each temperature. Five measurements were taken at each 
temperature. Incident light at 532 nm was generated by a 125 mW diode-pumped laser, and 
the scattered light was monitored at 90º to the incident beam. A digital autocorrelator 
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(BI-9000 AT) was used to create the autocorrelation function (Brookhaven Instrument Corp., 
Holtzille, NY). The diffusion coefficients of the particles were extracted by cumulant analysis 
of the auto correlation functions. The effective hydrodynamic diameter was calculated from 
the diffusion coefficients by the Stokes-Einstein equation. Viscosity and refractive index 
corrections were applied to each measurement using the NanoDLS Particle Sizing software 
(Brookhaven Instrument). In addition, viscosities of the buffers at pH 3 and 4 containing 30% 
sucrose were measured using the SVM 3000 viscometer (Anton Parr USA Inc., Ashland, VA).  
Measurements were recorded from 10 to 87.5 ºC at 2.5 ºC intervals, and the average values of 
three replicates at each temperature were applied to viscosity correction.  
6.2.9 Empirical Phase Diagrams 
Conformational changes can be determined independently by each of the above 
described techniques. The large sets of data obtained can be combined to construct empirical 
phase diagrams (EPDs) that connect similar data correlated with similar structure. The data 
sets are initially ordered by environmental parameter (e.g., temperature, pH). Each 
biophysical technique uses identical environmental parameters over the same ranges (e.g., pH 
from 3 to 8, temperature from 10 ºC to 87.5 ºC) at regular increments. The raw data sets from 
all of the measurements are defined as multi-dimensional vectors. These vectors are analyzed 
by principal components analysis in which the components with the three largest 
contributions are combined to construct an empirical phase diagram using a red, green, and 
blue (RGB) color system as described in detail elsewhere.
39
 The EPDs are used to identify 
coherent parameter regions that define VLP structural states as a function of solution 
variables (temperature and pH in this case) as described below. Note that these are not 
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thermodynamic phases and no equilibrium is implied across any of the observed apparent 
phase boundaries.  
6.3 RESULTS 
6.3.1Biophysical Characterization of Purified VLPs Produced in Insect Cells 
SDS-PAGE profile (Figure 1A) revealed that the major bands were VP40 and NP 
proteins in both VLPs. The glycoprotein (GP) was not visible in either of the eVLPs and 
mVLPs preparations, probably because of the mobility over a wider range due to multiple 
glycosylated forms and relatively low level of GP in VLPs. A protein band of about 64 KDa 
in molecular weight was also detected in both VLPs, which is likely a baculovirus GP64 
protein that co-purified with the VLPs.
28,32
 Western blot analysis was performed by using 
monoclonal antibodies against Ebola and Marburg viral proteins and revealed that GP, NP 
and VP40 are present in the two VLPs preparation (Figure 1B1-B6). The purified eVLPs and 
mVLPs in pH 7 citrate phosphate buffer were also examined by electron microscopy (Figure 
2). Both VLPs displayed filamentous morphology similar to filovirus. These filamentous 
VLPs at pH 7 have a diameter of 60-80 nm and are about 350 nm to 5000 nm in length. As 
discussed in detail in the following sections, the eVLPs and mVLPs displayed an effective 
hydrodynamic diameter of 250 – 400 nm in solution (pH 7, 10 ºC), as measured by dynamic 
light scattering. In addition, the proteins in the VLP samples were primarily α-helical in 
structure in solution (pH 7, 10ºC), as measured by circular dichroism. 
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Figure 1. (A): SDS-PAGE analysis of EBOV Zaire VLPs (eVLPs) and MARV Musoke 
VLPs (mVLPs) preparations stained with Coomassie blue. 4, 2 and 1 g of VLP preparations 
were mixed with reducing protein sample buffer, heated at 90 °C for 10 min, and then 
subjected to SDS-PAGE. Lanes 1 and 8, molecular weight markers; lanes 2, 3 and 4, MARV 
Musoke VLPs 4, 2 and 1 g; lanes 5, 6 and 7, EBOV Zaire VLPs 1, 2 and 4 g. (B1-B6): 
Western blot analysis of EBOV Zaire VLPs and MARV Musoke VLPs. All primary 
antibodies diluted 1:1000, (B1) anti-Zaire GP, (B2) anti-Zaire NP, and (B3) anti-Zaire VP40 
antibodies were used. Lanes 1, 2 and 3, MARV Musoke VLPs 4, 2 and 1 g; lanes 4, 5 and 6, 
EBOV Zaire VLPs 1, 2 and 4 g; lane 7, molecular weight marker. (B4) anti-Musoke GP, 
(B5) anti-Musoke NP, and (B6) anti-Musoke VP40 antibodies were used. Lanes 1 and 9, 
molecular weight markers; lanes 2 to 8, MARV Musoke VLPs 8, 4, 2, 1, 0.5, 0.25 and 0.1 g; 
lane 10, EBOV Zaire VLPs 8 g. 
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Figure 2. EVLPs (A) and mVLPs (B) in 20mM citrate phosphate buffer at pH 7 were 
analyzed by electron microscopy. 
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6.3.2 Dynamic Light Scattering  
The hydrodynamic properties of the VLPs were measured by dynamic light scattering 
(DLS) (Figure 3). Because the eVLPs and mVLPs are filamentous in shape, the effective 
diameter was measured primarily for qualitative purpose to evaluate the effect of pH and 
temperature on the size of the VLPs. For both VLPs, the particle size increased with 
increasing temperature (in the pH range of 6-8 and 3-8 for eVLPs and mVLPs, respectively).  
 For eVLPs (Figure 3A), the average hydrodynamic diameters at pH 3 and 4 were 
significantly larger than those at higher pH values, even at low temperatures. The measured 
values were around 1700 nm which exceeded the measuring range of the instrument 
employed in this study. These particles formed at low pH appeared to decrease in size as the 
temperature increased (data not shown). This result suggests a disruption of the particles, or 
their aggregates, at elevated temperature and low pH. In contrast, there was little 
temperature-dependence on the size of the eVLPs at pH 5. For eVLPs at pH 6-8, an increase 
in the size of the particles with increasing temperature was observed.  
In case of mVLPs (Figure 3B), samples at pH 3 and 4 demonstrated the fastest rates of 
size increase and aggregated significantly at elevated temperature. The diameter of the 
sample at pH 5 was largest at low temperatures, which suggests structural alteration with an 
expansion in size. The effective diameters of the particles increased as the temperature was 
raised and at least tripled in size for all samples at higher temperatures. It should be noted that 
particle sizes greater than a micron are not accurately measured by DLS instrumentation,  
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Figure 3. Effective diameters of eVLPs (A) and mVLPs (B) as a function of temperature and 
solution pH as measured by dynamic light scattering. Each data point represents the mean of 
five accumulations at each temperature point, and error bars show the standard deviation. 
 
 
 
 
 
 
 
 
 
168 
 
however, they are reported here to continue the observation of stability trends at higher 
temperatures. At pH 7 and 8, both VLP types manifested smaller particle sizes than those 
prepared at pH 5 and 6 over the entire temperature range. This result implies decreased 
stability of the VLPs at pH 5 and 6 due to particle aggregation.  
6.3.3 Static Light Scattering 
A static light scattering study was performed to monitor the aggregation behavior of the 
VLPs in solution as a function of temperature and pH. Increased scattering intensity is 
typically a consequence of protein association-related behavior (for example, aggregation). 
Decreased scattering intensity observed after the increased intensity is typically due to the 
precipitation of the aggregated VLP particles or a reduction of the refractive index of 
particles, as a result of decreased densities.  
For the eVLPs (Figure 4A), samples at pH 3 and 4 exhibited lower scattering intensities 
and demonstrated little change over the temperature range examined, in comparison to those 
prepared at other pH values. The change in scattered light intensity peaked at pH 6, with 
intermediate values at pH 5, 7 and 8. Weak transitions in apparent particle size are seen for 
the eVLPs at pH 5-8, with some variation in behavior over this pH range. For example, a 
double transition is observed at pH 5.  
Like the eVLPs, the mVLPs also display a complex effect of solution pH on scattering 
intensity (Figure 4B). For this case, the optimum scattering at lower temperatures is near pH 
5. Again, transitions are seen at all pH values although only a weak effect is observed at pH 8.  
For both the eVLPs and the mVLPs, the thermal transitions generally indicate small increases 
in size, followed by a maximum, and then a decrease at higher temperatures. Interestingly, for  
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Figure 4. Static light scattering intensities of eVLPs (A) and mVLPs (B) as a function of 
temperature and solution pH. Each data point represents the mean of three independent 
samples, and error bars show the standard deviation. 
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both VLP types the difference in initial scattering intensity at 10 ºC suggests that there may 
be temperature-independent difference in VLPs sizes due to solution pH. The DLS results 
(Figure 3) are consistent overall with the observations made from static light scattering 
(Figure 4).  
6.3.4 Far-UV Circular Dichroism Spectroscopy 
Far-UV CD is frequently used to study the conformational changes of proteins, and thus 
can be applied to VLPs with appropriate consideration for absorption flattening and 
differential scattering artifacts. The far UV region (190-250 nm) mainly reflects peptide bond 
absorption, and thus provides information about the secondary structure of proteins. For 
eVLPs and mVLPs in this study, several proteins contribute to the observed spectrum. Thus, 
the CD spectrum is a sum of the CD signals from all these proteins, although it may be 
dominated by contributions from the most abundant protein(s).  
The CD spectra of eVLPs and mVLPs at different pH values at 10 ºC are shown in 
Figures 5 (A) and (B). Spectra of both VLPs showed a shoulder at 210 nm and a broad peak 
at approximately 223-225 nm from pH 6 to 8. This result suggests that proteins in both VLPs 
contain significant amount of α-helical secondary structures, as may be expected for protein 
associated with lipids. In general, the ellipticity of the VLPs decreased with decreasing pH 
indicating a reduction in α-helical content. The minima at 210 nm and 225 nm were strongest 
at pH 7 and 8, and became more poorly resolved as the pH decreased. Spectra of both VLPs 
at pH 5 showed a shifted minimum to 227-228 nm while the mVLPs at pH 5 also produced 
stronger CD signals than samples at pH 6 and 7. These results argue for altered secondary  
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Figure 5. Far-UV circular dichroism (CD) spectra of eVLPs (A) and mVLPs (B) at 10 °C.  
Samples were examined from pH 3 to 8 at one pH unit intervals.  The CD spectra of eVLPs 
at pH 7 (C) and mVLPs at pH 7 (D) were collected at the indicated temperatures.  
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structure of the VLPs at pH 5 in contrast to those at pH 6-8. The spectra at pH 3 and 4 
exhibited much lower CD signals compared to samples at higher pH values. These spectra are 
broadened and the minimum at 223-225 nm is red-shifted. These observations suggested that 
the VLPs have lost secondary structures and/or are displaying absorption flattening due to 
aggregation at lower pH. 
Figures 5 (C) and (D) demonstrate the loss of secondary structure with increasing 
temperature for both VLPs at pH 7. Samples at other pH values display similar behavior (data 
not shown). Temperature-induced changes in secondary structure of the VLPs were also 
monitored at 225 nm from 10 to 87.5 ºC. Both eVLPs (Figure 6) and mVLPs (Figure 7) 
gradually lost secondary structure with increasing temperature, with significant pH dependent 
behavior. At pH 3 and 4, much weaker CD signals were observed at low temperature and the 
accompanying thermal transitions were quite broad. At pH 5 and 6, stronger CD signals are 
seen and the ranges of signal change are greater (8-10 mdeg units) when compared to the 
other conditions. The VLPs at pH 7 and 8 also demonstrated strong initial CD signals, but 
displayed smaller magnitudes of signal change (about 4 mdeg units) over the entire 
temperature range. These findings suggest that eVLP and mVLP samples at pH 5 and 6 
demonstrated greater structural sensitivity to temperature. Thus, they are more easily altered 
to produce thermal-induced non-native states compared to VLPs under neutral pH solutions. 
The breadth of the melting curves, however, does not permit a quantitative analysis of 
stability in terms of Tm changes. Most transitions appear to initiate between 40 - 45 ºC. 
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Figure 6. The CD signal of the eVLPs at 225 nm as a function of temperature and solution 
pH. Data were collected at 0.5 °C intervals and are shown here at 1 °C increments.  Each 
data point represents the mean of two independent runs with error bars showing the standard 
deviation. 
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Figure 7. The CD signal of the mVLPs at 225 nm as a function of temperature and solution 
pH. Data were collected at 0.5 °C intervals and are shown here at 1 °C increments.  Each 
data point represents the mean of two independent runs with error bars showing the standard 
deviation. 
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6.3.5 Intrinsic Fluorescence 
Intrinsic fluorescence spectroscopy is often employed to examine tertiary structural 
changes in proteins. The fluorescence of tryptophan (Trp) residues, which tend to dominate 
protein fluorescence spectra, is strongly dependent on their local environment. Tertiary 
structure changes in the eVLPs and mVLPs were monitored for changes in the position and 
intensity of their tryptophan emission peak. 
A slight shift to longer wavelength in peak position is seen with increasing temperature 
at pH 5-8 (eVLPs) and at pH 7-8 (mVLPs), although the results are pH dependent with 
increases in thermal stability generally observed at higher pH values (Figures 8 and 9). This 
observation suggests a pH-dependent partial unfolding of the VLP proteins at elevated 
temperature. A much sharper blue shift in peak position was observed for both the eVLPs and 
mVLPs at most temperatures higher than 70 ºC, including an increase in noise of the data 
above this temperature (data points shown in the figures were cut off at 82.5 ºC and 80 ºC for 
eVLPs and mVLPs, respectively). These results most likely reflect aggregation of the VLPs 
at higher temperatures (similar to the observations discussed in the previous section with the 
light scattering experiments).  
The initial emission peak positions of eVLP samples at pH 3 and 4 were around 329-330 nm 
(Figure 8), a value several nanometers less than that seen at higher pH (~332nm). This result 
suggests a more apolar environment for the Trp residues, presumably as a consequence of 
aggregation or increase in size (i.e., expansion). No clear thermal transition is seen at pH 3 
and 4, although a small transition may be present at approximately 50 ºC. Small thermal 
transitions were also observed for eVLPs at pH 7 at 52.5 ºC and 65 ºC. For eVLPs at pH 8, 
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however, similar significant blue shifts were not observed, although two small transitions 
were seen near 45 and 55 ºC.  
 
 
 
Figure 8. The change in intrinsic Trp fluorescence emission maximum (peak position) for 
eVLPs as a function of temperature and solution pH. Each data point represents the mean of 
three independent samples, and error bars show the standard deviation. 
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Figure 9. The change in intrinsic Trp fluorescence emission maximum (peak position) of 
mVLPs as a function of temperature and solution pH. Each data point represents the mean of 
three independent samples, and error bars show the standard deviation. 
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For mVLPs (Figure 9), the initial emission peak positions were observed around 333 nm 
over the entire pH range (3-8) suggesting an unchanged environment for Trp residues. Blue 
shifts occurred at approximately 65, 67, 57, 70, 72 and 70 ºC, respectively, as the solution pH 
ranged from pH 3 to 8. Samples at pH 7 and 8 also showed a transition in emission peak 
position near 45 ºC. 
Figures 10 (A) and (B) illustrate the effect of temperature and pH on the fluorescence 
emission intensity of the eVLPs and mVLPs, respectively. There are no major thermal 
transitions observed except for samples at pH 5. Small transitions do occur, however, at 
lower temperatures for some pH values. Both VLPs at pH 7 and 8 manifest a linear response 
to temperature (decrease) as expected due to the intrinsic effect of temperature on 
fluorescence. Both VLPs at pH 6 show slight deviations from linearity. The transitions in 
fluorescence intensity measurements occurring at pH 5 and 6 appear to correspond to the 
shaper transitions present in the CD (225 nm) (Figures 6 and 7) and the static light scattering 
measurements (Figure 4). VLPs at pH 3 and 4 exhibited broad changes in fluorescence 
emission intensity with increasing temperature, except for the slight deviation from linearity 
of the eVLPs at pH 4 from 30 to 50 ºC. In summary, the effects of pH and temperature on the 
fluorescence of the VLPs are quite complex, reflecting a similar complex response of the 
overall conformational structure of the VLPs to these two forms of environmental stress.  
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Figure 10. The intrinsic Trp fluorescence normalized intensities for eVLPs (A) and mVLPs 
(B) as a function of temperature and solution pH. (A): eVLPs from pH 3 to pH 8 on one plot. 
(B): mVLPs from pH 3 to pH 8 on one plot. Each data point represents the mean of three 
independent samples, and error bars show the standard deviation. 
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6.3.6 Extrinsic (Laurdan) Fluorescence 
Emission from the fluorescent probe laurdan (2-dimethlyamino-6-lauroylnaphthalene) is 
sensitive to the polarity of its environment, in this case, the lipid component of the VLPs. 
Such immediate analyses are typically performed by measuring the relative intensities of two 
of the fluorophore’s peaks in the form of a parameter known as the generalized polarization. 
Laurdan was used to characterize the membrane fluidity of the eVLPs and mVLPs under 
varying pH and temperature conditions. As the temperature was increased, the lipid bilayer 
became more fluid. The increased mobility within the membrane shifted the probe emission 
peak from 440 nm to around 480-490 nm, with excitation at 340 nm (data not shown). Thus, 
a decreased generalized polarization value with increasing temperature was observed for both 
VLPs as shown in Figures 11 and 12. 
Broad thermal transitions (generalized polarization vs. temperature) were observed for 
both VLPs across the range of solution pH 3-8. Initial generalized polarization values at 10 
ºC varied for all pH values. The difference in initial generalized polarization values at 10 ºC 
suggests differences in membrane fluidity as a function of pH. Samples at pH 3 had the 
highest initial generalized polarization values in both VLPs suggesting the lowest water 
density in the apolar interface environment. The eVLPs at pH 8 and mVLPs at pH 7 exhibited 
the greatest extent of membrane hydration at high temperatures (above 70 ºC). Both VLPs at 
pH 7 demonstrated a slower change of GP values with increasing temperature. A slower rate 
of change in generalized polarization values implies that membrane fluidity is less sensitive 
to temperature effects at these pH values. 
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Figure 11. Generalized polarization (GP) of laurdan fluorescence in the presence of eVLPs 
as a function of temperature and solution pH. Each data point represents the mean of three 
independent samples, and error bars show the standard deviation. See methods section for 
determination of GP values. 
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Figure 12. Generalized polarization (GP) of laurdan fluorescence in the presence of mVLPs 
as a function of temperature and solution pH. Each data point represents the mean of three 
independent samples, and error bars show the standard deviation. See methods section for 
determination of GP values. 
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6.3.7 Empirical Phase Diagrams 
Empirical phase diagrams of eVLPs and mVLPs generated by the experiments (pH 3 to 8) 
without DLS results and produced from all experiments described (pH 5-8) were shown in 
Figures 13A-D. EPDs of two VLPs generated from all experiments (Figures 13 (B) and (D) ) 
show similar defined “apparent” phases comparing those EPDs constructed without DLS 
results at the pH range of 5 to 8 (Figures 13 (A) and (C) ). EPDs provide a convenient 
effective way to summarize large amounts of complementary data and provide a 
comprehensive view of VLP structural changes induced by change in environmental 
factors.
40,41
 Due to the gradual signal changes observed in many of the techniques utilized in 
the study, especially for samples around neutral pH, there was some difficulty in defining the 
apparent phase boundaries to delineate the clear structural changes of eVLPs and mVLPs 
under neutral pH conditions. 
In the case of eVLPs, there are approximately 4 different phases existing at low 
temperature (Figure 13A). In region 1, samples at pH 7 and 8 manifest a similar color 
(reddish blue) below 50 °C. An intermediate phase is apparent at pH 5 and 6 (phase2/3), and 
a fourth phase is observed at pH 3 and 4. The distinction between these regions, and those at 
elevated temperatures, is evident with an apparent phase boundary progressing to a lower 
temperature as the pH is lowered. More heterogeneous region is present at elevated 
temperature with unique behavior at pH 6. Regions of gradual color change typically 
correspond to the broad, shallow transitions observed by different techniques.  
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Figure 13. Empirical phase diagrams (EPDs) of the eVLPs (A and B) and mVLPs (C and D). 
EPDs in Figures A and C were constructed without using the DLS data, EPDs in Figures B 
and D were constructed using all data sets including DLS data. In the eVLPs (A), 1: Native 
like state and thermally stable; 2 and 3: Intermediate phase with marginal stability; 4: 
Structurally altered and prone to aggregation. In the mVLPs (C), 1: Native like state and 
thermally stable (less stable in sample at pH 6); 2: Intermediate phase with marginal stability; 
3: Structurally altered and prone to aggregation. In original images, the color changes 
delineated by the dotted lines are more apparent. In addition, these transitions are also more 
evident in the data from specific techniques (see previous figures 3, 4 and 6 to 10). The EPDs 
were prepared from dynamic light scattering, static light scattering, CD at 225 nm, intrinsic 
fluorescence (peak position and normalized intensity), and extrinsic (Laurdan) fluorescence 
data collected across the pH range from 3 to 8 and temperature range from 10 °C to 87.5 °C.  
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There are approximately 3 different apparent phases present at low temperatures 
observed for the mVLPs (Figure 13C). The pH and temperature behavior observed in the 
EPD for mVLPs is somewhat similar to the EPDs of the eVLPs. The heterogeneous nature of 
the high temperature region clearly reflects the presence of aggregates. A decrease in stability 
with the lowering of pH is also apparent for the mVLPs. In region 1, light scattering and CD 
(225 nm) data revealed that the mVLPs prepared at pH 6 were less thermally stable than 
those prepared at pH 7 and 8. In both cases, pH 7-8 appears to produce maximum stability.  
6.4 DISCUSSION  
The stability of proteins is generally investigated by a variety of spectroscopic, 
calorimetric, and hydrodynamic techniques that provide a diverse perspective on the response 
of protein structure to environment stress. These techniques can provide insight into different 
levels of protein structure (primary, secondary, tertiary, and quaternary), but no single 
spectroscopic or hydrodynamic technique can provide all of the desired information about 
protein structure and conformation. Therefore, several methods are typically combined to 
monitor various aspects of protein structure to obtain a better understanding of protein 
stability. In this work, several different spectroscopic and hydrodynamic techniques were 
employed to characterize the conformational stability of eVLPs and mVLPs over a wide 
range of temperature and pH. The physical data were combined to generate EPDs which 
provide a visual tool for characterizing structural alternations of macromolecules and their 
complexes under stress, caused by shift in pH and temperature.  
The particles examined in this study primarily contain the NP, GP, and VP40 proteins of 
the corresponding viruses. Based on the estimated relative abundance of the three proteins in 
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the VLPs, their tryptophan contents, and with the assumption of similar emission from each 
indole side chain, their approximate contribution to the total Trp fluorescence would be about 
50% (NP), 10% (GP) and 40% (VP40). Both NP and GP are highly helical proteins 
containing coils,
42-47
  while VP 40 possesses approximately twice as much beta-sheet (30%) 
as helix (15%).
48
 Based on these considerations, the intrinsic fluorescence spectra of the 
particles will primarily reflect the behavior of the NP and VP proteins while CD spectra 
should reflect primarily helical contributions from the NP protein. Contribution from the 
contaminating 64 KDa protein may also be significant but are unclear at this time.  
Both eVLPs and mVLPs undergo conformational alternations induced by changes in 
temperature and pH. The EPDs reveal that the eVLPs and mVLPs have similar pH- and 
temperature-dependent stability profiles. At pH 3 and 4, both VLPs are structurally altered 
and highly aggregated at elevated temperatures. The VLPs are slightly more stable at pH 5 
compared to those at pH 3 and 4, but undergo structural transitions at lower temperatures 
compared to samples at pH 6-8. These observations depict a phase in which the protein 
structure is highly altered. Furthermore, both VLPs at pH 6 are less stable than those prepared 
at pH 7 and 8, which can be illustrated by a shaper change of CD signal (225nm); earlier 
transition was observed using static light scattering and larger effective diameter was 
measured by DLS.   
Greater stability and structural similarity are observed for eVLPs and mVLPs at pH 7 
and 8. Both VLPs at pH 7 and 8 presumably contain folded protein components and a lipid 
bilayer demonstrating mild thermal resistance, as evidenced by the very low thermal 
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sensitivity; no detectable transitions were observed, as assessed by the techniques used in this 
study (except aggregation observed at high temperatures). Based on the analysis of EPDs and 
individual data sets, as measured by the different biophysical techniques, the overall stability 
results show that both VLPs manifest the highest stability at pH 7. The similarity of the 
physical characteristics of the two VLPs is not surprising, since previous studies have shown 
that they are nearly identical in structure and biochemical properties. Additionally, the actual 
EBOV and MARV show high similarities in the amino acid sequences of NP and VP40 
structural proteins. Similarity is also evident in the N- and C- terminal regions of the GP 
protein.
15,16
  
The overall secondary structure of both the eVLP and mVLP proteins were highly 
sensitive to pH as suggested by the different CD signal intensities and the shape of their CD 
spectra at different pH values. As indicated above, the presence of the minimum observed 
near 224 nm and a shoulder around 210 nm reflects the presence of the expected helical 
structure. The matrix protein VP40 contains more beta than alpha-helical structure,
48
 but the 
surface glycoprotein, which is responsible for receptor binding and membrane fusion, 
contains significant amounts of helical structure.
45-47
 This protein, however, is present in low 
amounts in the VLP preparations compared to NP and VP40. In contrast, the NP protein 
which is highly helical in nature and relatively abundant in the particles might be expected to 
dominate the protein signal in the CD spectrum. The CD studies clearly show major 
alternations in secondary structure at high temperatures and at lower pH (3-5). Both VLPs 
possess higher stability at neutral pH and much lower stability at pH 3 and 4 even at low 
temperature (10 °C). 
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The tertiary structure of the VLPs was investigated by both intrinsic and extrinsic 
(Laurdan) fluorescence. The intrinsic fluorescence emission peak position of the eVLPs and 
mVLPs are around 332 nm and 333.5 nm, respectively. This observation suggests that the 
aromatic amino acid residues reside, on average, in a relatively apolar environment.  This 
result could also reflect an effect of either the interior of the VLP proteins, and/or the 
hydrophobic regions of the lipid bilayer. The results from Laurdan fluorescence indicate that 
pH and temperature both affect the rate and extent of particle membrane hydration. As 
expected, the generalized polarization values decrease with increasing temperature. The 
initial generalized polarization values of the eVLPs are higher than those of the mVLPs at 
each pH value. This suggests that the eVLPs possess a more apolar interfacial region 
compared to mVLPs. This observation is consistent with the results obtained from the 
intrinsic fluorescence experiments, in which the initial peak positions of the eVLPs are 
smaller than mVLPs by 1-2 nm for all samples.  
It is apparent that both VLPs have a strong tendency to aggregate at low pH and high 
temperature. This susceptibility to aggregation could potentially shorten the shelf life and 
decrease the biological activity of the VLP particles in inappropriate formulations. The sizes 
of the eVLPs and mVLPs are sensitive to changes in both pH and temperature. The VLPs 
aggregate more readily at lower pH. The DLS data clearly show that the eVLPs at pH 3 and 4 
are highly aggregated and that the mVLPs at the same pH values also aggregate quickly with 
increasing temperature. In contrast to the DLS results, static light scattering data detected a 
lower intensity of scattered light for VLPs at pH 3 and 4 compared to samples under other pH 
189 
 
conditions. This discrepancy is presumably due to precipitation followed by particles settling. 
Particles at pH 7 and 8 again manifest the highest stability based on the light scattering data. 
Stability optimization is an essential component of the vaccine-formulation process.  
Here, a combination of orthogonal physical techniques was employed to investigate the 
natural stability profiles of unformulated eVLPs and mVLPs as a function temperature and 
pH. The two VLPs show similar behavior in terms of their EPDs and have similar stability 
profiles. This study provides valuable information that could be used for the development of 
stable liquid formulations of VLP-based vaccines. More specifically, the EPDs constructed 
from the physical data facilitate the identification of formulation conditions for these vaccines 
and potential screening conditions for the identification of effective stabilizing excipients.  
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7.1 Summary and Conclusions 
The current and projected rapid increase in the number of protein drug candidates in 
clinical development highlights the need for high throughput instruments and methods to be 
used in the development of stable protein formulations. Signature features of high throughput 
methods are used to analyze a large number of samples using small amounts of material over 
a short time with limited resource requirements.
1
 The development of high throughput 
methods on currently available equipment is critical for the formulation development of 
protein drugs. High throughput methods can save material, time and resources, which are all 
typically constrained before and during a drug’s clinical evaluation. They provide a quick and 
ideally comprehensive view of complex properties of protein molecules over a wide range of 
experimental conditions in a short time period. They will also add significant value to the 
success of product development, including less resource use, a shorter time to market and an 
increased chance of success over competitors. Thus, the development of high throughput 
methods can play a critical role in the development of protein-based therapeutics, and much 
recent attention and effort have been involved in this area.  
In Chapter 2, I described the development of a reproducible, sensitive and robust 
method to investigate protein stability as a function of environmental stresses (pH and 
temperature in this case) by simultaneous data collection on a multifunctional instrument (the 
Chirascan-plus spectrometer).
2
 The method was developed by using four model proteins, 
which have different molecular sizes, thermal transition temperatures and secondary 
structural components. The new method has the capability to acquire near- and far- UV CD, 
UV absorption and turbidity data simultaneously in a single sample. Fluoresence capability is 
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also demonstrated. The method allows us to get maximum protein structural information 
(secondary, tertiary and aggregation information) from a minimum amount of samples over a 
reduced experiment time. We estimated that the new method will save at least 40% of 
experimental samples and total data acquisition time will be substantially reduced compared 
to the same experiments performed on separate instruments.  In combinaton with EPD data 
analysis, the method can be used to rapidly and comprehensively characterize the stability of 
biological systems in terms of their various structural levels with low sample requirements. 
The collection and evaluation of larger data sets of lower-resolution biophysical data by a 
high throughput method offers an alternative, more readily acessible and practical approach 
to rapidly evaluate protein structural integrity compared to higher resolution techniques such 
as X-ray crystallography and NMR. This new high throughput approach is useful for analysis 
of unknown proteins as well as screening for stable formulation conditions for protein drug 
candidates.  
In Chapters 3 and 4, I applied the new method of Chapter 2 to characterize the 
conformational stability of anthrax rPA, its analogue 2-FHis rPA and its double mutant DNI. 
In these studies, the conormational stability of these three proteins were characterized 
comprehensively as a function of pH and temperature by employing the multimodal 
spectrometer. The stability profiles of 2-FHis rPA and DNI were created employing EPD data 
analysis. Similarities and differences in the propetries of rPA and the two mutants (2-FHis 
rPA and DNI) were also identified. Results showed that rPA and 2-FHis rPA had the most 
similar and the highest stability at pH 7 to 8. With decreasing pH, however, 2-FHis rPA was 
found to be more stable than rPA, especially at pH 4 and 5. Measurements of their dynamic 
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properties at pH 5 found that 2-FHis rPA was more dynamic under acidic pH conditions. For 
the DNI protein, results showed that the thermally stressed molecule completely retained its 
native structure up to temperatures as high as 70 ºC for a month. The long-term stability of 
DNI was also demonstrated after refrigerated storage for about 8 years. More importantly, 
our collaborator’s work (Solegenix.Inc) showed that animals vaccinated with an aluminum 
salt adjuvanted DNI-based vaccine developed high titer neutralizing antibodies that confer 
protection against anthrax infection.  
PA is a protein antigen component in the currently used inactivated vaccine and 
provides a minimal level of protective immunity against anthrax infection. The current 
licensed U.S. anthrax vaccine (AVA, BioThrax) has a limited duration of protection, and 
requires multiple immunizations and yearly boosters.
3
 The AVA is composed of PA 
inactivated with formaldehyde and an incompletely defined culture supernatant adsorbed to 
an aluminum salt adjuvant, so the purity of the vaccine is not easily determined. Therefore, 
there is a need to develop newer versions of anthrax vaccines such as those based on 
recombinant PA, which have a better defined composition and can produce longer-lasting 
immunity. Recombinant protein analogue of PA such as 2-FHis rPA and DNI are promising 
candidates. Previous research shows that both 2-FHis rPA and DNI can potentially provide 
therapeutic activity in antitoxic therapy because of their ability to inhibit cytotoxicity in 
cells.
4,5,6,7
  In addition, DNI was also found to provide higher immunogenicity than PA in a 
mouse study.
7
 The characterization data presented here provides enhanced information for the 
development of alternative, more stable and immunogenic anthrax vaccines using these two 
mutated anthrax protective antigens. In addition, the successful application of the new high 
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throughput method to characterize the stability of these proteins demonstrates the utility of 
this approach for the analysis of unknown proteins. The reproducibility, senstivity and 
robustness of the method are also demonstrated in these studies. 
In Chapter 5, structural changes and aggregation behavior of the pneumolysin mutant 
(L460D) were monitored using various spectroscopic and light scattering techniques as a 
function of pH and temperature. Data were then summarized and analyzed by the empirical 
phase diagram method. The characterization data and EPD show that pneumolysin (L460D) 
is most stable in solution at pH 6- and loses its conformational integrity above about 48 ºC. 
Samples at pH 3 and 4, however, are much less stable and contain protein in a structurally 
altered state, even at low temperatures. In the following excipients screening study, potential 
stabilizers were identified and optimized by appropriate assays. Sugars such as trehalose and 
sucrose show stabilizing effects on pneumolysin with respect to improving thermal transition 
temperatures and minimizing its aggregation. Pneumolysin shows efficient binding to 
aluminum hydroxide. The stability of pneumolysin on the surface of alhydrogel does not 
seem to be affected by adsorption to the adjuvant, either with or without excipients. Finally, 
an optimal formulation containing 15% trehalose in 10 mM histidine buffer at pH 6 was 
identified.  
The development of recombinant protein-based vaccines offers an alternative way to 
produce cheaper, robust and broader coverage pneumococcal vaccines in comparison to 
current polysaccharide and conjugate based vaccines. Pneumolysin is a lead vaccine 
candidate and has been long known to be immunogenic. The characterization and formulation 
studies described above provide valuable information to aid in the development of stable 
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formulation for a recombinant pneumolysin antigen (L460D) as a pneumococcal vaccine that 
has the potential to be potent against all pneumococcal serotypes and therefore provide 
broader protection.  
In Chapter 6, the work focuses mainly on the preformulation development of 
eVLP-and mVLP-based vaccines. Preformulation stability data of VLPs aids in the design of 
a rational strategy to begin development of a final formulation. The VLPs examined in this 
study primarily contain the nucleoprotein (NP), glycoprotein and viral protein 40 (VP40) of 
the corresponding viruses. Therefore, several proteins contribute to the observed biophysical 
characterization results. The glycoprotein is present in low amounts in the VLP preparations 
compared with NP and VP40. Both NP and GP are primarily helical proteins containing coils, 
while VP 40 possesses approximately twice as much beta-sheet (30%) as helix (15%). The 
above properties of each protein need to be considered during the interpretation of the results 
obtained with the VLPS. The conformational stability of Ebola and Marburg VLPs was 
characterized by various techniques. Temperature/pH EPDs of the two VLPs were also 
constructed to analyze the large volume of data generated. The EPDs showed that both VLPs 
lost their conformational integrity above about 50-60 ºC, depending on solution pH. The 
VLPs were maximally thermal stable in solution at pH 7-8, with a significant reduction in 
stability at pH 5 and 6. They were much less stable in solution at pH 3-4 due to increased 
susceptibility of the VLPs to aggregation.  
 In summary, studies in Chapters 5 and 6 provide a description of the physical 
properties of a pneumolysin mutant (L460D) and Ebola and Marburg VLPs under a range of 
solution conditions (pH, temperature, ionic strength and solute). The information obtained 
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provides a basis for the rational design of long- term stable pharmaceutical formulations. The 
utility of the three step experimental design described in the Abstract is also illustated. 
Instead of collecting data from the individual, single-function instruments used in Chapters 5 
and 6, the use of the multimodal spectrometer method developed in Chapter 2 should provide 
an alternative and effective way to characterize stability in the preformulation and 
formulation stages of development of protein-based drugs.  
7.2 Future Directions 
 In Chapters 2, 3 and 4, a reproducible, accurate and sensitive method was developed and 
applied to characterize the stability of model and therapeutic proteins as well as to compare 
them in terms of various levels of macromolecular structure. In combination with EPD data 
analysis, a conformational stability profile of a protein as a function of pH (3-8) and 
temperature (10-87.5 ºC) can be obtained within 3 days by using only about a 200 µg of 
protein sample in each sample run.  
The process required to collect data and generate an EPD for individual proteins still 
can be accelerated by developing improved instrument software, a new generation of 
multifunctional instruments, and automated EPD data analysis software. First, the major 
instrument parameter of sampling time can be further optimized by improving current 
instrument software. Because the peptide sensitive CD signals in the far-UV region are much 
stronger than the aromatic CD signals in the near-UV, a much shorter sampling time such as 
1s or 0.5s can be applied in the far-UV CD measurements while retaining the longer 
optimized sampling time of 3s in the near-UV. The reproducibility of far-UV CD results is 
not compromised by reducing the sampling time (data not shown). The setting of different 
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sampling times in near- and far- UV regions can be achieved by further developments of the 
instrument’s software. The capability of varying the sampling time can also save about 30% 
of total data acquisition time compared to the current method of data collection. Second, time 
and energy can also be saved by developing and using an improved multimodal spectrometer. 
The instrument company (Applied Photophysics Ltd, Leatherhead, UK) has developed a new 
generation of CD spectrometers called “Chirascan-plus ACD Auto CD spectrometer”, which 
has an automated sampling system and a robotic work station. It employs a fully integrated, 
state-of-the-art robotic system providing unattended automation for up to 4x96 well plates. 
Applying the new method (Chapter 2) in this new instrument, it should be straightforward 
and permits the analysis of unattended overnight samples instead of switching batches 
manually during each day.  
Lastly, the new method can be improved by using automated EPD data analysis 
software. Our lab is developing a software tool to perform such automated analysis of large 
combined data sets. This new software can perform mathematical, graphical and file 
operations effectively.
8
 Use of the new method with the Chirascan and automated EPD data 
analysis will offer an efficient approach that provides comprehensive biophysical data of a 
protein with minimal sample and experiment time requirements. The new method has 
currently primarily been used for the characterization of the physical stability of proteins. 
This approach can also be used as a high-throughput analytical strategy to screen for 
stabilizing agents and thus more efficiently design optimally stable formulations for protein 
therapeutic drug candidates in the future. It should be applicable to more complex systems 
such as viruses as well as nucleic acids. 
203 
 
In Chapters 5 and 6, the preformulation and formulation work of Ebola and Marburg 
VLPs and the pneumolysin (L460D) provide some key stability data that can be of significant 
aid in the design of final liquid-formulations for these candidate vaccine antigens. The 
influence of various factors such as solution pH, temperature, buffer ion, salt, protein 
concentration and excipients on physical stability of these macromolecules was identified.  
Other formulation studies that need to be performed in the future are photostability, 
cavitation/shaking, freeze-thaw cycling, preservatives and material compatibility. All of these 
studies are used to address different aspects of protein stability in solution formulations and 
enable the rational development of a final liquid formulation. The accelerated stability studies 
provide rapid identification of formulation conditions and an improved understanding of the 
physicochemical characteristics of the protein molecule. They also provide information 
concerning which formulation conditions would be most suitable to maintain the stability of 
the protein. Long term stability studies, however, still need to be performed under the 
selected storage conditions over the desired storage period (1-3 years).
9
 In this period, the 
toxicity and immunogenicity studies will also need to be evaluated.  
In this dissertation, I presented my work on (1) Development and application of the 
high throughput method for the biophysical characterization of protein stability; and (2) 
Stability characterization and formulation of a pneumolysin (L460D) and Ebola and Marburg 
VLPs. Characterization and formulation of protein-based drugs and vaccines is a complex 
process, which requires the selection and combination of appropriate analytical methods. For 
the first part of my work, the new high throughput method employing the multifunctional 
instrument provides an effective approach to rapidly evaluate protein structural integrity with 
204 
 
low sample requirements. There is, however, still room to further improve the efficiency of 
the method with the new automated sampling system of instruments and the new EPD data 
analysis software. For the second part of my work, other future experiments are necessary to 
conduct studies such as freeze-thaw, shaking, photostability, material compatibility and 
long-term stability in order to develop stable final vaccine formulations of these protein 
antigens.  
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